

BMJ Open

The Prevention of Delirium and Complications Associated with Surgical Treatments (PODCAST) study: Protocol for an International Multicenter Randomized Controlled Trial

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-005651
Article Type:	Protocol
Date Submitted by the Author:	18-Jun-2014
Complete List of Authors:	Avidan, Michael; Washington University School of Medicine in St. Louis, Anesthesiology Fritz, Bradley; Washington University School of Medicine in St. Louis, Anesthesiology Maybrier, Hannah; Washington University School of Medicine in St. Louis, Anesthesiology Muench, Maxwell; Washington University School of Medicine in St. Louis, Anesthesiology Escallier, Krisztina; Washington University School of Medicine in St. Louis, Anesthesiology Chen, Yulong; Washington University School of Medicine in St. Louis, Anesthesiology Ben Abdallah, Arbi; Washington University School of Medicine in St. Louis, Anesthesiology Veselis, Robert; Memorial Sloan-Kettering Cancer Center, Anesthesiology Hudetz, Judith; Medical College of Wisconsin, Anesthesiology Pagel, P; Clement J. Zablocki VA Medical Center, Noh, Gyujeong; Asan Medical Center, Anesthesiology Pryor, Kane; Weill Cornell Medical College, Anesthesiology Kaiser, Heiko; University of Bern, Anesthesiology Arya, Virendra; Postgraduate Institute of Medical Education and Research, Anesthesiology Pong, Ryan; Virginia Mason Medical Center, Anesthesiology Jacobsohn, Eric; University of Manitoba-Faculty of Medicine, Anesthesiology Grocott, Hilary; University of Manitoba-Faculty of Medicine, Anesthesiology Choi, Stephen; Sunnybrook Health Sciences Center, Anesthesiology Downey, Robert; Memorial Sloan-Kettering Cancer Center, Surgery, Thoracic Inouye, Sharon; Hebrew Rehab Center for the Aged, Medicine- Beth Israel-Deaconess Mashour, George; University of Michigan Medical School, Anesthesiology
Primary Subject Heading:	Anaesthesia
Secondary Subject Heading:	Geriatric medicine, Surgery, Neurology
Keywords:	Pain management < ANAESTHETICS, Adult anaesthesia < ANAESTHETICS, Adult intensive & critical care < ANAESTHETICS, Delirium & cognitive disorders < PSYCHIATRY, Adult surgery < SURGERY

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



SCHOLARONE™
Manuscripts

For peer review only

1
2
3 **The Prevention of Delirium and Complications Associated with Surgical Treatments**
4
5 **(PODCAST) Study: Protocol for an International Multicenter Randomized Controlled Trial**
6
7

8
9
10 **Trial Registration:** NCT01690988 (last updated December, 2013)
11

12 **Version date: June 16, 2014**
13

14 **Corresponding author:** Michael S. Avidan
15 Campus Box 8054
16 660 S. Euclid Ave
17 Department of Anesthesiology
18 Washington University School of Medicine
19 St. Louis, MO 63110
20 United States
21 avidanm@anest.wustl.edu
22
23

24 **Co-authors:** Bradley A. Fritz
25 Department of Anesthesiology
26 Washington University School of Medicine
27 St. Louis, Missouri, United States
28

29
30 Hannah R. Maybrier
31 Department of Anesthesiology
32 Washington University School of Medicine
33 St. Louis, Missouri, United States
34

35 Maxwell R. Muench
36 Department of Anesthesiology
37 Washington University School of Medicine
38 St. Louis, Missouri, United States
39

40 Krisztina E. Escallier
41 Department of Anesthesiology
42 Washington University School of Medicine
43 St. Louis, Missouri, United States
44

45
46 Yulong Chen
47 Department of Anesthesiology
48 Washington University School of Medicine
49 St. Louis, Missouri, United States
50

51 Arbi Ben Abdallah
52 Department of Anesthesiology
53 Washington University School of Medicine
54 St. Louis, Missouri, United States
55 Robert A. Veselis
56 Department of Anesthesiology
57
58
59
60

1
2
3 Memorial Sloan-Kettering Cancer Center
4 New York, New York, United States
5

6
7 Judith A. Hudetz
8 Department of Anesthesiology
9 Medical College of Wisconsin
10 Milwaukee, Wisconsin, United States
11

12
13 Paul S. Pagel
14 Clement J. Zablocki VA Medical Center
15 Medical College of Wisconsin
16 Milwaukee, Wisconsin, United States
17

18
19 Gyujeong Noh
20 Department of Anesthesiology
21 Asan Medical Center
22 Seoul, South Korea
23

24
25 Kane Pryor
26 Department of Anesthesiology
27 Weill Cornell Medical College
28 New York, New York, United States
29

30
31 Heiko Kaiser
32 Department of Anesthesiology
33 University of Bern
34 Bern, Switzerland
35

36
37 Virendra Kumar Arya
38 Department of Anesthesiology
39 Postgraduate Institute of Medical Education and Research
40 Chandigarh, India
41

42
43 Ryan Pong
44 Department of Anesthesiology
45 Virginia Mason Medical Center
46 Seattle, Washington, United States
47

48
49 Eric Jacobsohn
50 Department of Anesthesiology
51 University of Manitoba-Faculty of Medicine
52 Winnipeg, Manitoba, Canada
53

54
55 Stephen Choi
56 Department of Anesthesiology
57 Sunnybrook Health Sciences Center
58 Toronto, Ontario, Canada
59

60
Robert J. Downey
Department of Surgery, Thoracic
Memorial Sloan-Kettering Cancer Center
New York, New York, United States

1
2
3
4 Sharon K. Inouye
5 Department of Medicine – Beth Israel-Deaconess
6 Hebrew Rehab Center for the Aged
7 Boston, Massachusetts, United States
8
9

10 George A. Mashour
11 Department of Anesthesiology
12 University of Michigan Medical School
13 Ann Arbor, Michigan, United States
14

15
16 **Keywords:** ketamine, delirium, postoperative delirium, neurological complications,
17
18 postoperative pain, surgery, general anesthetics, neurobehavioral manifestations, geriatric
19
20 syndrome
21
22

23
24
25 **Word Count:** 6,833
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

WORLD HEALTH ORGANIZATION DATA SET

Primary Registry and Trial Identifying Number	ClinicalTrials.gov: NCT01690988
Date of Registration in Primary Registry	August 7, 2012
Secondary Identifying Numbers	IRB ID#: 201206071
Source(s) of Monetary or Material Support	Department of Anesthesiology, Washington University School of Medicine in St. Louis Departments of each respective site
Primary Sponsor	Department of Anesthesiology, Washington University School of Medicine in St. Louis
Secondary Sponsor(s)	Department of Anesthesiology, University of Michigan Medical School in Ann Arbor
Contact for Public Queries	Michael Avidan, MBBCh avidanm@anest.wustl.edu 314-747-4155 660 S. Euclid Ave Department of Anesthesiology Washington University School of Medicine St. Louis, MO 63110 United States
Contact for Scientific Queries	Michael Avidan, MBBCh Study Principal Investigator avidanm@anest.wustl.edu 314-747-4155 Campus Box 8054 660 S. Euclid Ave Department of Anesthesiology Washington University School of Medicine St. Louis, MO 63110 United States
Public Title	The Prevention of Delirium and Complications After Surgical Treatment (PODCAST) Study
Scientific Title	The Prevention of Delirium and Complications After Surgical Treatment (PODCAST) Study: a randomized controlled trial
Countries of Recruitment	United States, Canada, Switzerland, India, South Korea

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	<p>Health Condition(s) or Problem(s) Studied</p> <p>Postoperative delirium, postoperative pain, and postoperative nausea and vomiting</p> <p>Intervention(s)</p> <p>Study arm 1: 0.5 mg/kg of ketamine diluted to 20 mL with saline given intravenously after anesthetic induction and before surgical incision.</p> <p>Study arm 2: 1 mg/kg of ketamine diluted to 20 mL with saline given intravenously after anesthetic induction and before surgical incision</p> <p>Placebo: 20 mL of saline solution given intravenously after anesthetic induction and before surgical incision.</p> <p>Key Inclusion Criteria and Exclusion Criteria</p> <p>Ages eligible for study: ≥ 60 years</p> <p>Sexes eligible for study: both</p> <p>Healthy volunteers: no</p> <p>Inclusion criteria: patients 60 years or older undergoing major open surgery receiving general anesthesia</p> <p>Exclusion criteria: allergy to ketamine, pheochromocytoma, aortic dissection, intracranial hemorrhage, intracranial mass, history of hypertensive emergency, uncontrolled glaucoma, history of drug misuse (e.g., ketamine, cocaine, heroin, amphetamine, methamphetamine, MDMA, phencyclidine, lysergic acid, mescaline, psilocybin), currently taking anti-psychotic medications (e.g., chlorpromazine, clozapine, olanzapine, risperidone, haloperidol, quetiapine, paliperidone, amisulpride, sertindole), weight <50 kg (110 lbs) or >200 kg (440 lbs).</p> <p>Study Type</p> <p>Interventional Allocation: randomized Intervention model: parallel assignment Masking: double blind (subject, healthcare providers, investigator, research personnel)</p> <p>Assignment: single arm Primary purpose: prevention Phase III</p> <p>Date of First Enrollment</p> <p>February 2014</p>
---	---

1		
2		
3	Target Sample Size	600
4		
5	Recruitment Status	Recruiting
6		
7	Primary Outcome(s)	Outcome name: postoperative delirium
8		
9		Method of measurement: Confusion Assessment Method
10		or Confusion Assessment Method for the ICU
11		
12		Timepoints of interest: two hours post-operation, mornings
13		and evenings of postoperative days one through three
14		
15		
16	Key Secondary Outcomes	Outcome name: postoperative pain
17		
18		Method of measurement: Visual Analog Scale and
19		Behavioral Pain Scale or Behavioral Pain Scale – Non-
20		Intubated
21		
22		Timepoints of interest: two hours post-operation, mornings
23		and evenings of postoperative days one through three
24		
25		
26		
27		
28		Outcome name: postoperative nausea and vomiting
29		
30		Method of measurement: patient self-report as present or
31		absent and degree of severity (mild, moderate, or severe).
32		
33		Timepoints of interest: two hours post-operation, mornings
34		and evenings of postoperative days one through three
35		
36		
37		
38		
39		
40		
41		
42		
43		
44		
45		
46		
47		
48		
49		
50		
51		
52		
53		
54		
55		
56		
57		
58		
59		
60		

ORGANIZATIONAL STRUCTURE AND RESPONSIBILITIES

Principal Investigators:

Michael Avidan, MBBCh
George Mashour, MD, PhD

Responsibilities include: design and conduct of PODCAST trial, preparation of protocol and revisions, organizing steering committee meetings, and publication of study reports.

Steering Committee:

Michael Avidan, MBBCh	Eric Jacobsohn, MBBCh	Kane Pryor, MD
Daniel Emmert, MD, PhD	Hilary Grocott, MD	Gyujeong Noh, MD, PhD
Robert Veselis, MD	Stephen Choi, MD	Paul Pagel, MD, PhD
Sharon Inouye, MD, MPH	Ryan Pong, MD	Judith Hudetz, PhD
George Mashour, MD, PhD	Virendra Kumar Arya, MD	Milo Engoren, MD
Robert Downey, MD	Heiko Kaiser, MD	

Responsibilities include: agreement of final protocol, recruitment of patients and coordinating with principle investigator, reviewing progress of study and if necessary, changes to the protocol.

Trial Management Committee:

Michael Avidan, MBBCh
George Mashour, MD, PhD
Hannah Maybrier

Responsibilities include: study planning, organization of steering committee meetings, provides annual risk report to the Human Research Protection Office at Washington University, reports SAEs (Serious Adverse Events) to Washington University IRB (Institutional Review Board), responsible for maintenance of electronic database, REDCap, advice for lead investigators, assistance with international review, ethics committee applications, data verification, and randomization of study participants

Lead Investigators:

Michael Avidan, MBBCh	Eric Jacobsohn, MBBCh	Kane Pryor, MD
Daniel Emmert, MD, PhD	Hilary Grocott, MD	Gyujeong Noh, MD, PhD
Robert Veselis, MD	Stephen Choi, MD	Paul Pagel, MD, PhD
Sharon Inouye, MD, MPH	Ryan Pong, MD	Judith Hudetz, PhD
George Mashour, MD, PhD	Virendra Kumar Arya, MD	Milo Engoren, MD
Robert Downey, MD	Heiko Kaiser, MD	

Responsibilities include: identification, recruitment, data collection and completion of CRFs, along with follow up of study patients and adherence to study protocol.

Data and Safety Monitoring Committee:

Arbi Ben Abdallah, PhD
Michael Avidan, MBBCh
Charlie Hantler, MD
Simon Haroutounian, PhD

Responsibilities include: reviewing and evaluating the study data to ensure participant safety, study conduct, progress, and efficacy, and making recommendations regarding the continuation, modification, and termination of the trial.

PROTOCOL VERSIONS**June 18, 2012**

Original

April 25, 2013

Amendment 01: Changes to study aims:

- Changed specific aim 1: removed associated adverse events, such as ICU stay, hospital stay, and mortality
- Changed specific aim 2: removed assessing symptoms of other chronic neuropsychiatric processes (such as depression and posttraumatic stress).
- Changed specific aim 3: testing the effects of ketamine on postoperative depression and stress to attenuating postoperative inflammation.

Amendment 02: Addition of study arm. Patients are randomized to one of three study arms: 0.5 mg/kg ketamine, 1 mg/kg ketamine, or placebo dose of equal volume

Amendment 03: Removed phrase that patients will be contacted between 1 and 3 months after surgery to ask about quality of life, lasting pain, feelings of depression or stress.

Amendment 04: Removed phrase that patients will be contacted 1 year after surgery to ask about quality of life and mental function.

Amendment 05: Changed inclusion criteria to patients older than 60 years (was 65 years)

Amendment 06: Removal of phrase regarding study of ketamine use with posttraumatic stress disorder.

Amendment 07: Addition of phrase that hypothesis is based on published data of reduced pain and opioid consumption after surgery. The study will resolve gap in the field by further assessing chronic pain

Amendment 09: Addition of phrase that discusses delirium and pain as two adverse and potentially linked outcomes that have not been previously jointly evaluated in a large clinical trial.

May 30, 2013

Amendment 01: Removal of specific aim 3: testing whether ketamine improves postoperative inflammation

January 3, 2014

Amendment 01: Addition of weight criterion to Exclusion Criteria; weight < 50 kg (110 lb.) and > 200 kg (440 lb.) are excluded.

Amendment 02: Addition of justification of sample size. Included statement that when assuming a two sided type one error of 5% the sample size of 600 patients will detect decrease in delirium from

1
2
3 25% to 15% with the use of ketamine with a power greater than
4 80%.

5
6
7 Amendment 03: Change in randomization protocol. We will not
8 randomize cardiac and non-cardiac surgery patients separately.

9
10 Amendment 04: Omission of one of the points of clarification of the
11 pilot study – to determine the efficacy of ketamine in cardiac vs.
12 non-cardiac surgery.

13
14 Amendment 05: Changes to baseline assessments. Addition of
15 Confusion Assessment Method (CAM), Behavioral Pain Scale –
16 Non-Intubated (BPS-NI), Visual Analog Scale (VAS), Barthel Index,
17 Patient Health Questionnaire-8 (PHQ-8), STOP-Bang, and
18 questions about falls.

19
20 Amendment 06: Addition of medical record review screening for
21 comorbid conditions included in the Charlson Comorbidity Index
22 and lab values including electrolytes and blood counts.

23
24 Amendment 07: Addition of the statement that clinicians are
25 instructed not to give enrolled patients ketamine as part of their
26 anesthetic technique.

27
28 Amendment 08: Addition of mailed survey sent 30 days
29 postoperatively assessing depression, positive and negative affect,
30 quality of life, functional independence, and pain using the PROMIS
31 v1.0 – Emotional Distress – Depression, Positive and Negative
32 Affect Scale (PANAS), Veteran's Rand-12 (VR-12), Barthel Index,
33 and the Brief Pain Inventory Short Form (BPI-SF), respectively.

34
35 Amendment 09: Addition of Family Confusion Assessment Method
36 (FAM-CAM) at Washington University, a tool in which family
37 members will assess patient's behavior and determine if delirium is
38 suggested.

39
40 Amendment 10: Addition of observational tools used to assess pain:
41 BPS, BPS-NI

42
43 Amendment 11: Addition of postoperative nausea and vomiting as a
44 secondary outcome.

45
46 Amendment 12: Addition of description of delirium assessment
47 training.

48
49 Amendment 13: Addition of statement that REDCap (Research
50 Electronic Data Capture) will be used.

51
52 Amendment 14: Addition of statement saying there are no planned
53 interim analyses.
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Amendment 15: Changes in statistical analysis:

- Cox proportional-hazards model for recurrent events used to determine the effects of low-dose ketamine on the occurrence and duration of delirium across study groups.
- Poisson hurdle regression used to determine the differences in patients with delirium and those without delirium, and the differences in recurrence in the patient population that does experience delirium.
- Both Poisson and Cox will also be used to compare effects of ketamine on cardiac vs. non-cardiac surgery patients.
- Cochran-Armitage test to determine dose-response trends
- Mixed-effects regression model to detect differences of continuous outcome variables in subgroups.

Amendment 16: Addition of list of short- and long-term side effects of ketamine

March 7, 2014

Amendment 01: Addition of Patient Health Questionnaire 8 (PHQ 8) for baseline assessments and postoperative day three assessments. This replaced the PROMIS depression screen. We would like to assess depression using the same tool at all time points.

Amendment 02: Collection of patient's email at baseline. Patients have the option to receive the 30 day survey by mail or email.

Amendment 03: Addition of Figure 1: Study Flow Chart. This is a visual representation of study conduct.

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

ABSTRACT

Introduction: Postoperative delirium is one of the most common complications of major surgery, affecting 10-70% of surgical patients 60 years and older. Delirium is an acute change in cognition that manifests as poor attention and illogical thinking, and is associated with longer ICU and hospital stay, long-lasting cognitive deterioration, and increased mortality. Ketamine has been used as an anesthetic drug for over 50 years and has an established safety record. Recent research suggests that, in addition to preventing acute postoperative pain, a sub-anesthetic dose of intraoperative ketamine could decrease the incidence of postoperative delirium as well as other neurologic and psychiatric outcomes. However, these proposed benefits of ketamine have not been tested in a large clinical trial.

Methods: The PODCAST study is an international, multicenter, randomized controlled trial. Six hundred cardiac and major non-cardiac surgery patients will be randomized to receive ketamine (0.5 mg/kg or 1 mg/kg) or placebo following anesthetic induction and prior to surgical incision. For the primary outcome, blinded observers will assess delirium on the day of surgery (postoperative day 0) and twice daily from postoperative days 1 to 3 using the Confusion Assessment Method or the Confusion Assessment Method for the ICU. For the secondary outcomes, blinded observers will estimate pain using the Behavioral Pain Scale or the Behavioral Pain Scale for Non-Intubated Patients and patient self-report.

Ethics and dissemination: The PODCAST trial has been approved by the ethics boards of five participating institutions; approval is ongoing at other sites. Recruitment began in February 2014 and is expected to continue through 2015. Dissemination plans include

1
2
3 presentations at scientific conferences, scientific publications, stakeholder engagement
4
5 and popular media.
6

7
8 Registration details: The study is registered at clinicaltrials.gov, NCT01690988 (last
9
10 updated December, 2013).
11

12 The PODCAST trial is being conducted under the auspices of the Neurological
13
14 Outcomes Network for Surgery (NEURONS).
15
16

17 18 19 20 **STRENGTHS:**

- 21
22 • The effects of ketamine are being observed in the routine clinical setting.
23
- 24
25 • Because PODCAST is a multicenter international trial, the results of the study will
26
27 potentially be generalizable.
28
- 29
30 • This trial has a novel focus of assessing delirium and pain concurrently. Results
31
32 could reveal that these two outcomes are potentially linked in the postoperative
33
34 setting.
35
- 36
37 • PODCAST is a randomized, controlled double-blinded study.
38
- 39
40 • Investigators assessing for delirium have been appropriately trained and
41
42 will use reliable and validated assessment tools.
43
44
45

46 47 **LIMITATIONS:**

- 48
49 • Pain is a subjective experience and is therefore difficult to measure.
50
- 51
52 • The Visual Analog Scale (VAS) is not a validated pain assessment instrument in
53
54 delirious patients. In an attempt to mitigate this limitation, pain will also be assessed
55
56
57
58
59
60

1
2
3 observationally using the Behavioral Pain Scale (BPS) and the Behavioral Pain
4 Scale – Non-intubated (BPS-NI).
5
6

- 7
8 • Delirium is fluctuating in nature. Because patients will be assessed at discrete time
9 points, it is possible that some episodes of delirium will not be detected.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Background and rationale

Delirium

Postoperative delirium is one of the most common complications of major surgery and affects between 10% and 70% of all surgical patients older than 60 years (Table 1).¹ The estimated additional healthcare costs associated with delirium exceed \$60,000 per patient per year.² While causal relationships have not been established, delirium is associated with increased morbidity and mortality, prolonged length of hospital and intensive care unit (ICU) stay, functional and cognitive decline with nursing home or long-term care facility placement.³⁻⁶ Furthermore, the acute deterioration in cognition and psychomotor agitation frequently seen with delirium is often distressing for both patients and their families.

Surgery type	Study (year)	Population	Delirium Rate	Detection method
Unselected	Radtke ⁷	Recovery room after elective general anesthesia	9.9%	Nu-DESC
Surgical ICU	Pandharipande ⁸	Surgical ICU	73%	CAM-ICU
		Trauma ICU	67%	
Head and neck	Weed ⁹	Major head and neck	17%	Not stated
Cardiac	Kazmierski ¹⁰	Cardiac surgery with CPB	Age <60: 16.3% Age ≥60: 24.7%	DSM-IV
	Rudolph ¹¹	Patients >60 undergoing elective or urgent cardiac surgery	43%	CAM
	Saczynski ¹²	Patients >60 undergoing elective coronary artery bypass grafting or valve replacement surgery	46%	CAM
Vascular	Marcantonio, ¹³ Schneider, ¹⁴ Bohner, ¹⁵ and Benoit ¹⁶	Abdominal aortic aneurysm repair	33-54%	CAM or DSM-IV

	Schneider, ¹⁴ and Bohner ¹⁵	Peripheral vascular	30-48%	DSM-IV
Orthopedic	Fisher ¹⁷	Patients >60 undergoing elective orthopedic procedures	17.5%	CAM
	Marcantonio ¹⁸ and Lee ¹⁹	Patients >65 undergoing emergent hip fracture repair	30.2-41%	CAM

Table 1: Incidence of Delirium in Major Surgeries. CAM, Confusion Assessment Method; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, 4th edition; ICU, Intensive Care Unit; Nu-DESC, The Nursing Delirium Screening Scale

The diagnostic criteria for delirium have recently been updated in the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5). Delirium is an acute neurocognitive disorder characterized by a fluctuating level of consciousness with impairment of attention and cognition. In the postoperative context, delirium typically manifests between 0 and 96 hours following the surgical intervention. It is unclear why postoperative delirium occurs so frequently. Age greater than 60, male gender, history of dementia or depression, sensory impairment, and chronic medical illness are consistently described as risk factors for delirium.²⁰ No effective prophylactic or curative treatments for postoperative delirium have been identified.

Ketamine and Delirium

Ketamine is an anesthetic agent that has been in common use for more than 50 years. Ketamine has a wide margin of safety, and as of 2005 had been studied in over 12,000 operative and diagnostic procedures, involving over 10,000 patients from 105 separate studies (Ketamine package insert 2005). There is a pharmacological rationale for using ketamine as a preventative measure against postoperative delirium based on its N-methyl-D-aspartate (NMDA) antagonism.²¹ Normally, excitatory amino acids such as glutamate and aspartate act as agonists at NMDA receptors, and, in the setting of surgery and inflammation, they might

1
2
3 promote excitotoxic injury and apoptosis.²¹ As an NMDA antagonist, ketamine has the potential
4
5 to protect against such neurological injury.²² Ketamine has also been posited to inhibit HCN1
6
7 receptors, which mediate the hyperpolarization-activated cation current.²³ Such inhibition is
8
9 pertinent to delirium because HCN1 channels are important for regulating states of
10
11 consciousness²⁴ and are up-regulated by inflammation.²⁵ HCN1 receptors are also thought to
12
13 play a critical role in neuropathic pain through inflammatory cascades.²⁶
14
15

16 Based on the pharmacological rationale for neuroprotection, a 58-patient randomized, controlled
17
18 trial was conducted to determine whether ketamine might prevent delirium after major cardiac
19
20 surgery.²⁷ There was a significant reduction in postoperative delirium from 31% to 3% with the
21
22 administration of low dose ketamine (0.5 mg/kg) upon induction of anesthesia. While
23
24 encouraging, this trial must be regarded as preliminary owing to its small sample size, and
25
26 single center design. Interestingly, the same investigators also found that ketamine was
27
28 associated with improved cognition beyond the immediate postoperative period.²⁸ Differences
29
30 between the ketamine and placebo groups were evident in tests of nonverbal memory, verbal
31
32 memory, and executive function. The investigators found that C reactive protein, a non-specific
33
34 inflammatory marker, was similar at baseline in the ketamine and the placebo groups. On the
35
36 first postoperative day, C reactive protein was elevated in both groups, but was significantly
37
38 higher in the placebo group. The investigators hypothesized that the neuroprotective effect of
39
40 ketamine might have been, in part, attributable to its anti-inflammatory actions.²⁸ In support of
41
42 the plausibility of this hypothesis, ketamine use in another cardiac surgical population was
43
44 similarly shown to attenuate postoperative increases in inflammatory markers.²⁹
45
46
47

48 Intraoperative sub-anesthetic dose ketamine is appealing as a potential preventative
49
50 intervention for delirium, since it is inexpensive and has an excellent safety profile. A number of
51
52 questions remain to be answered regarding postoperative delirium. Despite the fact that delirium
53
54 is a common and serious postoperative complication, intraoperative factors contributing to
55
56 pathogenesis have not been rigorously investigated, and only a few small trials have been
57
58
59
60

1
2
3 conducted examining interventions to decrease its incidence. It is also currently unknown
4
5 whether postoperative delirium is preventable, particularly in patients with underlying
6
7 vulnerabilities. Importantly, ketamine in higher (anesthetic) doses has become less popular over
8
9 time owing to side effects, including hallucinations and emergence reactions, especially in
10
11 younger patients.^{30,31} To ensure treatment effectiveness, the preliminary results identifying sub-
12
13 anesthetic dose ketamine as a useful preventative intervention for postoperative delirium should
14
15 therefore be confirmed or refuted using a large scale, pragmatic, randomized controlled trial
16
17 design prior to routine adoption of low dose ketamine for this purpose.
18
19

20 21 22 Acute and Persistent Pain

23
24 Similar to delirium, both acute and persistent pain are common postoperative complications,
25
26 with a negative impact on patients' lives. The Joint Commission has established the prevention
27
28 of severe postoperative pain as a benchmark of quality,³² and adequate pain management is
29
30 increasingly viewed as a fundamental human right.^{33,34} Unfortunately, this standard of care has
31
32 not been attained to date; it has previously been estimated that about a third of patients suffer
33
34 severe acute postsurgical pain following major procedures.³⁵ Furthermore, patients who have
35
36 acute postoperative pain are more likely to develop chronic pain, and the incidence of persistent
37
38 postoperative pain following major surgeries remains between 5% and 30%.³⁶ As an antagonist
39
40 at NMDA and HCN1 receptors, ketamine has powerful analgesic properties. A systematic
41
42 review showed that a single sub-anesthetic dose of intraoperative ketamine was associated with
43
44 decreased visual analog pain scores up to 48 hours postoperatively.³⁷ At 24 hours
45
46 postoperatively, ketamine was associated with an impressive 16 mg decrease in total morphine
47
48 consumption.³⁷ Furthermore, adverse effects such as hallucinations were rarely reported when
49
50 low dose ketamine was administered during general anesthesia.³⁷ Consistent with these
51
52 findings, a Cochrane systematic review reported that sub-anesthetic doses of perioperative
53
54 ketamine were associated with decreased postoperative pain, decreased morphine
55
56
57
58
59
60

1
2
3 consumption, and decreased nausea and vomiting.³⁸ Adverse effects were mild or absent.³⁸ An
4
5 updated systematic review, which included 70 small studies involving 4,701 patients, recently
6
7 confirmed that, in a dose-dependent manner, sub-anesthetic intraoperative ketamine was
8
9 consistently associated with decreased postoperative pain despite decreased opioid
10
11 consumption.³⁹ The more painful the surgical procedure, the greater was the analgesic benefit
12
13 attributable to ketamine.³⁹ In keeping with decreased opioid consumption, postoperative nausea
14
15 and vomiting were also less frequent in patients who received ketamine. However, patients who
16
17 had been randomized to ketamine reported hallucinations and nightmares more frequently.³⁹
18
19 While efficacy data, based on numerous small studies, strongly suggest that supplementary
20
21 ketamine should be used to decrease pain and opioid usage postoperatively, most practitioners
22
23 have not incorporated low dose ketamine into their routine practice. Preliminary data gathered
24
25 from 5 institutions (see below for details) involved in the PODCAST Trial suggest that, despite
26
27 their knowledge regarding the analgesic and opioid-sparing effects, practitioners do not
28
29 administer low-dose ketamine for pain because of concern for complications such as delirium.
30
31 Thus, effectiveness data regarding the relationship of ketamine, delirium and pain are needed.
32
33 Although numerous small efficacy studies have shown that ketamine decreases acute
34
35 postoperative pain, its role in preventing persistent postoperative pain has not been rigorously
36
37 explored. Many causal mechanisms that are thought to be implicated in persistent pain and a
38
39 single intraoperative intervention might not be sufficient to decrease its occurrence. However,
40
41 there have been encouraging findings about the potential of NMDA antagonists to decrease
42
43 postoperative persistent pain. In the ENIGMA trial, patients were randomized to receive
44
45 intraoperative oxygen with either nitrogen or nitrous oxide, which, like ketamine, is an NMDA
46
47 antagonist. The investigators found that among those patients who received nitrous oxide, there
48
49 was an absolute decrease in the percentage of patients who experience persistent pain
50
51 (baseline incidence = 15%) at 3 months postoperatively of 7% (95% CI, 1.9% to 13.9%).⁴⁰ A
52
53 randomized study has examined the potential beneficial effect of intraoperative ketamine on
54
55
56
57
58
59
60

1
2
3 persistent postoperative pain among patients undergoing total hip replacement.⁴¹ This trial
4
5 found a reduction in the ketamine group from 21% to 8% (reduction = 13%; 95% C.I., 1.3% to
6
7 24.9%) in patients experiencing persistent pain at 6 months after their surgery.⁴¹ The PODCAST
8
9 study would demonstrate whether sub-anesthetic dose intraoperative ketamine is effective at
10
11 preventing acute postoperative pain in a real world setting. If ketamine were shown to have a
12
13 substantial effect in decreasing acute postoperative pain, a next step would be to investigate
14
15 rigorously its impact on persistent pain.
16
17
18
19

20 21 Current Utilization of Low-Dose Ketamine

22
23 A survey of anesthesia clinicians was conducted at five of the institutions (Washington
24
25 University in St. Louis, University of Michigan, University of Manitoba, Weill Medical College of
26
27 Cornell University, and Medical College of Wisconsin) participating in the PODCAST clinical
28
29 trial. In total, 270 clinicians responded to the surveys; 18% (range among institutions 12% to
30
31 40%) of respondents currently incorporate adjunctive sub-anesthetic ketamine into their
32
33 practice. Interestingly, 84% of survey respondents believe that low dose ketamine decreases
34
35 acute postoperative pain, 81% feel that it decreases postoperative opioid consumption, and
36
37 51% believe that it decreases chronic postoperative pain. However, the reason that a minority of
38
39 practitioners are currently administering adjunctive ketamine is probably because many remain
40
41 concerned about the neurological side effects of even low dose ketamine; 68% of respondents
42
43 expressed concern about hallucinations, 62% about delirium and 55% about nightmares.
44
45
46
47
48
49

50 51 Potential Impact of PODCAST

52
53 The PODCAST trial has a novel focus in that it is assessing the impact of an intervention (sub-
54
55 anesthetic ketamine administration) on both delirium and pain, two adverse and potentially
56
57 linked outcomes that have not previously been jointly evaluated in a single large clinical trial.
58
59
60

1
2
3 Both delirium and pain are surprisingly common acute postoperative complications with major
4 negative consequences for patients.^{1,35} Currently, there are no official guidelines to screen
5 patients for delirium and only few preventive measures have been investigated, with
6 disappointing results. Since most patients with postoperative delirium have a hypoactive
7 phenotype, it is frequently missed in clinical practice. As noted previously, postoperative
8 delirium is associated with increased intensive care and hospital stay, with persistent cognitive
9 decline and with increased mortality. Thus, any intervention that could decrease the incidence of
10 postoperative delirium would probably have major positive implications for older patients
11 undergoing surgical procedures. Unlike delirium, acute postoperative pain is routinely assessed
12 and the Joint Commission has prioritized the prevention of severe postoperative pain as a
13 universal goal. Unfortunately this objective has not been met, and both severe acute pain and
14 debilitating chronic pain continue to afflict many surgical patients.^{35,36} Of note, both pain and its
15 treatment with opioid analgesics can be risk factors for delirium. Opioid analgesics are the
16 mainstay therapy for postoperative pain, but their administration is curtailed in older patients
17 particularly for safety considerations regarding respiratory depression, but also for concerns
18 about causing sedation and delirium.

19
20
21 Pragmatic trials are intended to generate evidence of effectiveness of a test, treatment,
22 procedure, or health-care service.^{42,43} At present, there is a lack of pragmatic trials for candidate
23 interventions to prevent important and common postoperative neurologic and psychiatric
24 complications including delirium and pain. Ketamine is a plausible prophylactic option for each
25 of these neurological and psychiatric complications. The American Society of Anesthesiologists
26 has published Practice Guidelines for the management of acute and chronic pain, which, based
27 on small efficacy or observational trials, include ketamine as a treatment option.^{44,45} There are
28 currently no guidelines for the prevention of postoperative delirium. Thus, a multicenter
29 pragmatic trial comparing low dose ketamine with placebo is timely. It is important to emphasize
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 that any one of several potential results of the PODCAST trial will have important and
4
5 immediate positive implications for older surgical patients. First ketamine might decrease both
6
7 delirium and pain. This result would provide clear support for a larger comparative effectiveness
8
9 trial testing ketamine as a prophylactic measure for both of these outcomes. Second, ketamine
10
11 might decrease pain without increasing delirium. This result would provide compelling data that
12
13 encourage the use of ketamine to prevent pain without concern for cognitive side effects such
14
15 as delirium. Third, ketamine might decrease delirium and have no impact on pain. Although the
16
17 lack of effect on pain is unlikely, this result would also encourage further study of the use of
18
19 prophylactic intraoperative ketamine. However, low dose ketamine may be found to increase
20
21 delirium, regardless of its impact on pain. This result would suggest that the incorporation of
22
23 intraoperative ketamine into routine clinical practice for older surgical patients is not warranted
24
25 and would negate the need for a larger pragmatic trial. Furthermore, the PODCAST trial will
26
27 help determine ketamine dose-related effects by comparing two doses (0.5 mg/kg and 1 mg/kg)
28
29 to placebo. As such, all of these potential results of the PODCAST trial have the potential to
30
31 impact clinical practice and will be generalizable to all older surgical patients undergoing major
32
33 surgical procedures because of the permissive inclusion criteria and the simplicity of
34
35 intervention.⁴²
36
37
38
39
40
41
42

43 **METHODS AND ANALYSIS**

44 **Study design**

45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
PODCAST is a prospective randomized controlled trial has been designed in accordance with
CONSORT guidelines⁴⁶ and will evaluate whether a single bolus dose of ketamine (0.5 mg/kg or
1 mg/kg) following induction of anesthesia and before surgical incision decreases the incidence
or severity of postoperative delirium and pain in a mixed elderly (>60 years) surgical patient
population. Patients will undergo the standard preoperative anesthesia assessment. Follow up

information will be collected from the medical chart for up to 5 years. The overall study design is outlined in Figure 1.




Figure 1: Study Enrollment

Eligibility criteria

1
2
3 Patients 60 years old and older, who are competent to provide informed consent and who are
4
5 undergoing major open cardiac surgery (e.g., coronary artery bypass graft, valve replacement)
6
7 or non-cardiac surgeries (e.g., thoracic surgery, major vascular surgery, intra-abdominal
8
9 surgery, open gynecologic surgery, open urologic surgery, major orthopedic surgery, hepato-
10
11 biliary surgery and major ENT surgery) receiving general anesthesia will be eligible for inclusion.
12
13 The exclusion criteria are based on the contraindications to ketamine from the 2005 ketamine
14
15 package insert. Patients with an allergy to ketamine and those in whom a significant elevation of
16
17 blood pressure would constitute a serious hazard (e.g., pheochromocytoma, aortic dissection)
18
19 will be excluded. We shall also exclude patients with drug misuse history (e.g., ketamine,
20
21 cocaine, heroin, amphetamine, methamphetamine, MDMA, phencyclidine, lysergic acid,
22
23 mescaline, psilocybin), patients taking anti-psychotic medications (e.g., chlorpromazine,
24
25 clozapine, olanzapine, risperidone, haloperidol, quetiapine, paliperidone, amisulpride,
26
27 sertindole), and patients with a weight outside the range 50 kg – 200 kg (110 lbs – 440 lbs).
28
29 Patients will be enrolled either during a preoperative clinic visit or in the hospital prior to surgery.
30
31
32
33
34
35

36 **Baseline Assessment**

37
38 At the time of enrollment, patients will undergo the same delirium and pain evaluation that will
39
40 be used postoperatively (see Outcomes section). Additionally patients will be screened for
41
42 functional dependence using the Barthel Index of Activities of Daily Living,⁴⁷ for depression
43
44 using the patient health questionnaire (PHQ-8),⁴⁸ and for obstructive sleep apnea using the
45
46 STOP-Bang criteria.⁴⁹ Patients will be asked if they have a history of delirium, and if this
47
48 presented after surgery. They will also be asked about any falls they have experienced in the six
49
50 months prior to surgery. Comorbid conditions, including the components of the Charlson
51
52 Comorbidity Index,⁵⁰ will be obtained by reviewing the patients' medical records. Any available
53
54 preoperative lab results, including electrolytes and blood counts, will also be recorded.
55
56
57
58
59
60

Interventions

As this is a pragmatic trial, apart from administration of the study drug (ketamine or normal saline), all decisions about anesthetic technique will be made by the anesthetic team assigned to each patient. The only exception is that clinicians will be instructed not to administer any ketamine other than the study drug. The intention of this trial is to interfere as little as possible with the usual process of care, which will increase the applicability of the findings.⁴³ Following induction of general anesthesia, an intravenous dose of 0.5 mg/kg ketamine, 1 mg/kg ketamine, or an equivalent volume of normal saline will be injected via a reliable (free flowing) central or peripheral intravenous line. Clinicians will be blinded to the treatment arm of the study. Anesthetic factors such as the use of nitrous oxide, protocols for pain prevention, use of neuraxial anesthesia, use of nerve blocks, and other practices that could potentially affect primary or secondary outcomes will be assessed in a *post hoc* manner.

Outcomes

Primary outcomes

Trained members of the research team who are blinded to the treatment arm of the study will assess patients for **delirium** (primary outcome) using the Confusion Assessment Method (CAM)⁵¹ and the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU)^{52,53} for patients who are unable to speak (e.g., have a tracheal tube or tracheostomy) on the intensive care unit. (Appendix A and B). These methods (the CAM and the CAM-ICU) have been shown to be reliable and to have good agreement with the DSM-IV criteria for delirium.⁵³⁻⁵⁵ Delirium assessments will be performed when patients can be aroused sufficiently in order to be assessed for delirium (Richmond Agitation and Sedation Score > -4). The first delirium assessment will be attempted if feasible on the day of surgery in the afternoon / evening. Patients will then be assessed for delirium twice daily (from postoperative day 1 to postoperative

1
2
3 day 3) in the morning and in the afternoon / evening with at least 6 hours between assessments.
4
5 Each patient will be assessed for delirium up to seven times. At the Washington University site,
6
7 the patients' family members will perform the Family Confusion Assessment Method (FAM-
8
9 CAM) separately from the investigators performing their assessments. (Appendix C)
10
11 Investigators and family members will be blinded to each other's assessments. The FAM-CAM
12
13 has demonstrated high sensitivity and specificity for detection of delirium and good agreement
14
15 with the CAM⁵⁶, but has not been specifically evaluated in the postoperative setting. After the
16
17 final delirium assessment, patients will complete the Delirium and Pain Self-Assessment
18
19 Questionnaire (Appendix D). Incident delirium subsequent to this period is unlikely to be directly
20
21 related to anesthetic or other intraoperative factors.
22
23
24
25
26
27

28 Secondary outcomes

29
30 Study team members blinded to the treatment group of the patient will assess all secondary
31
32 outcomes. **Acute pain** (secondary outcome) will be assessed prior to surgery and then
33
34 postoperatively by using the Behavioral Pain Scale (BPS)⁵⁷ or the Behavioral Pain Scale for the
35
36 Non-Intubated patient (BPS-NI)⁵⁸ and the 10-cm VAS (Visual Analog Scale) (Appendix E and F)
37
38 at the same times as patients are assessed for delirium. The BPS-NI has been shown to be a
39
40 valid and reliable tool for measuring pain in a predominantly delirious patient population.⁵⁸
41
42 Interviewers will rate the BPS or BPS-NI prior to asking the patient to complete the VAS to
43
44 prevent bias in the BPS and BPS-NI assessments. Postoperative daily amount of opioids and
45
46 sedatives administered will be ascertained from the patient's electronic health record spanning
47
48 the period after surgery until the final delirium assessment is complete. After the final delirium
49
50 assessment, patients will complete the Delirium and Pain Self-Assessment Questionnaire
51
52 (Appendix D). **Postoperative nausea and vomiting** (secondary outcome) will be assessed at
53
54 the same time points that patients are assessed for delirium by asking patients to rate the
55
56
57
58
59
60

1
2
3 severity of their nausea and vomiting, if present, on a three point scale (mild, moderate, severe).
4
5 Patients will be questioned at each assessment about side effects, especially hallucinations and
6
7 nightmares. Intensive care unit and hospital length of stay will be obtained from the patient's
8
9 medical record. At some of the participating sites in the PODCAST trial, patients will receive a
10
11 survey, which will be sent by mail or email one month following surgery. This survey will collect
12
13 patient reported outcomes (PROs) on depressive symptoms, affect, persistent pain, functionality
14
15 and quality of life. Depressive symptoms will be assessed with the eight item Patient Health
16
17 Questionnaire (PHQ-8), Affect will be assessed with two 10-item mood scales that comprise the
18
19 Positive and Negative Affect Schedule (PANAS) within three to six months postoperatively.⁵⁹
20
21 The same screens for depressive symptoms and affect will also be conducted in the hospital on
22
23 postoperative day 3. Persistent pain will be assessed with the Brief Pain Inventory Short Form
24
25 (BPI-SF). The Barthel Index will be used to report functionality and quality of life will be
26
27 assessed from the Veteran's Rand-12 (VR-12) questionnaire.
28
29
30
31
32
33

34 Standardization of training and outcomes assessment

35
36
37 All study team members who perform delirium assessments will undergo a rigorous training
38
39 process. For the initial training, representatives from each study site participated in a full-day
40
41 training program led by Dr. Sharon Inouye, the original creator of the CAM. Those who
42
43 attended this initial training will oversee the training of other team members at their sites.
44
45 Trainees must demonstrate competence at both conducting CAM interviews and in scoring
46
47 these interviews. For the initial part of training, trainees must conduct at least two satisfactory
48
49 CAM interviews in the presence of a trained team member. These interviews will not be on
50
51 patients enrolled in the PODCAST trial. To establish their ability to score CAM interviews
52
53 reliably, trainees will accompany trained team members to conduct CAM interviews. A trained
54
55 member of the research team will conduct each CAM interview for patients enrolled in the
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

PODCAST trial. The trainee will observe the interview, but will score the CAM independently.

The trainee must agree with the trainer on the presence or absence of all twelve cognitive features assessed by the CAM on a minimum of two delirious and two non-delirious patients.

After meeting the stipulations of training, the newly trained team member will conduct their first interview of a patient enrolled into the PODCAST trial in the presence of a previously trained team member.

Assessment of the standardization and reliability of delirium assessments

After training, all PODCAST team members administering delirium assessments will be invited to participate in a project to demonstrate the validity and reliability of the CAM in our study population. Participants will view and rate eight videos of standard interviews depicting delirious and non-delirious patients. Participants will independently score the CAM for each scenario.

Demographic information, level of education, level of clinical experience, and primary language will also be collected from all participants. Data will be de-identified. All scores and data will be submitted to the lead site, Washington University. The group's scores will then be compared to determine the reliability of delirium assessments across sites. Additionally, the group's scores will be compared to a set of "gold standard" scores for the videos (determined by Dr. Inouye's team) This comparison is intended to demonstrate validity of the CAM in our study setting.

Overall, the goal of the project is to demonstrate standardization of the delirium outcome across all study sites.

Sample size

Based on published delirium incidences in the scientific literature (Table 1), we estimate conservatively that the incidence of postoperative delirium in a mixed major surgical population

1
2
3 of older patients will be between 20% and 25%. Based on data from a sub-study of the BAG-
4 RECALL trial that we have recently completed, the incidence of delirium among patients
5 admitted to our cardiothoracic intensive care unit at Barnes-Jewish Hospital is 25% within three
6 postoperative days. Hudetz et al found that ketamine was associated with a 28% (95% CI, 8%
7 to 46%) absolute risk reduction in delirium (from a baseline incidence of 31%).²⁷ A 28%
8 reduction is likely to be an over-optimistic effect size for designing a pragmatic study; 10% is
9 more realistic as the most optimistic effect size and remains consistent with the confidence
10 interval for the effect size found by Hudetz et al.²⁷ Assuming a two-sided type I error rate of 5%,
11 a sample size of 600 will give greater than 80% power to detect a decrease in the incidence of
12 delirium from 25% to 15% with ketamine. On the other hand, we consider the minimum
13 clinically important difference (MCID) or effect size to be 2%, which corresponds to a number
14 needed to treat of 50 surgical patients to prevent one episode of delirium. The rationale for the
15 low MCID is that delirium is a serious postoperative complication that is associated with
16 increased mortality and the proposed intervention (low dose ketamine) is safe, inexpensive and
17 not likely to have adverse effects.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

36 There are two specific issues to clarify in this study: i) the likely effect size with ketamine; and ii)
37 the optimal ketamine dose. Ketamine might increase delirium, decrease delirium or have no
38 impact on delirium. If ketamine increases delirium, it is more likely to increase delirium at a
39 higher dose (1 mg/kg). If ketamine decreases delirium, it might have a dose response effect –
40 less delirium at the higher ketamine dose (1 mg/kg). We anticipate that ketamine will decrease
41 pain in a dose dependent manner – 1mg/kg will be superior to 0.5 mg/kg. Accrual of 200
42 patients to each dose of ketamine along with a placebo arm will allow a more robust
43 assessment of the dose-response efficacy for postoperative analgesia than previous studies
44 with fewer numbers. In general, the higher ketamine dose might have more side effects. As
45 such, this trial might inform whether the higher ketamine dose can be used, in view of its
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

possibly superior analgesia, with a potential benefit in relation to delirium and without excessive side effects. The dosage determination going forward will depend on the observed incidence of delirium with each dose, analgesia efficacy with each dose, and side effect profile with each dose. The proposed design for the study is shown in Table 2.

Group	N
Placebo	200 patients
Ketamine Low Dose (0.5 mg/kg)	200 patients
Ketamine Moderate Dose (1 mg/kg)	200 patients

Table 2: Patient Allocation.

With this approach, we believe that this study will clearly inform whether it is indicated, both in terms of efficacy and in terms of feasibility, to pursue a larger study. The purpose of the larger study (PODCAST2) will be to determine definitively whether ketamine is associated with a reduction in delirium (and pain) in high-risk older surgical patients, without incurring an increase in side effects. As the main effect evaluated will be whether ketamine decreases delirium, Table 3 provides a useful guide for the potential findings of the current study with their implications.

Delirium Incidence in Placebo Groups (N=200)	Delirium Incidence in Ketamine Groups (N=400)	Effect Size (Reduction in delirium with ketamine)	95% Confidence Interval (CI) for Effect Size
25% (N=50)	25% (N=100)	0%	-7.6% to 7.1%
<i>Implication: Consider Pursuing a larger study only if pain is decreased in ketamine groups, and there is no increase in side effects.</i>			
25% (N=50)	22.5% (N=90)	2.5%	-4.5% to 10.0%
<i>Implication: Although the point estimate is >2% (MCID), a 9,500 patient study would be required to</i>			

clarify more precisely the effectiveness of ketamine in preventing delirium. Other outcomes in the study (e.g., pain reduction and side effects) would inform the approach.			
25% (N=50)	20% (N=80)	5%	-1.9% to 12.4%
<i>Implication:</i> Pursue larger study with approximately 2,500 patients to clarify more precisely the effect of ketamine on preventing delirium.			
25% (N=50)	17.5% (N=70)	7.5%	0.7% to 14.8%
<i>Implication:</i> Pursue larger study (approximately 1,200 patients) to clarify whether effect size >2% (MCID) and to define it more precisely.			
25%	15%	10%	3.3% to 17.1%
<i>Implication:</i> For main effect, lower bound of CI >2% (MCID). Ketamine's benefit in decreasing delirium is very likely, but a larger study (approximately 1,200 patients) would define its effect more precisely.			

Table 3: Potential Findings of PODCAST.

Recruitment

This clinical trial will be conducted at Washington University in St. Louis and other sites. Our research team has conducted large randomized, controlled trials, which enrolled (approximately) 2,000 patients over 14 months in the B-unaware trial,⁶⁰ 6,000 patients over 26 months in the BAG-RECALL trial⁵⁹ and 22,000 patients over 24 months in the Michigan Awareness Control Study.⁶¹ Based on the inclusion criteria and the number of eligible surgical patients, we estimate that one year will be sufficient for patient enrollment to the proposed trial, and a further one year for data analysis.

Allocation

Subjects will be block randomized by the hospital pharmacy departments in groups of 15 (1:1:1 ratio - 0.5 mg/kg ketamine: 1 mg/kg ketamine: placebo), stratified by site, in order to keep the randomization balanced and the groups more homogeneous. The outcome of this random

1
2
3 assignment will be concealed from the study team and all study subjects and trial staff will be
4
5 blinded to the randomization. Codes will be held by the hospital pharmacies and they will
6
7 dispense medication. Randomization codes will remain concealed until the primary analysis is
8
9 completed. Prepared syringes of either placebo or ketamine will be directly delivered to the
10
11 operating room in which surgery of the consented patient will take place as soon as the
12
13 research team informs the pharmacy about the patient going to the operating room for surgery.
14
15
16
17
18
19

20 **Data analysis and management**

21
22 Data analysis for this investigation will require comparisons of patient outcomes (e.g., delirium,
23
24 pain, length of stay, adverse events) in the three study groups to assess for significant
25
26 differences among ketamine doses (placebo, 0.5 mg/kg and 1 mg/kg). For proportions and
27
28 categorical outcomes, such as incident delirium, we will use the chi square test (or Fisher's
29
30 exact test in the case of sparse data) to compare proportions across the three groups and the
31
32 Cochran-Armitage test to test for dose response trends. For continuous outcomes, such as
33
34 visual analog pain scores and opioid consumption, we will use repeated-measures analysis of
35
36 variance tests to detect the main effects. The Tukey post-hoc test will also be run on all
37
38 significant interactions to determine differences between individual and combined groups (e.g.,
39
40 placebo versus combined ketamine groups; 0.5 mg/kg ketamine versus 1 mg/kg ketamine). For
41
42 multivariate analyses, we will apply the Cox proportional-hazards model for recurrent events to
43
44 investigate the effects of low doses of intraoperative ketamine on delirium by comparing its
45
46 occurrence and timing across the study groups. We will also model the number of postoperative
47
48 delirium incidents using a Poisson hurdle regression to find out the difference in the proportion
49
50 of patients with and without delirium, and for those who experience delirium, the difference in its
51
52 recurrence. Both models (Cox proportional-hazards and hurdle model) will account for
53
54 differences in ketamine effectiveness in cardiac versus non-cardiac surgery by including
55
56
57
58
59
60

1
2
3 interaction terms for ketamine dose and cardiac surgery status, while adjusting for other
4
5 influential variables. We will also use mixed-effects regression models to assess differences
6
7 among the subgroups in continuous outcome variables over time (e.g., postoperative pain
8
9 scores and opioid consumption). These models will likewise account for interactions between
10
11 ketamine dose and cardiac surgery status. All statistical testing will be two sided, and p values
12
13 <0.05 will be regarded as significant. No interim analyses are planned. Appropriate adjustment
14
15 will be made for multiple analyses.
16
17

18
19 The Division of Biostatistics Informatics Core at Washington University will be used as a central
20
21 location for data processing and management. Washington University belongs to a consortium
22
23 of institutional partners that work to maintain a software toolset and workflow methodology for
24
25 electronic collection and management of research and clinical trial data. REDCap (Research
26
27 Electronic Data Capture) data collection projects rely on a thorough study-specific data
28
29 dictionary defined in an iterative self-documenting process by all members of the research team
30
31 with planning assistance from the Division of Biostatistics Informatics Core. The iterative
32
33 development and testing process result in a well-planned data collection strategy for individual
34
35 studies. REDCap servers are securely housed in an on-site limited access data center managed
36
37 by the Division of Biostatistics at Washington University. All web-based information transmission
38
39 is encrypted. The data is all stored on a private, firewall protected network. All users are given
40
41 individual user ids and passwords and their access is restricted on a role-specific basis.
42
43
44 REDCap was developed specifically around HIPAA-Security guidelines and is implemented and
45
46 maintained according to Washington University guidelines. REDCap currently supports >500
47
48 academic/non-profit consortium partners on six continents and 38,800 research end-users.⁶²
49
50
51
52
53

54 55 **Monitoring**

56
57
58
59
60

1
2
3 The research team will monitor the study for adverse events. All serious adverse events will be
4 reported to the IRB according to IRB stipulations. The monitoring plan for this study is
5 appropriate for the planned pragmatic trial. As an anesthetic drug, ketamine has an excellent
6 safety profile and record. In particular, low dose ketamine (0.5 mg/kg or 1 mg/kg) administered
7 prior to surgical incision is unlikely to be associated with major adverse events, and even minor
8 side effects manifesting after induction of anesthesia and the start of surgery are
9 improbable.^{37,38,63}

10
11 The PODCAST trial will have an appropriate data and safety monitoring plan for a low risk
12 clinical trial. There will be a charter to guide the functions of the Data Safety and Monitoring
13 Board (DSMB), and the DSMB will produce reports in accordance with NIH guidelines. The
14 DSMB will provide independent oversight of the PODCAST trial and will review general conduct
15 of the trial as well as study data for participant safety.⁶⁴ The DSMB will be comprised of
16 independent, multidisciplinary experts who will make recommendations regarding the
17 continuation, modification, or termination of the trial.⁶⁵ The members will have the requisite
18 expertise to examine accumulating data, to protect the integrity of the clinical experiments to
19 which the patients have consented to participate, and to assure the regulatory bodies and the
20 public (and possibly funding agencies) that conflicts of interest do not compromise either patient
21 safety or trial integrity.⁶⁶ There will be no pre-specified interim analysis given the size of this
22 study; frequent analyses might increase the likelihood of bias.⁶⁴ There will be a provision for
23 early stoppage for safety concerns, but not for efficacy or for futility.⁶⁴ Trials that stop early for
24 benefit show implausibly large treatment effects, particularly when the number of events is
25 small.⁶⁷ Truncated trials have been associated with greater effect sizes than trials not stopped
26 early, independent of the presence of statistical stopping rules.⁶⁸

1
2
3 All members of the DSMB will be at the Washington University site. Local investigators at all
4 participating sites will report serious adverse events, or unanticipated problems involving risks to
5 subjects or others, to their IRB and to the PI of the study at Washington University. If such
6 problems are considered related to the trial, then they will also be reported to IRBs at other
7 participating sites and to the chairperson of the DSMB. The members of the DSMB will have no
8 direct involvement in the conduct of the PODCAST trial. Neither will they have financial,
9 proprietary or professional conflicts of interest, which may affect the impartial, independent
10 decision-making responsibilities of the DSMB.^{64,65} Letters of invitation to prospective DSMB
11 members will include the following: "Acceptance of this invitation to serve on the PODCAST
12 DSMB confirms that I do not have any financial or other interest with any of the collaborating or
13 competing pharmaceutical firms or other organizations involved in the study that constitute a
14 potential conflict of interest." All DSMB members will sign a Conflict of Interest Certification to
15 confirm no conflict exists. There will be between three and eight people on the DSMB, in order
16 to optimize performance.⁶⁹ The DSMB will be advisory rather than executive on the basis that it
17 is the PODCAST trial investigators who are ultimately responsible for the conduct of the trial.⁶⁹
18
19 The risks associated with this study are low. There is a rare risk of breach of confidentiality. In
20 contrast to other anesthetics, protective reflexes such as coughing and swallowing are
21 maintained with low dose ketamine. The 2005 package insert for ketamine reports the induction
22 dose for anesthesia as follows: The initial dose of ketamine administered intravenously may
23 range from 1 mg/kg to 4.5 mg/kg. The average amount required to produce five to ten minutes
24 of surgical anesthesia has been 2 mg/kg. The short-term side effects of ketamine at higher
25 doses (>1-2 mg/kg) than the dosages proposed for this study (0.5 mg/kg or 1 mg/kg) include
26 tachycardia, nystagmus, hypersalivation, euphoria, emergence reactions, hallucinations and
27 nightmares.⁷⁰ It is possible, but very unlikely, that low dose ketamine (0.5 mg/kg or 1 mg/kg)
28 administered just after induction of anesthesia or administration of sedative medications will
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 cause these side effects.^{37,38,63} Emergence reactions, hallucinations and nightmares are more
4
5 common in younger patients receiving ketamine. In published studies on low dose ketamine
6
7 (0.25 to 1 mg/kg) administered during general anesthesia, side effects have generally not been
8
9 found.³⁷ The main side effects that might occur are nightmares and hallucinations. Other
10
11 neuropsychiatric side effects might occur, most likely within the first 24 hours after surgery, and
12
13 will be determined from patient interviews. The incidence of these side effects in this patient
14
15 population is currently unknown, and thus side effects will be reported separately and jointly.
16
17 Meta-analysis suggests that ketamine might be associated with an increase in neurologic and
18
19 psychiatric side effects from approximately 5% to 7.5%. This study will be >80% powered to
20
21 detect an increase in side effects from 5% to 12% and 20% powered to detect an increase in
22
23 side effects from approximately 5% to 7.5%. As part of the informed consent process for this
24
25 study, patients will be informed of the rare risks and will be asked about them after their surgery.
26
27 In the unlikely event that serious side effects occur, they will be documented and will be
28
29 reported to the human research protection office and to the study's DSMB. Participants will not
30
31 incur any study-related expenses, nor will they be financially compensated for their participation.
32
33
34
35
36
37
38

39 **Ethics and dissemination**

40 Ethics approval and consent

41
42 The PODCAST trial has been approved by the institutional review boards of the principal
43
44 investigators' home institutions (Washington University, St. Louis and University of Michigan,
45
46 Ann Arbor). Institutional review board approval has also been obtained at some of the
47
48 participating sites (Postgraduate Institute of Medical Education and Research, Chandigarh,
49
50 India; University of Manitoba, Winnipeg, Canada; Weill Medical College, Cornell University, New
51
52 York City; Medical College of Wisconsin, Milwaukee) and is ongoing at other sites. Recruitment
53
54 is anticipated to began in February of 2014 and continue through 2015. Potential participants
55
56
57
58
59
60

1
2
3 will be approached for enrollment by a member of the research team who will explain the
4 purpose of the study and written informed consent will be obtained for all participants. Patients
5 may choose not to participate in this study and there will be no penalty in terms of the care that
6 they receive.
7
8
9
10

11 Confidentiality

12
13
14
15
16
17
18 Necessary protected health information will only be shared with members of the research team.
19
20 To help protect confidentiality, research charts will be stored in a locked cabinet inside the
21 locked research office. Electronic data and demographic information will also be kept in a
22 password-protected electronic database stored on the departmental network drive and only
23 accessible via password-protected departmental computers. A member of the research team
24 will enter this information. Code numbers, rather than names, will appear on any data and
25 documents used for evaluation or statistical analyses.
26
27
28
29
30
31
32
33
34
35

36 Dissemination

37
38 Dissemination plans include presentations at local, national and international scientific
39 conferences. There are no publication restrictions and no professional writers will be involved in
40 the generation of the manuscript.
41
42
43
44
45

46 **CONCLUSIONS**

47
48 In the next four decades, the US population over the age of 60 is predicted to double to more
49 than 80 million individuals. The aging population often requires surgery, which can be
50 frequently complicated by postoperative pain and delirium. Delirium is defined as an acute brain
51 dysfunction that presents as fluctuating levels of inattention and disordered thinking, and has
52 been reported to affect up to 70% of surgical patients older than 60. Likewise, severe
53
54
55
56
57
58
59
60

1
2
3 postoperative pain continues to affect a large proportion of surgical patients, especially the
4 elderly, and is another major contributor to delirium. Unfortunately, opioid medications, the
5 current standard for analgesia, can themselves lead to delirium and other adverse
6 consequences. Clinicians therefore face the paradox that both pain and the mainstay treatment
7 of pain can lead to delirium. Although causal relationships have not been established,
8 postoperative delirium is associated with increased intensive care unit and hospital stay,
9 persistent cognitive decline, and increased mortality rate. What is needed is a therapeutic
10 intervention that can both attenuate pain and decrease the occurrence of delirium. Mounting
11 evidence suggests that the intraoperative administration of low dose (i.e., sub-anesthetic)
12 ketamine, an anesthetic drug that has been in common use for 50 years, prevents delirium,
13 lessens the severity of postoperative pain, and has an opioid-sparing effect. These multiple
14 beneficial effects have been attributed to ketamine's anti-inflammatory and anti-excitotoxic
15 actions. Despite these benefits, low-dose intraoperative ketamine currently does not enjoy
16 widespread adoption, primarily because clinicians are concerned that the psychoactive
17 properties of ketamine might compromise postoperative cognition. The PODCAST randomized
18 controlled trial intends to address a gap in the field through an international, multicenter study
19 that tests the effectiveness of ketamine in reducing both delirium and pain in surgical patients
20 older than 60.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

AUTHORS' CONTRIBUTORSHIP

Michael Avidan and George Mashour are the primary authors of the PODCAST protocol. Their contributions include drafting and editing the protocol, conceptualizing the study design, and organizing conduct across all sites. Bradley Fritz contributed to the PODCAST trial by editing the protocol, conceptualizing study design, creating the electronic database, REDCap used for data collection, and co-authoring a manual of operations for study conduct. Hannah Maybrier contributed to PODCAST by editing the protocol, co-authoring the manual of operations, recruiting patients for enrollment, collecting data, and coordinating the study across all sites. Maxwell Muench contributed to PODCAST by co-authoring a manual of operations, recruiting patients for enrollment, and collecting data. Krisztina Escallier contributed to PODCAST by editing the protocol, conceptualizing study design, and co-authoring a manual of operations. Yulong Chen contributed to PODCAST by editing the protocol and conceptualizing study design. Arbi Ben Abdallah contributed to PODCAST by editing the protocol and conceptualizing study design, including the statistical modelling of the study. Sharon Inouye contributed to PODCAST by training investigators to perform delirium assessments and conceptualizing study design. Stephen Choi, Robert Downey, Hilary Grocott, Gyujeong Noh, Judith Hudetz, Eric Jacobsohn, Heiko Kaiser, Paul Pagel, Kane Pryor, Ryan Pong, Robert Veselis, and Virendra Kumar Arya contributed to PODCAST by editing the study protocol, conceptualizing study design, recruiting participants, and collecting data.

All authors including Avidan, Mashour, Fritz, Maybrier, Muench, Escallier, Chen, Ben Abdallah, Inouye, Veselis, Grocott, Hudetz, Pryor, Pagel, Arya, Pong, Jacobsohn, Gyujeong, Kaiser, Downey, and Choi have critically revised the PODCAST protocol and approved the final version.

All authors agree to be accountable for the accuracy and integrity of all aspects of the PODCAST trial.

ACKNOWLEDGMENTS

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

PODCAST research group: A Alexander, R Arora, J Bang, M Bottros, A Cai, BM Choi, IC Choi, ME Davis, R Downey, D Emmert, M Engoren, SD Gandhi, L Girling, N Hanson, Z Iqbal, A Jayant, E Lenze, M Maile, ER Marcantonio, J McVagh, J Neal, S Oskar, KM Patterson, E Rogers, E Schmitt, B Tellor, T Wildes, A Villafranca, H Yulico

FUNDING

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

COMPETING INTERESTS

None of the authors have conflicts of interest to disclose.

Z'

REFERENCES:

1. Whitlock EL, Vannucci A, Avidan MS. Postoperative delirium. *Minerva Anestesiol* 2011;77:448-56.
2. Leslie DL, Marcantonio ER, Zhang Y, Leo-Summers L, Inouye SK. One-year health care costs associated with delirium in the elderly population. *Arch Intern Med* 2008;168:27-32.
3. Gottesman RF, Grega MA, Bailey MM, et al. Delirium after coronary artery bypass graft surgery and late mortality. *Ann Neurol* 2010;67:338-44.
4. Koster S, Hensens AG, Schuurmans MJ, van der Palen J. Consequences of Delirium After Cardiac Operations. *Ann Thorac Surg* 2011.
5. Kat MG, Vreeswijk R, de Jonghe JF, et al. Long-term cognitive outcome of delirium in elderly hip surgery patients. A prospective matched controlled study over two and a half years. *Dement Geriatr Cogn Disord* 2008;26:1-8.
6. Bickel H, Gradinger R, Kochs E, Forstl H. High risk of cognitive and functional decline after postoperative delirium. A three-year prospective study. *Dement Geriatr Cogn Disord* 2008;26:26-31.
7. Radtke FM, Franck M, Lorenz M, et al. Remifentanyl reduces the incidence of post-operative delirium. *The Journal of international medical research* 2010;38:1225-32.
8. Pandharipande P, Cotton BA, Shintani A, et al. Prevalence and risk factors for development of delirium in surgical and trauma intensive care unit patients. *The Journal of trauma* 2008;65:34-41.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
9. Weed HG, Lutman CV, Young DC, Schuller DE. Preoperative identification of patients at risk for delirium after major head and neck cancer surgery. *The Laryngoscope* 1995;105:1066-8.
10. Kazmierski J, Kowman M, Banach M, et al. Incidence and predictors of delirium after cardiac surgery: Results from The IPDACS Study. *J Psychosom Res* 2010;69:179-85.
11. Rudolph JL, Inouye SK, Jones RN, et al. Delirium: an independent predictor of functional decline after cardiac surgery. *J Am Geriatr Soc* 2010;58:643-9.
12. Saczynski JS, Marcantonio ER, Quach L, et al. Cognitive trajectories after postoperative delirium. *N Engl J Med* 2012;367:30-9.
13. Marcantonio ER, Goldman L, Mangione CM, et al. A clinical prediction rule for delirium after elective noncardiac surgery. *JAMA* 1994;271:134-9.
14. Schneider F, Bohner H, Habel U, et al. Risk factors for postoperative delirium in vascular surgery. *Gen Hosp Psychiatry* 2002;24:28-34.
15. Bohner H, Hummel TC, Habel U, et al. Predicting delirium after vascular surgery: a model based on pre- and intraoperative data. *Ann Surg* 2003;238:149-56.
16. Benoit AG, Campbell BI, Tanner JR, et al. Risk factors and prevalence of perioperative cognitive dysfunction in abdominal aneurysm patients. *J Vasc Surg* 2005;42:884-90.
17. Fisher BW, Flowerdew G. A simple model for predicting postoperative delirium in older patients undergoing elective orthopedic surgery. *J Am Geriatr Soc* 1995;43:175-8.
18. Marcantonio ER, Flacker JM, Michaels M, Resnick NM. Delirium is independently associated with poor functional recovery after hip fracture. *J Am Geriatr Soc* 2000;48:618-24.
19. Lee KH, Ha YC, Lee YK, Kang H, Koo KH. Frequency, risk factors, and prognosis of prolonged delirium in elderly patients after hip fracture surgery. *Clin Orthop Relat Res* 2011;469:2612-20.
20. Inouye SK. Delirium in older persons. *N Engl J Med* 2006;354:1157-65.
21. Hudetz JA, Pagel PS. Neuroprotection by ketamine: a review of the experimental and clinical evidence. *J Cardiothorac Vasc Anesth* 2010;24:131-42.
22. Wang L, Jing W, Hang YN. Glutamate-induced c-Jun expression in neuronal PC12 cells: the effects of ketamine and propofol. *J Neurosurg Anesthesiol* 2008;20:124-30.
23. Chen X, Shu S, Bayliss DA. HCN1 channel subunits are a molecular substrate for hypnotic actions of ketamine. *J of Neurosci* 2009;29:600-9.
24. Lewis AS, Chetkovich DM. HCN channels in behavior and neurological disease: too hyper or not active enough? *Mol cell neurosci* 2011;46:357-67.
25. Cho HJ, Staikopoulos V, Furness JB, Jennings EA. Inflammation-induced increase in hyperpolarization-activated, cyclic nucleotide-gated channel protein in trigeminal ganglion neurons and the effect of buprenorphine. *Neuroscience* 2009;162:453-61.
26. Emery EC, Young GT, Berrocso EM, Chen L, McNaughton PA. HCN2 ion channels play a central role in inflammatory and neuropathic pain. *Science* 2011;333:1462-6.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
27. Hudetz JA, Patterson KM, Iqbal Z, et al. Ketamine attenuates delirium after cardiac surgery with cardiopulmonary bypass. *J Cardiothorac Vasc Anesth* 2009;23:651-7.
28. Hudetz JA, Iqbal Z, Gandhi SD, et al. Ketamine attenuates post-operative cognitive dysfunction after cardiac surgery. *Acta Anaesthesiol Scand* 2009;53:864-72.
29. Bartoc C, Frumento RJ, Jalbout M, Bennett-Guerrero E, Du E, Nishanian E. A randomized, double-blind, placebo-controlled study assessing the anti-inflammatory effects of ketamine in cardiac surgical patients. *J Cardiothorac Vasc Anesth* 2006;20:217-22.
30. Fine J, Finestone SC. Sensory disturbances following ketamine anesthesia: recurrent hallucinations. *Anesth Analg* 1973;52:428-30.
31. Lilburn JK, Dundee JW, Nair SG, Fee JP, Johnston HM. Ketamine sequelae. Evaluation of the ability of various premedicants to attenuate its psychic actions. *Anaesthesia* 1978;33:307-11.
32. Phillips DM. JCAHO pain management standards are unveiled. Joint Commission on Accreditation of Healthcare Organizations. *JAMA* 2000;284:428-9.
33. Brennan F, Carr DB, Cousins M. Pain management: a fundamental human right. *Anesth Analg* 2007;105:205-21.
34. Cousins MJ, Lynch ME. The Declaration Montreal: access to pain management is a fundamental human right. *Pain* 2011;152:2673-4.
35. Dolin SJ, Cashman JN, Bland JM. Effectiveness of acute postoperative pain management: I. Evidence from published data. *Br J Anaesth* 2002;89:409-23.
36. Macrae WA. Chronic post-surgical pain: 10 years on. *Br J Anaesth* 2008;101:77-86.
37. Elia N, Tramer MR. Ketamine and postoperative pain--a quantitative systematic review of randomised trials. *Pain* 2005;113:61-70.
38. Bell RF, Dahl JB, Moore RA, Kalso E. Perioperative ketamine for acute postoperative pain. Cochrane database of systematic reviews 2006:CD004603.
39. Laskowski K, Stirling A, McKay WP, Lim HJ. A systematic review of intravenous ketamine for postoperative analgesia. *Can J Anaesth* 2011;58:911-23.
40. Chan MT, Wan AC, Gin T, Leslie K, Myles PS. Chronic postsurgical pain after nitrous oxide anesthesia. *Pain* 2011;152:2514-20.
41. Remerand F, Le Tendre C, Baud A, et al. The early and delayed analgesic effects of ketamine after total hip arthroplasty: a prospective, randomized, controlled, double-blind study. *Anesth Analg* 2009;109:1963-71.
42. Zwarenstein M, Treweek S, Gagnier JJ, et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. *Bmj* 2008;337:a2390.
43. Treweek S, Zwarenstein M. Making trials matter: pragmatic and explanatory trials and the problem of applicability. *Trials* 2009;10:37.
44. Practice guidelines for acute pain management in the perioperative setting: an updated report by the American Society of Anesthesiologists Task Force on Acute Pain Management. *Anesthesiology* 2012;116:248-73.
45. Practice guidelines for chronic pain management: an updated report by the American Society of Anesthesiologists Task Force on Chronic Pain Management

- 1
2
3 and the American Society of Regional Anesthesia and Pain Medicine.
4 *Anesthesiology* 2010;112:810-33.
5
6 46. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 Explanation and
7 Elaboration: Updated guidelines for reporting parallel group randomised trials. *J*
8 *Clin Epidemiol* 2010;63:e1-37.
9
10 47. Wade DT, Collin C. The Barthel ADL Index: a standard measure of physical
11 disability? *Int Disabil Stud* 1988;10:64-7.
12
13 48. Kocalevent RD, Hinz A, Brahler E. Standardization of the depression screener
14 patient health questionnaire (PHQ-9) in the general population. *Gen Hosp*
15 *Psychiatry* 2013;35:551-5.
16
17 49. Chung F, Yegneswaran B, Liao P, et al. STOP questionnaire: a tool to screen
18 patients for obstructive sleep apnea. *Anesthesiology* 2008;108:812-21.
19
20 50. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying
21 prognostic comorbidity in longitudinal studies: development and validation. *J*
22 *Chronic Dis* 1987;40:373-83.
23
24 51. Inouye SK, van Dyck CH, Alessi CA, Balkin S, Siegel AP, Horwitz RI. Clarifying
25 confusion: the confusion assessment method. A new method for detection of
26 delirium. *Ann Intern Med* 1990;113:941-8.
27
28 52. Ely EW, Inouye SK, Bernard GR, et al. Delirium in mechanically ventilated
29 patients: validity and reliability of the confusion assessment method for the
30 intensive care unit (CAM-ICU). *JAMA* 2001;286:2703-10.
31
32 53. Ely EW, Margolin R, Francis J, et al. Evaluation of delirium in critically ill patients:
33 validation of the Confusion Assessment Method for the Intensive Care Unit
34 (CAM-ICU). *Crit Care Med* 2001;29:1370-9.
35
36 54. Luetz A, Heymann A, Radtke FM, et al. Different assessment tools for intensive
37 care unit delirium: which score to use? *Crit Care Med* 2010;38:409-18.
38
39 55. Plaschke K, von Haken R, Scholz M, et al. Comparison of the confusion
40 assessment method for the intensive care unit (CAM-ICU) with the Intensive
41 Care Delirium Screening Checklist (ICDSC) for delirium in critical care patients
42 gives high agreement rate(s). *Intensive Care Med* 2008;34:431-6.
43
44 56. Steis MR, Evans L, Hirschman KB, et al. Screening for delirium using family
45 caregivers: convergent validity of the Family Confusion Assessment Method and
46 interviewer-rated Confusion Assessment Method. *J Am Geriatr Soc*
47 2012;60:2121-6.
48
49 57. Payen JF, Bru O, Bosson JL, et al. Assessing pain in critically ill sedated patients
50 by using a behavioral pain scale. *Crit Care Med* 2001;29:2258-63.
51
52 58. Chanques G, Payen JF, Mercier G, et al. Assessing pain in non-intubated
53 critically ill patients unable to self report: an adaptation of the Behavioral Pain
54 Scale. *Intensive Care Med* 2009;35:2060-7.
55
56 59. Avidan MS, Jacobsohn E, Glick D, et al. Prevention of intraoperative awareness
57 in a high-risk surgical population. *N Engl J Med* 2011;365:591-600.
58
59 60. Avidan MS, Zhang L, Burnside BA, et al. Anesthesia awareness and the
60 bispectral index. *N Engl J Med* 2008;358:1097-108.
61. Mashour GA, Shanks A, Tremper KK, et al. Prevention of intraoperative
awareness with explicit recall in an unselected surgical population: a randomized
comparative effectiveness trial. *Anesthesiology* 2012;117:717-25.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
62. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform* 2009;42:377-81.
63. Neshar N, Serovian I, Marouani N, Chazan S, Weinbroum AA. Ketamine spares morphine consumption after transthoracic lung and heart surgery without adverse hemodynamic effects. *Pharmacol Res* 2008;58:38-44.
64. Tharmanathan P, Calvert M, Hampton J, Freemantle N. The use of interim data and Data Monitoring Committee recommendations in randomized controlled trial reports: frequency, implications and potential sources of bias. *BMC Med Res Methodol* 2008;8:12.
65. Fleming TR, DeMets DL. Monitoring of clinical trials: issues and recommendations. *Control Clin Trials* 1993;14:183-97.
66. Smith MA, Ungerleider RS, Korn EL, Rubinstein L, Simon R. Role of independent data-monitoring committees in randomized clinical trials sponsored by the National Cancer Institute. *J Clin Oncol* 1997;15:2736-43.
67. Montori VM, Devereaux PJ, Adhikari NK, et al. Randomized trials stopped early for benefit: a systematic review. *JAMA* 2005;294:2203-9.
68. Bassler D, Briel M, Montori VM, et al. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. *JAMA* 2010;303:1180-7.
69. Grant AM, Altman DG, Babiker AB, et al. Issues in data monitoring and interim analysis of trials. *Health Technol Assess* 2005;9:1-238, iii-iv.
70. Strayer RJ, Nelson LS. Adverse events associated with ketamine for procedural sedation in adults. *Am J Emerg Med* 2008;26:985-1028.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Appendix A – Confusion Assessment Method

CONFUSION ASSESSMENT METHOD (CAM) SHORTENED VERSION WORKSHEET

EVALUATOR:

DATE:

I. ACUTE ONSET AND FLUCTUATING COURSE

BOX 1

a) Is there evidence of an acute change in mental status from the patient's baseline?

No _____

Yes _____

b) Did the (abnormal) behavior fluctuate during the day, that is tend to come and go or increase and decrease in severity?

No _____

Yes _____

II. INATTENTION

Did the patient have difficulty focusing attention, for example, being easily distractible or having difficulty keeping track of what was being said?

No _____

Yes _____

III. DISORGANIZED THINKING

Was the patient's thinking disorganized or incoherent, such as rambling or irrelevant conversation, unclear or illogical flow of ideas, or unpredictable switching from subject to subject?

No _____

Yes _____

BOX 2

IV. ALTERED LEVEL OF CONSCIOUSNESS

Overall, how would you rate the patient's level of consciousness?

-- Alert (normal)

- Vigilant (hyperalert)
- Lethargic (drowsy, easily aroused)
- Stupor (difficult to arouse)
- Coma (unarousable)

Do any checks appear in this box?

No _____

Yes _____

If all items in Box 1 are checked and at least one item in Box 2 is checked a diagnosis of delirium is suggested.

Adapted from Inouye SK et al, Clarifying Confusion: The Confusion Assessment Method. A New Method for Detection of Delirium. *Ann Intern Med.* 1990; 113:941-8.

only

Appendix B – Confusion Assessment Method for the Intensive Care Unit

CAM-ICU Worksheet

Feature 1: Acute Onset or Fluctuating Course	Score	Check here if Present
Is the pt different than his/her baseline mental status? OR Has the patient had any fluctuation in mental status in the past 24 hours as evidenced by fluctuation on a sedation scale (i.e., RASS), GCS, or previous delirium assessment?	Either question Yes →	<input type="checkbox"/>
Feature 2: Inattention		
Letters Attention Test (See training manual for alternate Pictures) <i>Directions:</i> Say to the patient, "I am going to read you a series of 10 letters. Whenever you hear the letter 'A,' indicate by squeezing my hand." Read letters from the following letter list in a normal tone 3 seconds apart. S A V E A H A A R T Errors are counted when patient fails to squeeze on the letter "A" and when the patient squeezes on any letter other than "A."	Number of Errors >2 →	<input type="checkbox"/>
Feature 3: Altered Level of Consciousness		
Present if the Actual RASS score is anything other than alert and calm (zero)	RASS anything other than zero →	<input type="checkbox"/>
Feature 4: Disorganized Thinking		
Yes/No Questions (See training manual for alternate set of questions) 1. Will a stone float on water? 2. Are there fish in the sea? 3. Does one pound weigh more than two pounds? 4. Can you use a hammer to pound a nail? Errors are counted when the patient incorrectly answers a question. Command Say to patient: "Hold up this many fingers" (Hold 2 fingers in front of patient) "Now do the same thing with the other hand" (Do not repeat number of fingers) *If pt is unable to move both arms, for 2 nd part of command ask patient to "Add one more finger" An error is counted if patient is unable to complete the entire command.	Combined number of errors >1 →	<input type="checkbox"/>
Overall CAM-ICU	Criteria Met →	<input type="checkbox"/> CAM-ICU Positive (Delirium Present)
Feature 1 plus 2 and either 3 or 4 present = CAM-ICU positive	Criteria Not Met →	<input type="checkbox"/> CAM-ICU Negative (No Delirium)

Copyright © 2002, E. Wesley Ely, MD, MPH and Vanderbilt University, all rights reserved

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Appendix C – Family Confusion Assessment Method

Scoring the FAM-CAM

It is important to remember that the FAM-CAM is intended only to assist with screening and is not intended to provide a clinical diagnosis. If a positive score is suggested on the FAM-CAM, further evaluation with cognitive testing of the patient is necessary.

The FAM-CAM is considered positive if the following features are present: a) acute onset or fluctuating course **and** b) inattention **and** c) either disorganized thinking or altered consciousness. Several of the questions may help to identify whether these features are present, as outlined below.

Feature	Question #	Positive Answer
Acute Onset -OR- Fluctuation	Question 1,10	Yes, <4 weeks ago
	Question 9	"Come and go"
-AND-		
Inattention	Question 2	Yes
-AND EITHER-		
Disorganized Thinking -OR- Altered Consciousness	Question 3,5,6 (7 supportive)	Yes
	Question 4	Yes

Scoring Algorithm: Check the box if the respondent's answer is as indicated.
Delirium is suggested if there is **at least one check in each of the 3 columns.**

Question	Column 1 Acute Onset or Fluctuation	Column 2 Inattention	Column 3 Disorganized Thinking or Altered Level of Consciousness
Question 1 = yes? (Any Change)	<input type="checkbox"/>		
Question 2 = yes? (Inattention)		<input type="checkbox"/>	
Question 3 = yes? (Disorganized Speech)			<input type="checkbox"/>
Question 4 = yes? (Excess Drowsiness)			<input type="checkbox"/>
Question 5 = yes? (Disorientation)			<input type="checkbox"/>
Question 6 = yes? (Perceptual Disturbance)			<input type="checkbox"/>
Question 9 = "come and go"? (Fluctuation)	<input type="checkbox"/>		
Question 10 = <4 weeks? (Acute Onset)	<input type="checkbox"/>		

Delirium is suggested if there is **at least one check in each of the 3 columns.**

Delirium Suggested? _____ yes _____ no














Appendix E - Behavioral Pain Scale and Behavioral Pain Scale for the Non-Intubated Patient

Behavioral Pain Scale (BPS and BPS-NI) Scoring System

1 + 2 + 3 = Total BPS Value; from 3(no) - 12(max) pain behavior rated

BPS (Intubated / Non-verbal)

BPS-NI (Non-intubated and verbal)

	1	2	3	4		1	2	3	4
1					=				
	Relaxed	Partially tightened = brow lowering	Fully tightened = eyelids closed	Grimacing = folded cheek		Relaxed	Partially tightened = brow lowering	Fully tightened = eyelids closed	Grimacing = folded cheek
2					=				
	No movement (At rest: mobilize limb to check tone)	Partially bent	Very bent; finger flexion	Retracted; opposition to care		No movement (At rest: mobilize limb to check tone)	Partially bent	Very bent; finger flexion	Retracted; opposition to care
3					≠				
	Tolerating ventilation	Coughing, but mostly tolerating ventilation	Fighting, but ventilation possible	Unable to control ventilation		No pain vocalization	Moaning not frequent (≤3/min) and not prolonged (≤3s)	Moaning frequent (>3/min) or prolonged (>3s)	Howling or verbal complaint "Ow!," "Ouch!," or breath-holding

Appendix D - Delirium and Pain Self-Assessment Questionnaire:

(Following the final delirium assessment, the following questionnaire will be given to patients):

A. Following your surgery, were there any periods that you felt you could not pay attention to people or things?

Yes

No

B. If yes, can you say when:

Today: morning

afternoon

Yesterday: morning

afternoon

Day before yesterday: morning

afternoon

C. Following your surgery, were there any period that you felt you were not thinking in a logical or organized way?

D. If yes, can you say when:

Today: morning

afternoon

Yesterday: morning

afternoon

Day before yesterday: morning

afternoon

E. Did these feelings negatively affect your experience after the surgery?

Yes

No

F. Following your surgery, were there any periods when your pain was uncontrolled?

Yes

No

1
2
3
4
5
6 G. If yes, can you say when:

7 Today: morning afternoon

8 Yesterday: morning afternoon

9 Day before yesterday: morning afternoon

10
11
12
13
14
15
16 H. Did any family members tell you that there were periods following your surgery that you felt
17 you could not pay attention to people or things?

18
19
20 Yes No

21
22
23
24
25 I. Did any of your family members tell you that there were periods following your surgery when
26 you were not thinking in a logical or organized way?

27
28 Yes No

29
30
31
32
33 J. Following your surgery, did you have bad dreams nightmares?

34
35 Yes No

36
37
38 K. If yes, can you say when:

39 Today: morning afternoon

40 Yesterday: morning afternoon

41 Day before yesterday: morning afternoon

42
43
44
45
46
47 L. Following your surgery, did you have hallucinations (you saw things or heard things or felt
48 things that were not there)?

49
50 Yes No

51
52
53
54 M. If yes, can you say when:

55 Today:

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Today:	morning	afternoon
Yesterday:	morning	afternoon
Day before yesterday:	morning	afternoon

For peer review only

1
2
3 For questions 1 to 3, the patient should use a pen to mark the VAS scale. The patient
4
5 should be shown their previous responses to use as a reference.
6
7
8
9

10 1. What is your pain at **rest**?

11
12 no pain _____ worst pain
13 imaginable
14
15
16
17
18
19

20 2. What is your pain when taking a **deep breath** (or coughing)?

21
22 no pain _____ worst pain
23 imaginable
24
25
26
27
28
29

30 3. What is your pain when **moving** (sitting up, walking, or moving extremities)?

31
32
33 no pain _____ worst pain
34 imaginable
35
36
37
38
39
40

41 4. If you have pain at rest or with movement, please indicate **where** (check all that apply)

42
43 Head/neck

44
45 Chest

46
47 Abdomen

48
49 Upper back

50
51 Lower back

52
53 Arms
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Legs

5. Do you currently have **nausea and/or vomiting**?

None Mild Moderate Severe

6. Are you currently experiencing **anxiety**?

None Mild Moderate Severe

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	_____1_____
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	_____1_____
	2b	All items from the World Health Organization Trial Registration Data Set	_____4_____
Protocol version	3	Date and version identifier	_____1_____
Funding	4	Sources and types of financial, material, and other support	_____4_____
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	_____1_____
	5b	Name and contact information for the trial sponsor	_____1-3_____
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	_____n/a_____
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	_____7_____

1
2
3 **Introduction**
4

5 Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	14
	6b	Explanation for choice of comparators	21
10 Objectives	7	Specific objectives or hypotheses	19
12 Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	21

15
16 **Methods: Participants, interventions, and outcomes**
17

18 Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	30, 5
21 Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	23
24 Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	24
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	33
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	n/a
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	24
35 Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	24-26
41 Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	22

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	_____28_____
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	_____30_____

Methods: Assignment of interventions (for controlled trials)

Allocation:

Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	_____31_____
Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	_____31_____
Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	_____31_____
Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	_____24-25_____
	17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	_____31_____

Methods: Data collection, management, and analysis

Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	_____24-26_____
	18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	_____n/a_____

1				
2				
3	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	_____ 32 _____
4				
5				
6				
7	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	_____ 31 _____
8				
9				
10		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	_____ 32 _____
11				
12		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	_____ n/a _____
13				
14				
15				
16	Methods: Monitoring			
17				
18	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	_____ 34 _____
19				
20				
21				
22				
23		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	_____ 33 _____
24				
25				
26	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	_____ 33 _____
27				
28				
29	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	_____ 34 _____
30				
31				
32				
33	Ethics and dissemination			
34				
35	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	_____ 35 _____
36				
37				
38	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	_____ n/a _____
39				
40				
41				
42				
43				
44				
45				
46				
47				
48				
49				

1				
2				
3	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	_____36_____
4				
5				
6		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	_____n/a_____
7				
8				
9	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	_____36_____
10				
11				
12	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	_____44_____
13				
14				
15	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	_____32_____
16				
17				
18	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	_____35_____
19				
20				
21	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	_____36_____
22				
23				
24				
25				
26		31b	Authorship eligibility guidelines and any intended use of professional writers	_____36_____
27				
28		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	_____36_____
29				
30	Appendices			
31				
32	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	_____separate file_____
33				
34				
35	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	_____n/a_____
36				
37				

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.

BMJ Open

The Prevention of Delirium and Complications Associated with Surgical Treatments (PODCAST) study: Protocol for an International Multicenter Randomized Controlled Trial

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-005651.R1
Article Type:	Protocol
Date Submitted by the Author:	06-Aug-2014
Complete List of Authors:	Avidan, Michael; Washington University School of Medicine in St. Louis, Anesthesiology Fritz, Bradley; Washington University School of Medicine in St. Louis, Anesthesiology Maybrier, Hannah; Washington University School of Medicine in St. Louis, Anesthesiology Muench, Maxwell; Washington University School of Medicine in St. Louis, Anesthesiology Escallier, Krisztina; Washington University School of Medicine in St. Louis, Anesthesiology Chen, Yulong; Washington University School of Medicine in St. Louis, Anesthesiology Ben Abdallah, Arbi; Washington University School of Medicine in St. Louis, Anesthesiology Veselis, Robert; Memorial Sloan-Kettering Cancer Center, Anesthesiology Hudetz, Judith; Medical College of Wisconsin, Anesthesiology Pagel, P; Clement J. Zablocki VA Medical Center, Noh, Gyujeong; Asan Medical Center, Anesthesiology Pryor, Kane; Weill Cornell Medical College, Anesthesiology Kaiser, Heiko; University of Bern, Anesthesiology Arya, Virendra; Postgraduate Institute of Medical Education and Research, Anesthesiology Pong, Ryan; Virginia Mason Medical Center, Anesthesiology Jacobsohn, Eric; University of Manitoba-Faculty of Medicine, Anesthesiology Grocott, Hilary; University of Manitoba-Faculty of Medicine, Anesthesiology Choi, Stephen; Sunnybrook Health Sciences Center, Anesthesiology Downey, Robert; Memorial Sloan-Kettering Cancer Center, Surgery, Thoracic Inouye, Sharon; Hebrew Rehab Center for the Aged, Medicine- Beth Israel-Deaconess Mashour, George; University of Michigan Medical School, Anesthesiology
Primary Subject Heading:	Anaesthesia
Secondary Subject Heading:	Geriatric medicine, Surgery, Neurology
Keywords:	Pain management < ANAESTHETICS, Adult anaesthesia < ANAESTHETICS, Adult intensive & critical care < ANAESTHETICS, Delirium & cognitive disorders < PSYCHIATRY, Adult surgery < SURGERY

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



SCHOLARONE™
Manuscripts

For peer review only

1
2
3 **The Prevention of Delirium and Complications Associated with Surgical Treatments**
4
5 **(PODCAST) Study: Protocol for an International Multicenter Randomized Controlled Trial**
6
7

8
9
10 **Trial Registration:** NCT01690988 (last updated December, 2013)
11

12 **Version date: August 5, 2014**
13

14 **Corresponding author:** Michael S. Avidan
15 Campus Box 8054
16 660 S. Euclid Ave
17 Department of Anesthesiology
18 Washington University School of Medicine
19 St. Louis, MO 63110
20 United States
21 avidanm@anest.wustl.edu
22
23

24 **Co-authors:** Bradley A. Fritz
25 Department of Anesthesiology
26 Washington University School of Medicine
27 St. Louis, Missouri, United States
28

29
30 Hannah R. Maybrier
31 Department of Anesthesiology
32 Washington University School of Medicine
33 St. Louis, Missouri, United States
34

35 Maxwell R. Muench
36 Department of Anesthesiology
37 Washington University School of Medicine
38 St. Louis, Missouri, United States
39

40 Krisztina E. Escallier
41 Department of Anesthesiology
42 Washington University School of Medicine
43 St. Louis, Missouri, United States
44

45 Yulong Chen
46 Department of Anesthesiology
47 Washington University School of Medicine
48 St. Louis, Missouri, United States
49

50 Arbi Ben Abdallah
51 Department of Anesthesiology
52 Washington University School of Medicine
53 St. Louis, Missouri, United States
54

55 Robert A. Veselis
56
57
58
59
60

1
2
3 Department of Anesthesiology
4 Memorial Sloan-Kettering Cancer Center
5 New York, New York, United States
6

7
8 Judith A. Hudetz
9 Department of Anesthesiology
10 Medical College of Wisconsin
11 Milwaukee, Wisconsin, United States
12

13 P Pagel
14 Clement J. Zablocki VA Medical Center
15 Medical College of Wisconsin
16 Milwaukee, Wisconsin, United States
17

18 Gyujeong Noh
19 Department of Anesthesiology
20 Asan Medical Center
21 Seoul, South Korea
22

23 Kane Pryor
24 Department of Anesthesiology
25 Weill Cornell Medical College
26 New York, New York, United States
27

28 Heiko Kaiser
29 Department of Anesthesiology
30 University of Bern
31 Bern, Switzerland
32

33 Virendra Kumar Arya
34 Department of Anesthesiology
35 Postgraduate Institute of Medical Education and Research
36 Chandigarh, India
37

38 Ryan Pong
39 Department of Anesthesiology
40 Virginia Mason Medical Center
41 Seattle, Washington, United States
42

43 Eric Jacobsohn
44 Department of Anesthesiology
45 University of Manitoba-Faculty of Medicine
46 Winnipeg, Manitoba, Canada
47

48 Hilary Grocott
49 Department of Anesthesiology
50 University of Manitoba-Faculty of Medicine
51 Winnipeg, Manitoba, Canada
52

53 Stephen Choi
54 Department of Anesthesiology
55
56
57
58
59
60

1
2
3 Sunnybrook Health Sciences Center
4 Toronto, Ontario, Canada
5

6 Robert J. Downey
7 Department of Surgery, Thoracic
8 Memorial Sloan-Kettering Cancer Center
9 New York, New York, United States
10

11 Sharon K. Inouye
12 Department of Medicine – Beth Israel-Deaconess
13 Hebrew Rehab Center for the Aged
14 Boston, Massachusetts, United States
15

16 George A. Mashour
17 Department of Anesthesiology
18 University of Michigan Medical School
19 Ann Arbor, Michigan, United States
20
21

22
23
24 **Keywords:** ketamine, delirium, postoperative delirium, neurological complications,
25
26 postoperative pain, surgery, general anesthetics, neurobehavioral manifestations, geriatric
27
28 syndrome
29

30
31
32 **Word Count:** 7,444
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

ABSTRACT

Introduction: Postoperative delirium is one of the most common complications of major surgery, affecting 10-70% of surgical patients 60 years and older. Delirium is an acute change in cognition that manifests as poor attention and illogical thinking, and is associated with longer ICU and hospital stay, long-lasting cognitive deterioration, and increased mortality. Ketamine has been used as an anesthetic drug for over 50 years and has an established safety record. Recent research suggests that, in addition to preventing acute postoperative pain, a sub-anesthetic dose of intraoperative ketamine could decrease the incidence of postoperative delirium as well as other neurologic and psychiatric outcomes. However, these proposed benefits of ketamine have not been tested in a large clinical trial.

Methods: The PODCAST study is an international, multicenter, randomized controlled trial. Six hundred cardiac and major non-cardiac surgery patients will be randomized to receive ketamine (0.5 mg/kg or 1 mg/kg) or placebo following anesthetic induction and prior to surgical incision. For the primary outcome, blinded observers will assess delirium on the day of surgery (postoperative day 0) and twice daily from postoperative days 1 to 3 using the Confusion Assessment Method or the Confusion Assessment Method for the ICU. For the secondary outcomes, blinded observers will estimate pain using the Behavioral Pain Scale or the Behavioral Pain Scale for Non-Intubated Patients and patient self-report.

Ethics and dissemination: The PODCAST trial has been approved by the ethics boards of five participating institutions; approval is ongoing at other sites. Recruitment began in February 2014 and will continue through 2016. Dissemination plans include

1
2
3 presentations at scientific conferences, scientific publications, stakeholder engagement
4
5 and popular media.
6

7
8 Registration details: The study is registered at clinicaltrials.gov, NCT01690988 (last
9
10 updated December, 2013).

11
12 The PODCAST trial is being conducted under the auspices of the Neurological
13
14 Outcomes Network for Surgery (NEURONS).
15
16

17 18 19 20 **STRENGTHS:**

- 21
22 • The effects of ketamine are being observed in the routine clinical setting.
- 23
24 • Because PODCAST is a multicenter international trial, the results of the study will
25
26 potentially be generalizable.
- 27
28 • This trial has a novel focus of assessing delirium and pain concurrently. Results
29
30 could reveal that these two outcomes are potentially linked in the postoperative
31
32 setting.
33
34
- 35
36 • PODCAST is a randomized, controlled double-blinded study.
- 37
38 • Investigators assessing for delirium have been appropriately trained and
39
40 will use reliable and validated assessment tools.
41
42
43
44
45

46 47 **LIMITATIONS:**

- 48
49 • Pain is a subjective experience and is therefore difficult to measure.
- 50
51 • The Visual Analog Scale (VAS) is not a validated pain assessment instrument in
52
53 delirious patients. In an attempt to mitigate this limitation, pain will also be assessed
54
55
56
57
58
59
60

1
2
3 observationally using the Behavioral Pain Scale (BPS) and the Behavioral Pain
4
5 Scale – Non-intubated (BPS-NI).
6
7

- 8 • Delirium is fluctuating in nature. Because patients will be assessed at discrete time
9
10 points, it is possible that some episodes of delirium will not be detected.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Background and rationale

Delirium

Postoperative delirium is one of the most common complications of major surgery and affects between 10% and 70% of all surgical patients older than 60 years (Table 1).¹ The estimated additional healthcare costs associated with delirium exceed \$60,000 per patient per year.² While causal relationships have not been established, delirium is associated with increased morbidity and mortality, prolonged length of hospital and intensive care unit (ICU) stay, functional and cognitive decline with nursing home or long-term care facility placement.³⁻⁶ Furthermore, the acute deterioration in cognition and psychomotor agitation frequently seen with delirium is often distressing for both patients and their families.

Surgery type	Study (year)	Population	Delirium Rate	Detection method
Unselected	Radtko ⁷	Recovery room after elective general anesthesia	9.9%	Nu-DESC
Surgical ICU	Pandharipande ⁸	Surgical ICU	73%	CAM-ICU
		Trauma ICU	67%	
Head and neck	Weed ⁹	Major head and neck	17%	Not stated
Cardiac	Kazmierski ¹⁰	Cardiac surgery with CPB	Age <60: 16.3% Age ≥60: 24.7%	DSM-IV
	Rudolph ¹¹	Patients >60 undergoing elective or urgent cardiac surgery	43%	CAM
	Saczynski ¹²	Patients >60 undergoing elective coronary artery bypass grafting or valve replacement surgery	46%	CAM
Vascular	Marcantonio, ¹³ Schneider, ¹⁴ Bohner, ¹⁵ and Benoit ¹⁶	Abdominal aortic aneurysm repair	33-54%	CAM or DSM-IV

	Schneider, ¹⁴ and Bohner ¹⁵	Peripheral vascular	30-48%	DSM-IV
Orthopedic	Fisher ¹⁷	Patients >60 undergoing elective orthopedic procedures	17.5%	CAM
	Marcantonio ¹⁸ and Lee ¹⁹	Patients >65 undergoing emergent hip fracture repair	30.2-41%	CAM

Table 1: Incidence of Delirium in Major Surgeries. CAM, Confusion Assessment Method; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, 4th edition; ICU, Intensive Care Unit; Nu-DESC, The Nursing Delirium Screening Scale

The diagnostic criteria for delirium have recently been updated in the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5). Delirium is an acute neurocognitive disorder characterized by a fluctuating level of consciousness with impairment of attention and cognition. In the postoperative context, delirium typically manifests between 0 and 96 hours following the surgical intervention. It is unclear why postoperative delirium occurs so frequently. Age greater than 60, male gender, history of dementia or depression, sensory impairment, and chronic medical illness are consistently described as risk factors for delirium.²⁰ No effective prophylactic or curative treatments for postoperative delirium have been identified.

Ketamine and Delirium

Ketamine is an anesthetic agent that has been in common use for more than 50 years. Ketamine has a wide margin of safety, and as of 2005 had been studied in over 12,000 operative and diagnostic procedures, involving over 10,000 patients from 105 separate studies (Ketamine package insert 2005). There is a pharmacological rationale for using ketamine as a preventative measure against postoperative delirium based on its N-methyl-D-aspartate (NMDA) antagonism.²¹ Normally, excitatory amino acids such as glutamate and aspartate act as agonists at NMDA receptors, and, in the setting of surgery and inflammation, they might

1
2
3 promote excitotoxic injury and apoptosis.²¹ As an NMDA antagonist, ketamine has the potential
4
5 to protect against such neurological injury.²² Ketamine has also been posited to inhibit HCN1
6
7 receptors, which mediate the hyperpolarization-activated cation current.²³ Such inhibition is
8
9 pertinent to delirium because HCN1 channels are important for regulating states of
10
11 consciousness²⁴ and are up-regulated by inflammation.²⁵ HCN1 receptors are also thought to
12
13 play a critical role in neuropathic pain through inflammatory cascades.²⁶
14
15

16 Based on the pharmacological rationale for neuroprotection, a 58-patient randomized, controlled
17
18 trial was conducted to determine whether ketamine might prevent delirium after major cardiac
19
20 surgery.²⁷ There was a significant reduction in postoperative delirium from 31% to 3% with the
21
22 administration of low dose ketamine (0.5 mg/kg) upon induction of anesthesia. While
23
24 encouraging, this trial must be regarded as preliminary owing to its small sample size, and
25
26 single center design. Interestingly, the same investigators also found that ketamine was
27
28 associated with improved cognition beyond the immediate postoperative period.²⁸ Differences
29
30 between the ketamine and placebo groups were evident in tests of nonverbal memory, verbal
31
32 memory, and executive function. The investigators found that C reactive protein, a non-specific
33
34 inflammatory marker, was similar at baseline in the ketamine and the placebo groups. On the
35
36 first postoperative day, C reactive protein was elevated in both groups, but was significantly
37
38 higher in the placebo group. The investigators hypothesized that the neuroprotective effect of
39
40 ketamine might have been, in part, attributable to its anti-inflammatory actions.²⁸ In support of
41
42 the plausibility of this hypothesis, ketamine use in another cardiac surgical population was
43
44 similarly shown to attenuate postoperative increases in inflammatory markers.²⁹
45
46
47

48 Intraoperative sub-anesthetic dose ketamine is appealing as a potential preventative
49
50 intervention for delirium, since it is inexpensive and has an excellent safety profile. A number of
51
52 questions remain to be answered regarding postoperative delirium. Despite the fact that delirium
53
54 is a common and serious postoperative complication, intraoperative factors contributing to
55
56 pathogenesis have not been rigorously investigated, and only a few small trials have been
57
58
59
60

1
2
3 conducted examining interventions to decrease its incidence. It is also currently unknown
4
5 whether postoperative delirium is preventable, particularly in patients with underlying
6
7 vulnerabilities. Importantly, ketamine in higher (anesthetic) doses has become less popular over
8
9 time owing to side effects, including hallucinations and emergence reactions, especially in
10
11 younger patients.^{30,31} To ensure treatment effectiveness, the preliminary results identifying sub-
12
13 anesthetic dose ketamine as a useful preventative intervention for postoperative delirium should
14
15 therefore be confirmed or refuted using a large scale, pragmatic, randomized controlled trial
16
17 design prior to routine adoption of low dose ketamine for this purpose.
18
19
20

21 22 23 Acute and Persistent Pain

24
25 Similar to delirium, both acute and persistent pain are common postoperative complications,
26
27 with a negative impact on patients' lives. The Joint Commission has established the prevention
28
29 of severe postoperative pain as a benchmark of quality,³² and adequate pain management is
30
31 increasingly viewed as a fundamental human right.^{33,34} Unfortunately, this standard of care has
32
33 not been attained to date; it has previously been estimated that about a third of patients suffer
34
35 severe acute postsurgical pain following major procedures.³⁵ Furthermore, patients who have
36
37 acute postoperative pain are more likely to develop chronic pain, and the incidence of persistent
38
39 postoperative pain following major surgeries remains between 5% and 30%.³⁶ As an antagonist
40
41 at NMDA and HCN1 receptors, ketamine has powerful analgesic properties. A systematic
42
43 review showed that a single sub-anesthetic dose of intraoperative ketamine was associated with
44
45 decreased visual analog pain scores up to 48 hours postoperatively.³⁷ At 24 hours
46
47 postoperatively, ketamine was associated with an impressive 16 mg decrease in total morphine
48
49 consumption.³⁷ Furthermore, adverse effects such as hallucinations were rarely reported when
50
51 low dose ketamine was administered during general anesthesia.³⁷ Consistent with these
52
53 findings, a Cochrane systematic review reported that sub-anesthetic doses of perioperative
54
55 ketamine were associated with decreased postoperative pain, decreased morphine
56
57
58
59
60

1
2
3 consumption, and decreased nausea and vomiting.³⁸ Adverse effects were mild or absent.³⁸ An
4
5 updated systematic review, which included 70 small studies involving 4,701 patients, recently
6
7 confirmed that, in a dose-dependent manner, sub-anesthetic intraoperative ketamine was
8
9 consistently associated with decreased postoperative pain despite decreased opioid
10
11 consumption.³⁹ The more painful the surgical procedure, the greater was the analgesic benefit
12
13 attributable to ketamine.³⁹ In keeping with decreased opioid consumption, postoperative nausea
14
15 and vomiting were also less frequent in patients who received ketamine. However, patients who
16
17 had been randomized to ketamine reported hallucinations and nightmares more frequently.³⁹
18
19 While efficacy data, based on numerous small studies, strongly suggest that supplementary
20
21 ketamine should be used to decrease pain and opioid usage postoperatively, most practitioners
22
23 have not incorporated low dose ketamine into their routine practice. Preliminary data gathered
24
25 from 5 institutions (see below for details) involved in the PODCAST Trial suggest that, despite
26
27 their knowledge regarding the analgesic and opioid-sparing effects, practitioners do not
28
29 administer low-dose ketamine for pain because of concern for complications such as delirium.
30
31 Thus, effectiveness data regarding the relationship of ketamine, delirium and pain are needed.
32
33 Although numerous small efficacy studies have shown that ketamine decreases acute
34
35 postoperative pain, its role in preventing persistent postoperative pain has not been rigorously
36
37 explored. Many causal mechanisms that are thought to be implicated in persistent pain and a
38
39 single intraoperative intervention might not be sufficient to decrease its occurrence. However,
40
41 there have been encouraging findings about the potential of NMDA antagonists to decrease
42
43 postoperative persistent pain. In the ENIGMA trial, patients were randomized to receive
44
45 intraoperative oxygen with either nitrogen or nitrous oxide, which, like ketamine, is an NMDA
46
47 antagonist. The investigators found that among those patients who received nitrous oxide, there
48
49 was an absolute decrease in the percentage of patients who experience persistent pain
50
51 (baseline incidence = 15%) at 3 months postoperatively of 7% (95% CI, 1.9% to 13.9%).⁴⁰ A
52
53 randomized study has examined the potential beneficial effect of intraoperative ketamine on
54
55
56
57
58
59
60

1
2
3 persistent postoperative pain among patients undergoing total hip replacement.⁴¹ This trial
4
5 found a reduction in the ketamine group from 21% to 8% (reduction = 13%; 95% C.I., 1.3% to
6
7 24.9%) in patients experiencing persistent pain at 6 months after their surgery.⁴¹ The PODCAST
8
9 study would demonstrate whether sub-anesthetic dose intraoperative ketamine is effective at
10
11 preventing acute postoperative pain in a real world setting. If ketamine were shown to have a
12
13 substantial effect in decreasing acute postoperative pain, a next step would be to investigate
14
15 rigorously its impact on persistent pain.
16
17
18
19

20 21 Current Utilization of Low-Dose Ketamine

22
23 A survey of anesthesia clinicians was conducted at five of the institutions (Washington
24
25 University in St. Louis, University of Michigan, University of Manitoba, Weill Medical College of
26
27 Cornell University, and Medical College of Wisconsin) participating in the PODCAST clinical
28
29 trial. In total, 270 clinicians responded to the surveys; 18% (range among institutions 12% to
30
31 40%) of respondents currently incorporate adjunctive sub-anesthetic ketamine into their
32
33 practice. Interestingly, 84% of survey respondents believe that low dose ketamine decreases
34
35 acute postoperative pain, 81% feel that it decreases postoperative opioid consumption, and
36
37 51% believe that it decreases chronic postoperative pain. However, the reason that a minority of
38
39 practitioners are currently administering adjunctive ketamine is probably because many remain
40
41 concerned about the neurological side effects of even low dose ketamine; 68% of respondents
42
43 expressed concern about hallucinations, 62% about delirium and 55% about nightmares.
44
45
46
47
48
49

50 51 Potential Impact of PODCAST

52
53 The PODCAST trial has a novel focus in that it is assessing the impact of an intervention (sub-
54
55 anesthetic racemic ketamine administration) on both delirium and pain, two adverse and
56
57 potentially linked outcomes that have not previously been jointly evaluated in a single large
58
59
60

1
2
3 clinical trial. Both delirium and pain are surprisingly common acute postoperative complications
4 with major negative consequences for patients.^{1,35} Currently, there are no official guidelines to
5 screen patients for delirium and only few preventive measures have been investigated, with
6 disappointing results. Since most patients with postoperative delirium have a hypoactive
7 phenotype, it is frequently missed in clinical practice. As noted previously, postoperative
8 delirium is associated with increased intensive care and hospital stay, with persistent cognitive
9 decline and with increased mortality. Thus, any intervention that could decrease the incidence of
10 postoperative delirium would probably have major positive implications for older patients
11 undergoing surgical procedures. Unlike delirium, acute postoperative pain is routinely assessed
12 and the Joint Commission has prioritized the prevention of severe postoperative pain as a
13 universal goal. Unfortunately this objective has not been met, and both severe acute pain and
14 debilitating chronic pain continue to afflict many surgical patients.^{35,36} Of note, both pain and its
15 treatment with opioid analgesics can be risk factors for delirium. Opioid analgesics are the
16 mainstay therapy for postoperative pain, but their administration is curtailed in older patients
17 particularly for safety considerations regarding respiratory depression, but also for concerns
18 about causing sedation and delirium.

19
20
21 Pragmatic trials are intended to generate evidence of effectiveness of a test, treatment,
22 procedure, or health-care service.^{42,43} At present, there is a lack of pragmatic trials for candidate
23 interventions to prevent important and common postoperative neurologic and psychiatric
24 complications including delirium and pain. Ketamine is a plausible prophylactic option for each
25 of these neurological and psychiatric complications. The American Society of Anesthesiologists
26 has published Practice Guidelines for the management of acute and chronic pain, which, based
27 on small efficacy or observational trials, include ketamine as a treatment option.^{44,45} There are
28 currently no guidelines for the prevention of postoperative delirium. Thus, a multicenter
29 pragmatic trial comparing low dose ketamine with placebo is timely. It is important to emphasize
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 that any one of several potential results of the PODCAST trial will have important and
4
5 immediate positive implications for older surgical patients. First ketamine might decrease both
6
7 delirium and pain. This result would provide clear support for a larger comparative effectiveness
8
9 trial testing ketamine as a prophylactic measure for both of these outcomes. Second, ketamine
10
11 might decrease pain without increasing delirium. This result would provide compelling data that
12
13 encourage the use of ketamine to prevent pain without concern for cognitive side effects such
14
15 as delirium. Third, ketamine might decrease delirium and have no impact on pain. Although the
16
17 lack of effect on pain is unlikely, this result would also encourage further study of the use of
18
19 prophylactic intraoperative ketamine. However, low dose ketamine may be found to increase
20
21 delirium, regardless of its impact on pain. This result would suggest that the incorporation of
22
23 intraoperative ketamine into routine clinical practice for older surgical patients is not warranted
24
25 and would negate the need for a larger pragmatic trial. Furthermore, the PODCAST trial will
26
27 help determine ketamine dose-related effects by comparing two doses (0.5 mg/kg and 1 mg/kg)
28
29 to placebo. As such, all of these potential results of the PODCAST trial have the potential to
30
31 impact clinical practice and will be generalizable to all older surgical patients undergoing major
32
33 surgical procedures because of the permissive inclusion criteria and the simplicity of
34
35 intervention.⁴²
36
37
38
39
40
41
42

43 **METHODS AND ANALYSIS**

44 **Study design**

45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
PODCAST is a prospective randomized controlled trial has been designed in accordance with
CONSORT guidelines⁴⁶ and will evaluate whether a single bolus dose of racemic ketamine (0.5
mg/kg or 1 mg/kg) following induction of anesthesia and before surgical incision decreases the
incidence or severity of postoperative delirium and pain in a mixed elderly (>60 years) surgical
patient population. Patients will undergo the standard preoperative anesthesia assessment.

1
2
3 Follow up information will be collected from the medical chart for up to 5 years. The overall
4
5 study design is outlined in Figure 1.
6
7
8
9

10 **Eligibility criteria**

11
12 Patients 60 years old and older, who are competent to provide informed consent and who are
13
14 undergoing major open cardiac surgery (e.g., coronary artery bypass graft, valve replacement)
15
16 or non-cardiac surgeries (e.g., thoracic surgery, major vascular surgery, intra-abdominal
17
18 surgery, open gynecologic surgery, open urologic surgery, major orthopedic surgery, hepato-
19
20 biliary surgery and major ENT surgery) receiving general anesthesia will be eligible for inclusion.
21
22 The exclusion criteria are based on the contraindications to ketamine from the 2005 ketamine
23
24 package insert. Patients with an allergy to ketamine and those in whom a significant elevation of
25
26 blood pressure would constitute a serious hazard (e.g., pheochromocytoma, aortic dissection)
27
28 will be excluded. We shall also exclude patients with drug misuse history (e.g., ketamine,
29
30 cocaine, heroin, amphetamine, methamphetamine, MDMA, phencyclidine, lysergic acid,
31
32 mescaline, psilocybin), patients taking anti-psychotic medications (e.g., chlorpromazine,
33
34 clozapine, olanzapine, risperidone, haloperidol, quetiapine, paliperidone, amisulpride,
35
36 sertindole), and patients with a weight outside the range 50 kg – 200 kg (110 lbs – 440 lbs).
37
38 Patients will be enrolled either during a preoperative clinic visit or in the hospital prior to surgery.
39
40
41
42
43
44

45 **Baseline Assessment**

46
47 At the time of enrollment, patients will undergo the same delirium and pain evaluation that will
48
49 be used postoperatively (see Outcomes section). Additionally patients will be screened for
50
51 functional dependence using the Barthel Index of Activities of Daily Living,⁴⁷ for depression
52
53 using the patient health questionnaire (PHQ-8),⁴⁸ and for obstructive sleep apnea using the
54
55 STOP-Bang criteria.⁴⁹ Patients will be asked if they have a history of delirium, and if this
56
57
58
59
60

1
2
3 presented after surgery. They will also be asked about any falls they have experienced in the six
4
5 months prior to surgery. Comorbid conditions, including the components of the Charlson
6
7 Comorbidity Index,⁵⁰ will be obtained by reviewing the patients' medical records. Any available
8
9 preoperative lab results, including electrolytes and blood counts, will also be recorded.
10
11

12 13 14 15 **Interventions**

16
17 As this is a pragmatic trial, apart from administration of the study drug (ketamine or normal
18
19 saline), all decisions about anesthetic technique will be made by the anesthetic team assigned
20
21 to each patient. The only exception is that clinicians will be instructed not to administer any
22
23 ketamine other than the study drug. The intention of this trial is to interfere as little as possible
24
25 with the usual process of care, which will increase the applicability of the findings.⁴³ Following
26
27 induction of general anesthesia, an intravenous dose of 0.5 mg/kg racemic ketamine, 1 mg/kg
28
29 racemic ketamine, or an equivalent volume of normal saline will be injected via a reliable (free
30
31 flowing) central or peripheral intravenous line. Clinicians will be blinded to the treatment arm of
32
33 the study. Anesthetic factors such as the use of nitrous oxide, protocols for pain prevention, use
34
35 of neuraxial anesthesia, use of nerve blocks, and other practices that could potentially affect
36
37 primary or secondary outcomes will be assessed in a *post hoc* manner.
38
39
40
41
42

43 44 **Outcomes**

45 46 **Primary outcomes**

47
48 Trained members of the research team who are blinded to the treatment arm of the study will
49
50 assess patients for **delirium** (primary outcome) using the Confusion Assessment Method
51
52 (CAM)⁵¹ and the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU)^{52,53} for
53
54 patients who are unable to speak (e.g., have a tracheal tube or tracheostomy) on the intensive
55
56
57
58
59
60

1
2
3 care unit. These methods (the CAM and the CAM-ICU) have been shown to be reliable and to
4 have good agreement with the DSM-IV criteria for delirium.⁵³⁻⁵⁵ Delirium assessments will be
5 performed when patients can be aroused sufficiently in order to be assessed for delirium
6 (Richmond Agitation and Sedation Score > -4). The first delirium assessment will be attempted
7 if feasible on the day of surgery in the afternoon / evening. Patients will then be assessed for
8 delirium twice daily (from postoperative day 1 to postoperative day 3) in the morning and in the
9 afternoon / evening with at least 6 hours between assessments. Each patient will be assessed
10 for delirium up to seven times. At the Washington University site, the patients' family members
11 will perform the Family Confusion Assessment Method (FAM-CAM) separately from the
12 investigators performing their assessments.⁵⁶ Investigators and family members will be blinded
13 to each other's assessments. The FAM-CAM has demonstrated high sensitivity and specificity
14 for detection of delirium and good agreement with the CAM⁵⁶, but has not been specifically
15 evaluated in the postoperative setting. After the final delirium assessment, patients will
16 complete the Delirium and Pain Self-Assessment Questionnaire (Appendix A). Incident delirium
17 subsequent to this period is unlikely to be directly related to anesthetic or other intraoperative
18 factors.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41 Secondary outcomes

42
43 Study team members blinded to the treatment group of the patient will assess all secondary
44 outcomes. **Acute pain** (secondary outcome) will be assessed prior to surgery and then
45 postoperatively by using the Behavioral Pain Scale (BPS)⁵⁷ or the Behavioral Pain Scale for the
46 Non-Intubated patient (BPS-NI)⁵⁸ and the 10-cm VAS (Visual Analog Scale) at the same times
47 as patients are assessed for delirium. The BPS-NI has been shown to be a valid and reliable
48 tool for measuring pain in a predominantly delirious patient population.⁵⁸ Interviewers will rate
49 the BPS or BPS-NI prior to asking the patient to complete the VAS to prevent bias in the BPS
50
51
52
53
54
55
56
57
58
59
60

1
2
3 and BPS-NI assessments. Postoperative daily amount of opioids and sedatives administered
4 will be ascertained from the patient's electronic health record spanning the period after surgery
5 until the final delirium assessment is complete. After the final delirium assessment, patients will
6 complete the Delirium and Pain Self-Assessment Questionnaire (Appendix A). **Postoperative**
7 **nausea and vomiting** (secondary outcome) will be assessed at the same time points that
8 patients are assessed for delirium by asking patients to rate the severity of their nausea and
9 vomiting, if present, on a three point scale (mild, moderate, severe). Patients will be questioned
10 at each assessment about side effects, especially hallucinations and nightmares. Intensive care
11 unit and hospital length of stay will be obtained from the patient's medical record. At some of the
12 participating sites in the PODCAST trial, patients will receive a survey, which will be sent by mail
13 or email one month following surgery. This survey will collect patient reported outcomes (PROs)
14 on depressive symptoms, affect, persistent pain, functionality and quality of life. Depressive
15 symptoms will be assessed with the eight item Patient Health Questionnaire (PHQ-8), Affect will
16 be assessed with two 10-item mood scales that comprise the Positive and Negative Affect
17 Schedule (PANAS) within three to six months postoperatively.⁵⁹ The same screens for
18 depressive symptoms and affect will also be conducted in the hospital on postoperative day 3.
19 Persistent pain will be assessed with the Brief Pain Inventory Short Form (BPI-SF). The Barthel
20 Index will be used to report functionality and quality of life will be assessed from the Veteran's
21 Rand-12 (VR-12) questionnaire.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

48 Standardization of training and outcomes assessment

49
50 All study team members who perform delirium assessments will undergo a rigorous training
51 process. For the initial training, representatives from each study site participated in a full-day
52 training program led by Dr. Sharon Inouye, the original creator of the CAM. Those who
53 attended this initial training will oversee the training of other team members at their sites.
54
55
56
57
58
59
60

1
2
3 Trainees must demonstrate competence at both conducting CAM interviews and in scoring
4 these interviews. For the initial part of training, trainees must conduct at least two satisfactory
5 CAM interviews in the presence of a trained team member. These interviews will not be on
6 patients enrolled in the PODCAST trial. To establish their ability to score CAM interviews
7 reliably, trainees will accompany trained team members to conduct CAM interviews. A trained
8 member of the research team will conduct each CAM interview for patients enrolled in the
9 PODCAST trial. The trainee will observe the interview, but will score the CAM independently.
10 The trainee must agree with the trainer on the presence or absence of all twelve cognitive
11 features assessed by the CAM on a minimum of two delirious and two non-delirious patients.
12 After meeting the stipulations of training, the newly trained team member will conduct their first
13 interview of a patient enrolled into the PODCAST trial in the presence of a previously trained
14 team member.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31

32 Assessment of the standardization and reliability of delirium assessments

33
34
35 After training, all PODCAST team members administering delirium assessments will be invited
36 to participate in a project to demonstrate the validity and reliability of the CAM in our study
37 population. Participants will view and rate eight videos of standard interviews depicting delirious
38 and non-delirious patients. Participants will independently score the CAM for each scenario.
39 Demographic information, level of education, level of clinical experience, and primary language
40 will also be collected from all participants. Data will be de-identified. All scores and data will be
41 submitted to the lead site, Washington University. The group's scores will then be compared to
42 determine the reliability of delirium assessments across sites. Additionally, the group's scores
43 will be compared to a set of "gold standard" scores for the videos (determined by Dr. Inouye's
44 team) This comparison is intended to demonstrate validity of the CAM in our study setting.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Overall, the goal of the project is to demonstrate standardization of the delirium outcome across
4 all study sites.
5
6
7
8
9

10 **Sample size**

11
12 Based on published delirium incidences in the scientific literature (Table 1), we estimate
13 conservatively that the incidence of postoperative delirium in a mixed major surgical population
14 of older patients will be between 20% and 25%. Based on data from a sub-study of the BAG-
15 RECALL trial that we have recently completed, the incidence of delirium among patients
16 admitted to our cardiothoracic intensive care unit at Barnes-Jewish Hospital is 25% within three
17 postoperative days. Hudetz et al found that ketamine was associated with a 28% (95% CI, 8%
18 to 46%) absolute risk reduction in delirium (from a baseline incidence of 31%).²⁷ A 28%
19 reduction is likely to be an over-optimistic effect size for designing a pragmatic study; 10% is
20 more realistic as the most optimistic effect size and remains consistent with the confidence
21 interval for the effect size found by Hudetz et al.²⁷ Assuming a two-sided type I error rate of 5%,
22 a sample size of 600 will give greater than 80% power to detect a decrease in the incidence of
23 delirium from 25% to 15% with ketamine. On the other hand, we consider the minimum
24 clinically important difference (MCID) or effect size to be 2%, which corresponds to a number
25 needed to treat of 50 surgical patients to prevent one episode of delirium. The rationale for the
26 low MCID is that delirium is a serious postoperative complication that is associated with
27 increased mortality and the proposed intervention (low dose ketamine) is safe, inexpensive and
28 not likely to have adverse effects.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

50
51 There are two specific issues to clarify in this study: i) the likely effect size with ketamine; and ii)
52 the optimal ketamine dose. Ketamine might increase delirium, decrease delirium or have no
53 impact on delirium. If ketamine increases delirium, it is more likely to increase delirium at a
54 higher dose (1 mg/kg). If ketamine decreases delirium, it might have a dose response effect –
55
56
57
58
59
60

less delirium at the higher ketamine dose (1 mg/kg). We anticipate that ketamine will decrease pain in a dose dependent manner – 1mg/kg will be superior to 0.5 mg/kg. Accrual of 200 patients to each dose of ketamine along with a placebo arm will allow a more robust assessment of the dose-response efficacy for postoperative analgesia than previous studies with fewer numbers. In general, the higher ketamine dose might have more side effects. As such, this trial might inform whether the higher ketamine dose can be used, in view of its possibly superior analgesia, with a potential benefit in relation to delirium and without excessive side effects. The dosage determination going forward will depend on the observed incidence of delirium with each dose, analgesia efficacy with each dose, and side effect profile with each dose. The proposed design for the study is shown in Table 2.

Group	N
Placebo	200 patients
Ketamine Low Dose (0.5 mg/kg)	200 patients
Ketamine Moderate Dose (1 mg/kg)	200 patients

Table 2: Patient Allocation.

With this approach, we believe that this study will clearly inform whether it is indicated, both in terms of efficacy and in terms of feasibility, to pursue a larger study. The purpose of the larger study (PODCAST2) will be to determine definitively whether ketamine is associated with a reduction in delirium (and pain) in high-risk older surgical patients, without incurring an increase in side effects. As the main effect evaluated will be whether ketamine decreases delirium, Table 3 provides a useful guide for the potential findings of the current study with their implications.

Delirium Incidence in Placebo Groups (N=200)	Delirium Incidence in Ketamine Groups (N=400)	Effect Size (Reduction in delirium with	95% Confidence Interval (CI) for Effect Size

		ketamine)	
25% (N=50)	25% (N=100)	0%	-7.6% to 7.1%
<i>Implication:</i> Consider Pursuing a larger study only if pain is decreased in ketamine groups, and there is no increase in side effects.			
25% (N=50)	22.5% (N=90)	2.5%	-4.5% to 10.0%
<i>Implication:</i> Although the point estimate is >2% (MCID), a 9,500 patient study would be required to clarify more precisely the effectiveness of ketamine in preventing delirium. Other outcomes in the study (e.g., pain reduction and side effects) would inform the approach.			
25% (N=50)	20% (N=80)	5%	-1.9% to 12.4%
<i>Implication:</i> Pursue larger study with approximately 2,500 patients to clarify more precisely the effect of ketamine on preventing delirium.			
25% (N=50)	17.5% (N=70)	7.5%	0.7% to 14.8%
<i>Implication:</i> Pursue larger study (approximately 1,200 patients) to clarify whether effect size >2% (MCID) and to define it more precisely.			
25%	15%	10%	3.3% to 17.1%
<i>Implication:</i> For main effect, lower bound of CI >2% (MCID). Ketamine's benefit in decreasing delirium is very likely, but a larger study (approximately 1,200 patients) would define its effect more precisely.			

Table 3: Potential Findings of PODCAST.

Recruitment

This clinical trial will be conducted at Washington University in St. Louis and other sites. Our research team has conducted large randomized, controlled trials, which enrolled (approximately) 2,000 patients over 14 months in the B-unaware trial,⁶⁰ 6,000 patients over 26 months in the BAG-RECALL trial⁵⁹ and 22,000 patients over 24 months in the Michigan Awareness Control Study.⁶¹ Based on the inclusion criteria and the number of eligible surgical patients, we estimate that one year will be sufficient for patient enrollment to the proposed trial, and a further one year for data analysis.

Allocation

Subjects will be block randomized by the hospital pharmacy departments in groups of 15 (1:1:1 ratio - 0.5 mg/kg ketamine: 1 mg/kg ketamine: placebo), stratified by site, in order to keep the randomization balanced and the groups more homogeneous. The outcome of this random assignment will be concealed from the study team and all study subjects and trial staff will be blinded to the randomization. Codes will be held by the hospital pharmacies and they will dispense medication. Randomization codes will remain concealed until the primary analysis is completed. Prepared syringes of either placebo or ketamine will be directly delivered to the operating room in which surgery of the consented patient will take place as soon as the research team informs the pharmacy about the patient going to the operating room for surgery.

Data analysis and management

Data analysis for this investigation will require comparisons of patient outcomes (e.g., delirium, pain, length of stay, adverse events) in the three study groups to assess for significant differences among ketamine doses (placebo, 0.5 mg/kg and 1 mg/kg). For proportions and categorical outcomes, such as incident delirium, we will use the chi square test (or Fisher's exact test in the case of sparse data) to compare proportions across the three groups and the Cochran-Armitage test to test for dose response trends. For continuous outcomes, such as visual analog pain scores and opioid consumption, we will use repeated-measures analysis of variance tests to detect the main effects. The Tukey post-hoc test will also be run on all significant interactions to determine differences between individual and combined groups (e.g., placebo versus combined ketamine groups; 0.5 mg/kg ketamine versus 1 mg/kg ketamine). For multivariate analyses, we will apply the Cox proportional-hazards model for recurrent events to

1
2
3 investigate the effects of low doses of intraoperative ketamine on delirium by comparing its
4 occurrence and timing across the study groups. We will also model the number of postoperative
5 delirium incidents using a Poisson hurdle regression to find out the difference in the proportion
6 of patients with and without delirium, and for those who experience delirium, the difference in its
7 recurrence. Both models (Cox proportional-hazards and hurdle model) will account for
8 differences in ketamine effectiveness in cardiac versus non-cardiac surgery by including
9 interaction terms for ketamine dose and cardiac surgery status, while adjusting for other
10 influential variables. We will also use mixed-effects regression models to assess differences
11 among the subgroups in continuous outcome variables over time (e.g., postoperative pain
12 scores and opioid consumption). These models will likewise account for interactions between
13 ketamine dose and cardiac surgery status. All statistical testing will be two sided, and p values
14 <0.05 will be regarded as significant. No interim analyses are planned. Appropriate adjustment
15 will be made for multiple analyses.

16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32 The Division of Biostatistics Informatics Core at Washington University will be used as a central
33 location for data processing and management. Washington University belongs to a consortium
34 of institutional partners that work to maintain a software toolset and workflow methodology for
35 electronic collection and management of research and clinical trial data. REDCap (Research
36 Electronic Data Capture) data collection projects rely on a thorough study-specific data
37 dictionary defined in an iterative self-documenting process by all members of the research team
38 with planning assistance from the Division of Biostatistics Informatics Core. The iterative
39 development and testing process result in a well-planned data collection strategy for individual
40 studies. REDCap servers are securely housed in an on-site limited access data center managed
41 by the Division of Biostatistics at Washington University. All web-based information transmission
42 is encrypted. The data is all stored on a private, firewall protected network. All users are given
43 individual user ids and passwords and their access is restricted on a role-specific basis.

1
2
3 REDCap was developed specifically around HIPAA-Security guidelines and is implemented and
4 maintained according to Washington University guidelines. REDCap currently supports >500
5 academic/non-profit consortium partners on six continents and 38,800 research end-users.⁶²
6
7
8
9

10 11 12 13 **Monitoring**

14
15 The research team will monitor the study for adverse events. All serious adverse events will be
16 reported to the IRB according to IRB stipulations. The monitoring plan for this study is
17 appropriate for the planned pragmatic trial. As an anesthetic drug, ketamine has an excellent
18 safety profile and record. In particular, low dose ketamine (0.5 mg/kg or 1 mg/kg) administered
19 prior to surgical incision is unlikely to be associated with major adverse events, and even minor
20 side effects manifesting after induction of anesthesia and the start of surgery are
21 improbable.^{37,38,63}
22
23
24
25
26
27
28
29
30

31 The PODCAST trial will have an appropriate data and safety monitoring plan for a low risk
32 clinical trial. There will be a charter to guide the functions of the Data Safety and Monitoring
33 Board (DSMB), and the DSMB will produce reports in accordance with NIH guidelines. The
34 DSMB will provide independent oversight of the PODCAST trial and will review general conduct
35 of the trial as well as study data for participant safety.⁶⁴ The DSMB will be comprised of
36 independent, multidisciplinary experts who will make recommendations regarding the
37 continuation, modification, or termination of the trial.⁶⁵ The members will have the requisite
38 expertise to examine accumulating data, to protect the integrity of the clinical experiments to
39 which the patients have consented to participate, and to assure the regulatory bodies and the
40 public (and possibly funding agencies) that conflicts of interest do not compromise either patient
41 safety or trial integrity.⁶⁶ There will be no pre-specified interim analysis given the size of this
42 study; frequent analyses might increase the likelihood of bias.⁶⁴ There will be a provision for
43 early stoppage for safety concerns, but not for efficacy or for futility.⁶⁴ Trials that stop early for
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 benefit show implausibly large treatment effects, particularly when the number of events is
4 small.⁶⁷ Truncated trials have been associated with greater effect sizes than trials not stopped
5 early, independent of the presence of statistical stopping rules.⁶⁸
6
7
8
9

10
11
12 All members of the DSMB will be at the Washington University site. Local investigators at all
13 participating sites will report serious adverse events, or unanticipated problems involving risks to
14 subjects or others, to their IRB and to the PI of the study at Washington University. If such
15 problems are considered related to the trial, then they will also be reported to IRBs at other
16 participating sites and to the chairperson of the DSMB. The members of the DSMB will have no
17 direct involvement in the conduct of the PODCAST trial. Neither will they have financial,
18 proprietary or professional conflicts of interest, which may affect the impartial, independent
19 decision-making responsibilities of the DSMB.^{64,65} Letters of invitation to prospective DSMB
20 members will include the following: "Acceptance of this invitation to serve on the PODCAST
21 DSMB confirms that I do not have any financial or other interest with any of the collaborating or
22 competing pharmaceutical firms or other organizations involved in the study that constitute a
23 potential conflict of interest." All DSMB members will sign a Conflict of Interest Certification to
24 confirm no conflict exists. There will be between three and eight people on the DSMB, in order
25 to optimize performance.⁶⁹ The DSMB will be advisory rather than executive on the basis that it
26 is the PODCAST trial investigators who are ultimately responsible for the conduct of the trial.⁶⁹
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 The risks associated with this study are low. There is a rare risk of breach of confidentiality. In
46 contrast to other anesthetics, protective reflexes such as coughing and swallowing are
47 maintained with low dose ketamine. The 2005 package insert for ketamine reports the induction
48 dose for anesthesia as follows: The initial dose of ketamine administered intravenously may
49 range from 1 mg/kg to 4.5 mg/kg. The average amount required to produce five to ten minutes
50 of surgical anesthesia has been 2 mg/kg. The short-term side effects of ketamine at higher
51
52
53
54
55
56
57
58
59
60

1
2
3 doses (>1-2 mg/kg) than the dosages proposed for this study (0.5 mg/kg or 1 mg/kg) include
4
5 tachycardia, nystagmus, hypersalivation, euphoria, emergence reactions, hallucinations and
6
7 nightmares.⁷⁰ It is possible, but very unlikely, that low dose ketamine (0.5 mg/kg or 1 mg/kg)
8
9 administered just after induction of anesthesia or administration of sedative medications will
10
11 cause these side effects.^{37,38,63} Emergence reactions, hallucinations and nightmares are more
12
13 common in younger patients receiving ketamine. In published studies on low dose ketamine
14
15 (0.25 to 1 mg/kg) administered during general anesthesia, side effects have generally not been
16
17 found.³⁷ The main side effects that might occur are nightmares and hallucinations. Other
18
19 neuropsychiatric side effects might occur, most likely within the first 24 hours after surgery, and
20
21 will be determined from patient interviews. The incidence of these side effects in this patient
22
23 population is currently unknown, and thus side effects will be reported separately and jointly.
24
25 Meta-analysis suggests that ketamine might be associated with an increase in neurologic and
26
27 psychiatric side effects from approximately 5% to 7.5%. This study will be >80% powered to
28
29 detect an increase in side effects from 5% to 12% and 20% powered to detect an increase in
30
31 side effects from approximately 5% to 7.5%. As part of the informed consent process for this
32
33 study, patients will be informed of the rare risks and will be asked about them after their surgery.
34
35 In the unlikely event that serious side effects occur, they will be documented and will be
36
37 reported to the human research protection office and to the study's DSMB. Participants will not
38
39 incur any study-related expenses, nor will they be financially compensated for their participation.
40
41
42
43
44
45
46

47 **Ethics and dissemination**

48 Ethics approval and consent

49
50
51 The PODCAST trial has been approved by the institutional review boards of the principal
52
53 investigators' home institutions (Washington University, St. Louis and University of Michigan,
54
55 Ann Arbor). Institutional review board approval has also been obtained at some of the
56
57
58
59
60

1
2
3 participating sites (Postgraduate Institute of Medical Education and Research, Chandigarh,
4 India; University of Manitoba, Winnipeg, Canada; Weill Medical College, Cornell University, New
5 York City; Medical College of Wisconsin, Milwaukee) and is ongoing at other sites. Recruitment
6 began in February of 2014 and will continue through 2015. Potential participants will be
7 approached for enrollment by a member of the research team who will explain the purpose of
8 the study and written informed consent will be obtained for all participants. Patients may choose
9 not to participate in this study and there will be no penalty in terms of the care that they receive.
10
11
12
13
14
15
16
17
18
19
20

21 Confidentiality

22
23 Necessary protected health information will only be shared with members of the research team.
24
25 To help protect confidentiality, research charts will be stored in a locked cabinet inside the
26 locked research office. Electronic data and demographic information will also be kept in a
27 password-protected electronic database stored on the departmental network drive and only
28 accessible via password-protected departmental computers. A member of the research team
29 will enter this information. Code numbers, rather than names, will appear on any data and
30 documents used for evaluation or statistical analyses.
31
32
33
34
35
36
37
38
39
40
41

42 Dissemination

43
44 Dissemination plans include presentations at local, national and international scientific
45 conferences. There are no publication restrictions and no professional writers will be involved in
46 the generation of the manuscript.
47
48
49
50
51

52 CONCLUSIONS

53
54
55 In the next four decades, the US population over the age of 60 is predicted to double to more
56 than 80 million individuals. The aging population often requires surgery, which can be
57
58
59
60

1
2
3 frequently complicated by postoperative pain and delirium. Delirium is defined as an acute brain
4
5 dysfunction that presents as fluctuating levels of inattention and disordered thinking, and has
6
7 been reported to affect up to 70% of surgical patients older than 60. Likewise, severe
8
9 postoperative pain continues to affect a large proportion of surgical patients, especially the
10
11 elderly, and is another major contributor to delirium. Unfortunately, opioid medications, the
12
13 current standard for analgesia, can themselves lead to delirium and other adverse
14
15 consequences. Clinicians therefore face the paradox that both pain and the mainstay treatment
16
17 of pain can lead to delirium. Although causal relationships have not been established,
18
19 postoperative delirium is associated with increased intensive care unit and hospital stay,
20
21 persistent cognitive decline, and increased mortality rate. What is needed is a therapeutic
22
23 intervention that can both attenuate pain and decrease the occurrence of delirium. Mounting
24
25 evidence suggests that the intraoperative administration of low dose (i.e., sub-anesthetic)
26
27 ketamine, an anesthetic drug that has been in common use for 50 years, prevents delirium,
28
29 lessens the severity of postoperative pain, and has an opioid-sparing effect. These multiple
30
31 beneficial effects have been attributed to ketamine's anti-inflammatory and anti-excitotoxic
32
33 actions. Despite these benefits, low-dose intraoperative ketamine currently does not enjoy
34
35 widespread adoption, primarily because clinicians are concerned that the psychoactive
36
37 properties of ketamine might compromise postoperative cognition. The PODCAST randomized
38
39 controlled trial intends to address a gap in the field through an international, multicenter study
40
41 that tests the effectiveness of ketamine in reducing both delirium and pain in surgical patients
42
43 older than 60.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

AUTHORS' CONTRIBUTORSHIP

Michael Avidan and George Mashour are the primary authors of the PODCAST protocol. Their contributions include drafting and editing the protocol, conceptualizing the study design, and organizing conduct across all sites. Bradley Fritz contributed to the PODCAST trial by editing the protocol, conceptualizing study design, creating the electronic database, REDCap used for data collection, and co-authoring a manual of operations for study conduct. Hannah Maybrier contributed to PODCAST by editing the protocol, co-authoring the manual of operations, recruiting patients for enrollment, collecting data, and coordinating the study across all sites.

Maxwell Muench contributed to PODCAST by co-authoring a manual of operations, recruiting patients for enrollment, and collecting data. Krisztina Escallier contributed to PODCAST by editing the protocol, conceptualizing study design, and co-authoring a manual of operations.

Yulong Chen contributed to PODCAST by editing the protocol and conceptualizing study design. Arbi Ben Abdallah contributed to PODCAST by editing the protocol and conceptualizing study design, including the statistical modelling of the study. Sharon Inouye contributed to PODCAST by training investigators to perform delirium assessments and conceptualizing study design. Stephen Choi, Robert Downey, Hilary Grocott, Gyujeong Noh, Judith Hudetz, Eric Jacobsohn, Heiko Kaiser, Paul Pagel, Kane Pryor, Ryan Pong, Robert Veselis, and Virendra Kumar Arya contributed to PODCAST by editing the study protocol, conceptualizing study design, recruiting participants, and collecting data.

All authors including Avidan, Mashour, Fritz, Maybrier, Muench, Escallier, Chen, Ben Abdallah, Inouye, Veselis, Grocott, Hudetz, Pryor, Pagel, Arya, Pong, Jacobsohn, Gyujeong, Kaiser, Downey, and Choi have critically revised the PODCAST protocol and approved the final version.

All authors agree to be accountable for the accuracy and integrity of all aspects of the PODCAST trial.

ACKNOWLEDGMENTS

PODCAST research group: A Alexander, R Arora, J Bang, M Bottros, A Cai, BM Choi, IC Choi, ME Davis, R Downey, D Emmert, M Engoren, SD Gandhi, L Girling, N Hanson, Z Iqbal, A Jayant, E Lenze, M Maile, J McVagh, J Neal, S Oskar, KM Patterson, E Rogers, B Tellor, T Wildes, A Villafranca, H Yulico

FUNDING

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

COMPETING INTERESTS

None of the authors have conflicts of interest to disclose.

REFERENCES:

1. Whitlock EL, Vannucci A, Avidan MS. Postoperative delirium. *Minerva Anestesiol* 2011;77:448-56.
2. Leslie DL, Marcantonio ER, Zhang Y, et al. One-year health care costs associated with delirium in the elderly population. *Arch Intern Med* 2008;168:27-32.
3. Gottesman RF, Grega MA, Bailey MM, et al. Delirium after coronary artery bypass graft surgery and late mortality. *Ann Neurol* 2010;67:338-44.
4. Koster S, Hensens AG, Schuurmans MJ, et al. Consequences of Delirium After Cardiac Operations. *Ann Thorac Surg* 2011.
5. Kat MG, Vreeswijk R, de Jonghe JF, et al. Long-term cognitive outcome of delirium in elderly hip surgery patients. A prospective matched controlled study over two and a half years. *Dement Geriatr Cogn Disord* 2008;26:1-8.
6. Bickel H, Gradinger R, Kochs E, et al. High risk of cognitive and functional decline after postoperative delirium. A three-year prospective study. *Dement Geriatr Cogn Disord* 2008;26:26-31.
7. Radtke FM, Franck M, Lorenz M, et al. Remifentanyl reduces the incidence of post-operative delirium. *The Journal of international medical research* 2010;38:1225-32.
8. Pandharipande P, Cotton BA, Shintani A, et al. Prevalence and risk factors for development of delirium in surgical and trauma intensive care unit patients. *The Journal of trauma* 2008;65:34-41.
9. Weed HG, Lutman CV, Young DC, et al. Preoperative identification of patients at risk for delirium after major head and neck cancer surgery. *The Laryngoscope* 1995;105:1066-8.
10. Kazmierski J, Kowman M, Banach M, et al. Incidence and predictors of delirium after cardiac surgery: Results from The IPDACS Study. *J Psychosom Res* 2010;69:179-85.
11. Rudolph JL, Inouye SK, Jones RN, et al. Delirium: an independent predictor of functional decline after cardiac surgery. *J Am Geriatr Soc* 2010;58:643-9.
12. Saczynski JS, Marcantonio ER, Quach L, et al. Cognitive trajectories after postoperative delirium. *N Engl J Med* 2012;367:30-9.
13. Marcantonio ER, Goldman L, Mangione CM, et al. A clinical prediction rule for delirium after elective noncardiac surgery. *JAMA* 1994;271:134-9.
14. Schneider F, Bohner H, Habel U, et al. Risk factors for postoperative delirium in vascular surgery. *Gen Hosp Psychiatry* 2002;24:28-34.
15. Bohner H, Hummel TC, Habel U, et al. Predicting delirium after vascular surgery: a model based on pre- and intraoperative data. *Ann Surg* 2003;238:149-56.
16. Benoit AG, Campbell BI, Tanner JR, et al. Risk factors and prevalence of perioperative cognitive dysfunction in abdominal aneurysm patients. *J Vasc Surg* 2005;42:884-90.

17. Fisher BW, Flowerdew G. A simple model for predicting postoperative delirium in older patients undergoing elective orthopedic surgery. *J Am Geriatr Soc* 1995;43:175-8.
18. Marcantonio ER, Flacker JM, Michaels M, et al. Delirium is independently associated with poor functional recovery after hip fracture. *J Am Geriatr Soc* 2000;48:618-24.
19. Lee KH, Ha YC, Lee YK, et al. Frequency, risk factors, and prognosis of prolonged delirium in elderly patients after hip fracture surgery. *Clin Orthop Relat Res* 2011;469:2612-20.
20. Inouye SK. Delirium in older persons. *N Engl J Med* 2006;354:1157-65.
21. Hudetz JA, Pagel PS. Neuroprotection by ketamine: a review of the experimental and clinical evidence. *J Cardiothorac Vasc Anesth* 2010;24:131-42.
22. Wang L, Jing W, Hang YN. Glutamate-induced c-Jun expression in neuronal PC12 cells: the effects of ketamine and propofol. *J Neurosurg Anesthesiol* 2008;20:124-30.
23. Chen X, Shu S, Bayliss DA. HCN1 channel subunits are a molecular substrate for hypnotic actions of ketamine. *J of Neurosci* 2009;29:600-9.
24. Lewis AS, Chetkovich DM. HCN channels in behavior and neurological disease: too hyper or not active enough? *Mol cell neurosci* 2011;46:357-67.
25. Cho HJ, Staikopoulos V, Furness JB, et al. Inflammation-induced increase in hyperpolarization-activated, cyclic nucleotide-gated channel protein in trigeminal ganglion neurons and the effect of buprenorphine. *Neuroscience* 2009;162:453-61.
26. Emery EC, Young GT, Berrocoso EM, et al. HCN2 ion channels play a central role in inflammatory and neuropathic pain. *Science* 2011;333:1462-6.
27. Hudetz JA, Patterson KM, Iqbal Z, et al. Ketamine attenuates delirium after cardiac surgery with cardiopulmonary bypass. *J Cardiothorac Vasc Anesth* 2009;23:651-7.
28. Hudetz JA, Iqbal Z, Gandhi SD, et al. Ketamine attenuates post-operative cognitive dysfunction after cardiac surgery. *Acta Anaesthesiol Scand* 2009;53:864-72.
29. Bartoc C, Frumento RJ, Jalbout M, et al. A randomized, double-blind, placebo-controlled study assessing the anti-inflammatory effects of ketamine in cardiac surgical patients. *J Cardiothorac Vasc Anesth* 2006;20:217-22.
30. Fine J, Finestone SC. Sensory disturbances following ketamine anesthesia: recurrent hallucinations. *Anesth Analg* 1973;52:428-30.
31. Lilburn JK, Dundee JW, Nair SG, et al. Ketamine sequelae. Evaluation of the ability of various premedicants to attenuate its psychic actions. *Anaesthesia* 1978;33:307-11.
32. Phillips DM. JCAHO pain management standards are unveiled. Joint Commission on Accreditation of Healthcare Organizations. *JAMA* 2000;284:428-9.
33. Brennan F, Carr DB, Cousins M. Pain management: a fundamental human right. *Anesth Analg* 2007;105:205-21.
34. Cousins MJ, Lynch ME. The Declaration Montreal: access to pain management is a fundamental human right. *Pain* 2011;152:2673-4.

- 1
- 2
- 3
- 4 35. Dolin SJ, Cashman JN, Bland JM. Effectiveness of acute postoperative pain
- 5 management: I. Evidence from published data. *Br J Anaesth* 2002;89:409-23.
- 6 36. Macrae WA. Chronic post-surgical pain: 10 years on. *Br J Anaesth* 2008;101:77-
- 7 86.
- 8 37. Elia N, Tramer MR. Ketamine and postoperative pain--a quantitative systematic
- 9 review of randomised trials. *Pain* 2005;113:61-70.
- 10 38. Bell RF, Dahl JB, Moore RA, et al. Perioperative ketamine for acute
- 11 postoperative pain. Cochrane database of systematic reviews 2006:CD004603.
- 12 39. Laskowski K, Stirling A, McKay WP, et al. A systematic review of intravenous
- 13 ketamine for postoperative analgesia. *Can J Anaesth* 2011;58:911-23.
- 14 40. Chan MT, Wan AC, Gin T, et al. Chronic postsurgical pain after nitrous oxide
- 15 anesthesia. *Pain* 2011;152:2514-20.
- 16 41. Remerand F, Le Tendre C, Baud A, et al. The early and delayed analgesic
- 17 effects of ketamine after total hip arthroplasty: a prospective, randomized,
- 18 controlled, double-blind study. *Anesth Analg* 2009;109:1963-71.
- 19 42. Zwarenstein M, Treweek S, Gagnier JJ, et al. Improving the reporting of
- 20 pragmatic trials: an extension of the CONSORT statement. *Bmj* 2008;337:a2390.
- 21 43. Treweek S, Zwarenstein M. Making trials matter: pragmatic and explanatory trials
- 22 and the problem of applicability. *Trials* 2009;10:37.
- 23 44. Practice guidelines for acute pain management in the perioperative setting: an
- 24 updated report by the American Society of Anesthesiologists Task Force on
- 25 Acute Pain Management. *Anesthesiology* 2012;116:248-73.
- 26 45. Practice guidelines for chronic pain management: an updated report by the
- 27 American Society of Anesthesiologists Task Force on Chronic Pain Management
- 28 and the American Society of Regional Anesthesia and Pain Medicine.
- 29 *Anesthesiology* 2010;112:810-33.
- 30 46. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 Explanation and
- 31 Elaboration: Updated guidelines for reporting parallel group randomised trials. *J*
- 32 *Clin Epidemiol* 2010;63:e1-37.
- 33 47. Wade DT, Collin C. The Barthel ADL Index: a standard measure of physical
- 34 disability? *Int Disabil Stud* 1988;10:64-7.
- 35 48. Kocalevent RD, Hinz A, Braehler E. Standardization of the depression screener
- 36 patient health questionnaire (PHQ-9) in the general population. *Gen Hosp*
- 37 *Psychiatry* 2013;35:551-5.
- 38 49. Chung F, Yegneswaran B, Liao P, et al. STOP questionnaire: a tool to screen
- 39 patients for obstructive sleep apnea. *Anesthesiology* 2008;108:812-21.
- 40 50. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic
- 41 comorbidity in longitudinal studies: development and validation. *J Chronic Dis*
- 42 1987;40:373-83.
- 43 51. Inouye SK, van Dyck CH, Alessi CA, et al. Clarifying confusion: the confusion
- 44 assessment method. A new method for detection of delirium. *Ann Intern Med*
- 45 1990;113:941-8.
- 46 52. Ely EW, Inouye SK, Bernard GR, et al. Delirium in mechanically ventilated
- 47 patients: validity and reliability of the confusion assessment method for the
- 48 intensive care unit (CAM-ICU). *JAMA* 2001;286:2703-10.
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1
- 2
- 3
- 4 53. Ely EW, Margolin R, Francis J, et al. Evaluation of delirium in critically ill patients: validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). *Crit Care Med* 2001;29:1370-9.
- 5
- 6
- 7 54. Luetz A, Heymann A, Radtke FM, et al. Different assessment tools for intensive care unit delirium: which score to use? *Crit Care Med* 2010;38:409-18.
- 8
- 9
- 10 55. Plaschke K, von Haken R, Scholz M, et al. Comparison of the confusion assessment method for the intensive care unit (CAM-ICU) with the Intensive Care Delirium Screening Checklist (ICDSC) for delirium in critical care patients gives high agreement rate(s). *Intensive Care Med* 2008;34:431-6.
- 11
- 12
- 13 56. Steis MR, Evans L, Hirschman KB, et al. Screening for delirium using family caregivers: convergent validity of the Family Confusion Assessment Method and interviewer-rated Confusion Assessment Method. *J Am Geriatr Soc* 2012;60:2121-6.
- 14
- 15
- 16
- 17
- 18
- 19 57. Payen JF, Bru O, Bosson JL, et al. Assessing pain in critically ill sedated patients by using a behavioral pain scale. *Crit Care Med* 2001;29:2258-63.
- 20
- 21 58. Chanques G, Payen JF, Mercier G, et al. Assessing pain in non-intubated critically ill patients unable to self report: an adaptation of the Behavioral Pain Scale. *Intensive Care Med* 2009;35:2060-7.
- 22
- 23
- 24 59. Avidan MS, Jacobsohn E, Glick D, et al. Prevention of intraoperative awareness in a high-risk surgical population. *N Engl J Med* 2011;365:591-600.
- 25
- 26 60. Avidan MS, Zhang L, Burnside BA, et al. Anesthesia awareness and the bispectral index. *N Engl J Med* 2008;358:1097-108.
- 27
- 28 61. Mashour GA, Shanks A, Tremper KK, et al. Prevention of intraoperative awareness with explicit recall in an unselected surgical population: a randomized comparative effectiveness trial. *Anesthesiology* 2012;117:717-25.
- 29
- 30 62. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform* 2009;42:377-81.
- 31
- 32 63. Neshar N, Serovian I, Marouani N, et al. Ketamine spares morphine consumption after transthoracic lung and heart surgery without adverse hemodynamic effects. *Pharmacol Res* 2008;58:38-44.
- 33
- 34 64. Tharmanathan P, Calvert M, Hampton J, et al. The use of interim data and Data Monitoring Committee recommendations in randomized controlled trial reports: frequency, implications and potential sources of bias. *BMC Med Res Methodol* 2008;8:12.
- 35
- 36 65. Fleming TR, DeMets DL. Monitoring of clinical trials: issues and recommendations. *Control Clin Trials* 1993;14:183-97.
- 37
- 38 66. Smith MA, Ungerleider RS, Korn EL, et al. Role of independent data-monitoring committees in randomized clinical trials sponsored by the National Cancer Institute. *J Clin Oncol* 1997;15:2736-43.
- 39
- 40 67. Montori VM, Devereaux PJ, Adhikari NK, et al. Randomized trials stopped early for benefit: a systematic review. *JAMA* 2005;294:2203-9.
- 41
- 42 68. Bassler D, Briel M, Montori VM, et al. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. *JAMA* 2010;303:1180-7.
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1
2
3
4 69. Grant AM, Altman DG, Babiker AB, et al. Issues in data monitoring and interim
5 analysis of trials. *Health Technol Assess* 2005;9:1-238, iii-iv.
6
7 70. Strayer RJ, Nelson LS. Adverse events associated with ketamine for procedural
8 sedation in adults. *Am J Emerg Med* 2008;26:985-1028.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9 **The Prevention of Delirium and Complications Associated with Surgical Treatments**
10 **(PODCAST) Study: Protocol for an International Multicenter Randomized Controlled Trial**
11

12
13
14 **Trial Registration:** NCT01690988 (last updated December, 2013)

15 **Version date:** ~~August 5 June 16, 2014~~
16

17
18 **Corresponding author:** Michael S. Avidan
19 Campus Box 8054
20 660 S. Euclid Ave
21 Department of Anesthesiology
22 Washington University School of Medicine
23 St. Louis, MO 63110
24 United States
avidanm@anest.wustl.edu

25
26 **Co-authors:** Bradley A. Fritz
27 Department of Anesthesiology
28 Washington University School of Medicine
29 St. Louis, Missouri, United States

30
31 Hannah R. Maybrier
32 Department of Anesthesiology
33 Washington University School of Medicine
34 St. Louis, Missouri, United States

35
36 Maxwell R. Muench
37 Department of Anesthesiology
38 Washington University School of Medicine
39 St. Louis, Missouri, United States

40
41 Krisztina E. Escallier
42 Department of Anesthesiology
43 Washington University School of Medicine
44 St. Louis, Missouri, United States

45
46 Yulong Chen
47 Department of Anesthesiology
48 Washington University School of Medicine
49 St. Louis, Missouri, United States

50
51 Arbi Ben Abdallah
52 Department of Anesthesiology
53 Washington University School of Medicine
54 St. Louis, Missouri, United States
55 Robert A. Veselis
56 Department of Anesthesiology
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Memorial Sloan-Kettering Cancer Center
New York, New York, United States

Judith A. Hudetz
Department of Anesthesiology
Medical College of Wisconsin
Milwaukee, Wisconsin, United States

Paul S. Pagel
Clement J. Zablocki VA Medical Center
Medical College of Wisconsin
Milwaukee, Wisconsin, United States

Gyujeong Noh
Department of Anesthesiology
Asan Medical Center
Seoul, South Korea

Kane Pryor
Department of Anesthesiology
Weill Cornell Medical College
New York, New York, United States

Heiko Kaiser
Department of Anesthesiology
University of Bern Bern, Switzerland

Virendra Kumar Arya
Department of Anesthesiology
Postgraduate Institute of Medical Education and Research
Chandigarh, India

Ryan Pong
Department of Anesthesiology
Virginia Mason Medical Center
Seattle, Washington, United States

Eric Jacobsohn
Department of Anesthesiology
University of Manitoba-Faculty of Medicine
Winnipeg, Manitoba, Canada

Stephen Choi
Department of Anesthesiology
Sunnybrook Health Sciences Center
Toronto, Ontario, Canada

Robert J. Downey
Department of Surgery, Thoracic
Memorial Sloan-Kettering Cancer Center
New York, New York, United States

1
2
3
4
5
6
7
8
9
10 Sharon K. Inouye
11 Department of Medicine – Beth Israel-Deaconess
12 Hebrew Rehab Center for the Aged
13 Boston, Massachusetts, United States

14 George A. Mashour
15 Department of Anesthesiology
16 University of Michigan Medical School
17 Ann Arbor, Michigan, United States

18
19 **Keywords:** ketamine, delirium, postoperative delirium, neurological complications,
20 postoperative pain, surgery, general anesthetics, neurobehavioral manifestations, geriatric
21 syndrome
22
23

24
25
26 **Word Count:** 7,4446,833

Formatted: Not Highlight

Formatted: Not Highlight

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

WORLD HEALTH ORGANIZATION DATA SET

Primary Registry and Trial Identifying Number	ClinicalTrials.gov: NCT01690988
Date of Registration in Primary Registry	August 7, 2012
Secondary Identifying Numbers	IRB ID#: 201206071
Source(s) of Monetary or Material Support	Department of Anesthesiology, Washington University School of Medicine in St. Louis Departments of each respective site
Primary Sponsor	Department of Anesthesiology, Washington University School of Medicine in St. Louis
Secondary Sponsor(s)	Department of Anesthesiology, University of Michigan Medical School in Ann Arbor
Contact for Public Queries	Michael Avidan, MBCh avidanm@anest.wustl.edu 314-747-4155 660 S. Euclid Ave Department of Anesthesiology Washington University School of Medicine St. Louis, MO 63110 United States
Contact for Scientific Queries	Michael Avidan, MBCh Study Principal Investigator avidanm@anest.wustl.edu 314-747-4155 Campus Box 8054 660 S. Euclid Ave Department of Anesthesiology Washington University School of Medicine St. Louis, MO 63110 United States
Public Title	The Prevention of Delirium and Complications After Surgical Treatment (PODCAST) Study
Scientific Title	The Prevention of Delirium and Complications After Surgical Treatment (PODCAST) Study: a randomized controlled trial
Countries of Recruitment	United States, Canada, Switzerland, India, South Korea

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	<p>Health Condition(s) or Problem(s) Studied</p> <p>Intervention(s)</p> <p>Key Inclusion Criteria and Exclusion Criteria</p> <p>Study Type</p> <p>Date of First Enrollment</p>	<p>Postoperative delirium, postoperative pain, and postoperative nausea and vomiting</p> <p>Study arm 1: 0.5 mg/kg of ketamine diluted to 20 mL with saline given intravenously after anesthetic induction and before surgical incision.</p> <p>Study arm 2: 1 mg/kg of ketamine diluted to 20 mL with saline given intravenously after anesthetic induction and before surgical incision</p> <p>Placebo: 20 mL of saline solution given intravenously after anesthetic induction and before surgical incision.</p> <p>Ages eligible for study: ≥ 60 years</p> <p>Sexes eligible for study: both</p> <p>Healthy volunteers: no</p> <p>Inclusion criteria: patients 60 years or older undergoing major open surgery receiving general anesthesia</p> <p>Exclusion criteria: allergy to ketamine, pheochromocytoma, aortic dissection, intracranial hemorrhage, intracranial mass, history of hypertensive emergency, uncontrolled glaucoma, history of drug misuse (e.g., ketamine, cocaine, heroin, amphetamine, methamphetamine, MDMA, phencyclidine, lysergic acid, mescaline, psilocybin), currently taking anti-psychotic medications (e.g., chlorpromazine, clozapine, olanzapine, risperidone, haloperidol, quetiapine, paliperidone, amisulpride, sertindole), weight <50 kg (110 lbs) or >200 kg (440 lbs).</p> <p>Interventional Allocation: randomized Intervention model: parallel assignment Masking: double blind (subject, healthcare providers, investigator, research personnel)</p> <p>Assignment: single arm Primary purpose: prevention Phase III</p> <p>February 2014</p>
---	---	---

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Target Sample Size 600

Recruitment Status Recruiting

Primary Outcome(s) Outcome name: postoperative delirium

Method of measurement: Confusion Assessment Method or Confusion Assessment Method for the ICU

Time points of interest: two hours post-operation, mornings and evenings of postoperative days one through three

Key Secondary Outcomes Outcome name: postoperative pain

Method of measurement: Visual Analog Scale and Behavioral Pain Scale or Behavioral Pain Scale – Non-Intubated

Time points of interest: two hours post-operation, mornings and evenings of postoperative days one through three

Outcome name: postoperative nausea and vomiting

Method of measurement: patient self-report as present or absent and degree of severity (mild, moderate, or severe).

Time points of interest: two hours post-operation, mornings and evenings of postoperative days one through three

ORGANIZATIONAL STRUCTURE AND RESPONSIBILITIES

Principal Investigators:

Michael Avidan, MBBCh
George Mashour, MD, PhD

Responsibilities include: design and conduct of PODCAST trial, preparation of protocol and revisions, organizing steering committee meetings, and publication of study reports.

Steering Committee:

Michael Avidan, MBBCh	Eric Jacobsohn, MBBCh	Kane Pryor, MD
Daniel Emmert, MD, PhD	Hilary Grocott, MD	Gyujeong Noh, MD, PhD
Robert Veselis, MD	Stephen Choi, MD	Paul Pagel, MD, PhD
Sharon Inouye, MD, MPH	Ryan Pong, MD	Judith Hudetz, PhD
George Mashour, MD, PhD	Virendra Kumar Arya, MD	Milo Engoren, MD
Robert Downey, MD	Heiko Kaiser, MD	

Responsibilities include: agreement of final protocol, recruitment of patients and coordinating with principle investigator, reviewing progress of study and if necessary, changes to the protocol.

Trial Management Committee:

Michael Avidan, MBBCh
George Mashour, MD, PhD
Hannah Maybrier

Responsibilities include: study planning, organization of steering committee meetings, provides annual risk report to the Human Research Protection Office at Washington University, reports SAEs (Serious Adverse Events) to Washington University IRB (Institutional Review Board), responsible for maintenance of electronic database, REDCap, advice for lead investigators, assistance with international review, ethics committee applications, data verification, and randomization of study participants

Lead Investigators:

Michael Avidan, MBBCh	Eric Jacobsohn, MBBCh	Kane Pryor, MD
Daniel Emmert, MD, PhD	Hilary Grocott, MD	Gyujeong Noh, MD, PhD
Robert Veselis, MD	Stephen Choi, MD	Paul Pagel, MD, PhD
Sharon Inouye, MD, MPH	Ryan Pong, MD	Judith Hudetz, PhD
George Mashour, MD, PhD	Virendra Kumar Arya, MD	Milo Engoren, MD
Robert Downey, MD	Heiko Kaiser, MD	

Responsibilities include: identification, recruitment, data collection and completion of CRFs, along with follow up of study patients and adherence to study protocol.

Data and Safety Monitoring Committee:

Arbi Ben Abdallah, PhD
Michael Avidan, MBBCh
Charlie Hantler, MD
Simon Haroutounian, PhD

Responsibilities include: reviewing and evaluating the study data to ensure participant safety, study conduct, progress, and efficacy, and making recommendations regarding the continuation, modification, and termination of the trial.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

PROTOCOL VERSIONS

June 18, 2012 Original

April 25, 2013

Amendment 01: Changes to study aims:

- Changed specific aim 1: removed associated adverse events, such as ICU stay, hospital stay, and mortality
- Changed specific aim 2: removed assessing symptoms of other chronic neuropsychiatric processes (such as depression and posttraumatic stress).
- Changed specific aim 3: testing the effects of ketamine on postoperative depression and stress to attenuating postoperative inflammation.

Amendment 02: Addition of study arm. Patients are randomized to one of three study arms: 0.5 mg/kg ketamine, 1 mg/kg ketamine, or placebo dose of equal volume

Amendment 03: Removed phrase that patients will be contacted between 1 and 3 months after surgery to ask about quality of life, lasting pain, feelings of depression or stress.

Amendment 04: Removed phrase that patients will be contacted 1 year after surgery to ask about quality of life and mental function.

Amendment 05: Changed inclusion criteria to patients older than 60 years (was 65 years)

Amendment 06: Removal of phrase regarding study of ketamine use with posttraumatic stress disorder.

Amendment 07: Addition of phrase that hypothesis is based on published data of reduced pain and opioid consumption after surgery. The study will resolve gap in the field by further assessing chronic pain

Amendment 09: Addition of phrase that discusses delirium and pain as two adverse and potentially linked outcomes that have not been previously jointly evaluated in a large clinical trial.

May 30, 2013

Amendment 01: Removal of specific aim 3: testing whether ketamine improves postoperative inflammation

January 3, 2014

Amendment 01: Addition of weight criterion to Exclusion Criteria; weight < 50 kg (110 lb.) and > 200 kg (440 lb.) are excluded.

Amendment 02: Addition of justification of sample size. Included statement that when assuming a two sided type one error of 5% the sample size of 600 patients will detect decrease in delirium from

1
2
3
4
5
6
7
8
9 25% to 15% with the use of ketamine with a power greater than
10 80%.

11 Amendment 03: Change in randomization protocol. We will not
12 randomize cardiac and non-cardiac surgery patients separately.

13
14 Amendment 04: Omission of one of the points of clarification of the
15 pilot study – to determine the efficacy of ketamine in cardiac vs.
16 non-cardiac surgery.

17
18 Amendment 05: Changes to baseline assessments. Addition of
19 Confusion Assessment Method (CAM), Behavioral Pain Scale –
20 Non-Intubated (BPS-NI), Visual Analog Scale (VAS), Barthel Index,
21 Patient Health Questionnaire-8 (PHQ-8), STOP-Bang, and
22 questions about falls.

23
24 Amendment 06: Addition of medical record review screening for
25 comorbid conditions included in the Charlson Comorbidity Index
26 and lab values including electrolytes and blood counts.

27
28 Amendment 07: Addition of the statement that clinicians are
29 instructed not to give enrolled patients ketamine as part of their
30 anesthetic technique.

31
32 Amendment 08: Addition of mailed survey sent 30 days
33 postoperatively assessing depression, positive and negative affect,
34 quality of life, functional independence, and pain using the PROMIS
35 v1.0 – Emotional Distress – Depression, Positive and Negative
36 Affect Scale (PANAS), Veteran's Rand-12 (VR-12), Barthel Index,
37 and the Brief Pain Inventory Short Form (BPI-SF), respectively.

38
39 Amendment 09: Addition of Family Confusion Assessment Method
40 (FAM-CAM) at Washington University, a tool in which family
41 members will assess patient's behavior and determine if delirium is
42 suggested.

43
44 Amendment 10: Addition of observational tools used to assess pain:
45 BPS, BPS-NI

46
47 Amendment 11: Addition of postoperative nausea and vomiting as a
48 secondary outcome.

49
50 Amendment 12: Addition of description of delirium assessment
51 training.

52
53 Amendment 13: Addition of statement that REDCap (Research
54 Electronic Data Capture) will be used.

55
56 Amendment 14: Addition of statement saying there are no planned
57 interim analyses.
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Amendment 15: Changes in statistical analysis:

- Cox proportional-hazards model for recurrent events used to determine the effects of low-dose ketamine on the occurrence and duration of delirium across study groups.
- Poisson hurdle regression used to determine the differences in patients with delirium and those without delirium, and the differences in recurrence in the patient population that does experience delirium.
- Both Poisson and Cox will also be used to compare effects of ketamine on cardiac vs. non-cardiac surgery patients.
- Cochran-Armitage test to determine dose-response trends
- Mixed-effects regression model to detect differences of continuous outcome variables in subgroups.

Amendment 16: Addition of list of short- and long-term side effects of ketamine

March 7, 2014

Amendment 01: Addition of Patient Health Questionnaire 8 (PHQ 8) for baseline assessments and postoperative day three assessments. This replaced the PROMIS depression screen. We would like to assess depression using the same tool at all time points.

Amendment 02: Collection of patient's email at baseline. Patients have the option to receive the 30 day survey by mail or email.

Amendment 03: Addition of Figure 1: Study Flow Chart. This is a visual representation of study conduct.

ABSTRACT

Introduction: Postoperative delirium is one of the most common complications of major surgery, affecting 10-70% of surgical patients 60 years and older. Delirium is an acute change in cognition that manifests as poor attention and illogical thinking, and is associated with longer ICU and hospital stay, long-lasting cognitive deterioration, and increased mortality. Ketamine has been used as an anesthetic drug for over 50 years and has an established safety record. Recent research suggests that, in addition to preventing acute postoperative pain, a sub-anesthetic dose of intraoperative ketamine could decrease the incidence of postoperative delirium as well as other neurologic and psychiatric outcomes. However, these proposed benefits of ketamine have not been tested in a large clinical trial.

Methods: The PODCAST study is an international, multicenter, randomized controlled trial. Six hundred cardiac and major non-cardiac surgery patients will be randomized to receive ketamine (0.5 mg/kg or 1 mg/kg) or placebo following anesthetic induction and prior to surgical incision. For the primary outcome, blinded observers will assess delirium on the day of surgery (postoperative day 0) and twice daily from postoperative days 1 to 3 using the Confusion Assessment Method or the Confusion Assessment Method for the ICU. For the secondary outcomes, blinded observers will estimate pain using the Behavioral Pain Scale or the Behavioral Pain Scale for Non-Intubated Patients and patient self-report.

Ethics and dissemination: The PODCAST trial has been approved by the ethics boards of five participating institutions; approval is ongoing at other sites. Recruitment began in February 2014 and ~~willis-expected-to~~ continue through 2016⁵. Dissemination plans

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

include presentations at scientific conferences, scientific publications, stakeholder engagement and popular media.

Registration details: The study is registered at clinicaltrials.gov, NCT01690988 (last updated December, 2013).

The PODCAST trial is being conducted under the auspices of the Neurological Outcomes Network for Surgery (NEURONS).

STRENGTHS:

- The effects of ketamine are being observed in the routine clinical setting.
- Because PODCAST is a multicenter international trial, the results of the study will potentially be generalizable.
- This trial has a novel focus of assessing delirium and pain concurrently. Results could reveal that these two outcomes are potentially linked in the postoperative setting.
- PODCAST is a randomized, controlled double-blinded study.
- Investigators assessing for delirium have been appropriately trained and will use reliable and validated assessment tools.

LIMITATIONS:

- Pain is a subjective experience and is therefore difficult to measure.
- The Visual Analog Scale (VAS) is not a validated pain assessment instrument in delirious patients. In an attempt to mitigate this limitation, pain will also be assessed

1
2
3
4
5
6
7
8
9 observationally using the Behavioral Pain Scale (BPS) and the Behavioral Pain
10 Scale – Non-intubated (BPS-NI).

- 11 • Delirium is fluctuating in nature. Because patients will be assessed at discrete time
12 points, it is possible that some episodes of delirium will not be detected.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Background and rationale

Delirium

Postoperative delirium is one of the most common complications of major surgery and affects between 10% and 70% of all surgical patients older than 60 years (Table 1).¹ The estimated additional healthcare costs associated with delirium exceed \$60,000 per patient per year.² While causal relationships have not been established, delirium is associated with increased morbidity and mortality, prolonged length of hospital and intensive care unit (ICU) stay, functional and cognitive decline with nursing home or long-term care facility placement.³⁻⁶ Furthermore, the acute deterioration in cognition and psychomotor agitation frequently seen with delirium is often distressing for both patients and their families.

Surgery type	Study (year)	Population	Delirium Rate	Detection method
Unselected	Radtko ⁷	Recovery room after elective general anesthesia	9.9%	Nu-DESC
Surgical ICU	Pandharipande ⁸	Surgical ICU	73%	CAM-ICU
		Trauma ICU	67%	
Head and neck	Weed ⁹	Major head and neck	17%	Not stated
Cardiac	Kazmierski ¹⁰	Cardiac surgery with CPB	Age <60: 16.3% Age ≥60: 24.7%	DSM-IV
	Rudolph ¹¹	Patients >60 undergoing elective or urgent cardiac surgery	43%	CAM
	Saczynski ¹²	Patients >60 undergoing elective coronary artery bypass grafting or valve replacement surgery	46%	CAM
Vascular	Marcantonio, ¹³ Schneider, ¹⁴ Bohner, ¹⁵ and Benoit ¹⁶	Abdominal aortic aneurysm repair	33-54%	CAM or DSM-IV

	Schneider, ¹⁴ and Bohner ¹⁵	Peripheral vascular	30-48%	DSM-IV
Orthopedic	Fisher ¹⁷	Patients >60 undergoing elective orthopedic procedures	17.5%	CAM
	Marcantonio ¹⁸ and Lee ¹⁹	Patients >65 undergoing emergent hip fracture repair	30.2-41%	CAM

Table 1: Incidence of Delirium in Major Surgeries. CAM, Confusion Assessment Method; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, 4th edition; ICU, Intensive Care Unit; Nu-DESC, The Nursing Delirium Screening Scale

The diagnostic criteria for delirium have recently been updated in the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5). Delirium is an acute neurocognitive disorder characterized by a fluctuating level of consciousness with impairment of attention and cognition. In the postoperative context, delirium typically manifests between 0 and 96 hours following the surgical intervention. It is unclear why postoperative delirium occurs so frequently. Age greater than 60, male gender, history of dementia or depression, sensory impairment, and chronic medical illness are consistently described as risk factors for delirium.²⁰ No effective prophylactic or curative treatments for postoperative delirium have been identified.

Ketamine and Delirium

Ketamine is an anesthetic agent that has been in common use for more than 50 years. Ketamine has a wide margin of safety, and as of 2005 had been studied in over 12,000 operative and diagnostic procedures, involving over 10,000 patients from 105 separate studies (Ketamine package insert 2005). There is a pharmacological rationale for using ketamine as a preventative measure against postoperative delirium based on its N-methyl-D-aspartate (NMDA) antagonism.²¹ Normally, excitatory amino acids such as glutamate and aspartate act as agonists at NMDA receptors, and, in the setting of surgery and inflammation, they might

1
2
3
4
5
6
7
8
9 promote excitotoxic injury and apoptosis.²¹ As an NMDA antagonist, ketamine has the potential
10 to protect against such neurological injury.²² Ketamine has also been posited to inhibit HCN1
11 receptors, which mediate the hyperpolarization-activated cation current.²³ Such inhibition is
12 pertinent to delirium because HCN1 channels are important for regulating states of
13 consciousness²⁴ and are up-regulated by inflammation.²⁵ HCN1 receptors are also thought to
14 play a critical role in neuropathic pain through inflammatory cascades.²⁶
15
16 Based on the pharmacological rationale for neuroprotection, a 58-patient randomized, controlled
17 trial was conducted to determine whether ketamine might prevent delirium after major cardiac
18 surgery.²⁷ There was a significant reduction in postoperative delirium from 31% to 3% with the
19 administration of low dose ketamine (0.5 mg/kg) upon induction of anesthesia. While
20 encouraging, this trial must be regarded as preliminary owing to its small sample size, and
21 single center design. Interestingly, the same investigators also found that ketamine was
22 associated with improved cognition beyond the immediate postoperative period.²⁸ Differences
23 between the ketamine and placebo groups were evident in tests of nonverbal memory, verbal
24 memory, and executive function. The investigators found that C reactive protein, a non-specific
25 inflammatory marker, was similar at baseline in the ketamine and the placebo groups. On the
26 first postoperative day, C reactive protein was elevated in both groups, but was significantly
27 higher in the placebo group. The investigators hypothesized that the neuroprotective effect of
28 ketamine might have been, in part, attributable to its anti-inflammatory actions.²⁸ In support of
29 the plausibility of this hypothesis, ketamine use in another cardiac surgical population was
30 similarly shown to attenuate postoperative increases in inflammatory markers.²⁹
31
32 Intraoperative sub-anesthetic dose ketamine is appealing as a potential preventative
33 intervention for delirium, since it is inexpensive and has an excellent safety profile. A number of
34 questions remain to be answered regarding postoperative delirium. Despite the fact that delirium
35 is a common and serious postoperative complication, intraoperative factors contributing to
36 pathogenesis have not been rigorously investigated, and only a few small trials have been
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9 conducted examining interventions to decrease its incidence. It is also currently unknown
10 whether postoperative delirium is preventable, particularly in patients with underlying
11 vulnerabilities. Importantly, ketamine in higher (anesthetic) doses has become less popular over
12 time owing to side effects, including hallucinations and emergence reactions, especially in
13 younger patients.^{30,31} To ensure treatment effectiveness, the preliminary results identifying sub-
14 anesthetic dose ketamine as a useful preventative intervention for postoperative delirium should
15 therefore be confirmed or refuted using a large scale, pragmatic, randomized controlled trial
16 design prior to routine adoption of low dose ketamine for this purpose.
17
18
19
20
21
22
23

24 Acute and Persistent Pain

25
26 Similar to delirium, both acute and persistent pain are common postoperative complications,
27 with a negative impact on patients' lives. The Joint Commission has established the prevention
28 of severe postoperative pain as a benchmark of quality,³² and adequate pain management is
29 increasingly viewed as a fundamental human right.^{33,34} Unfortunately, this standard of care has
30 not been attained to date; it has previously been estimated that about a third of patients suffer
31 severe acute postsurgical pain following major procedures.³⁵ Furthermore, patients who have
32 acute postoperative pain are more likely to develop chronic pain, and the incidence of persistent
33 postoperative pain following major surgeries remains between 5% and 30%.³⁶ As an antagonist
34 at NMDA and HCN1 receptors, ketamine has powerful analgesic properties. A systematic
35 review showed that a single sub-anesthetic dose of intraoperative ketamine was associated with
36 decreased visual analog pain scores up to 48 hours postoperatively.³⁷ At 24 hours
37 postoperatively, ketamine was associated with an impressive 16 mg decrease in total morphine
38 consumption.³⁷ Furthermore, adverse effects such as hallucinations were rarely reported when
39 low dose ketamine was administered during general anesthesia.³⁷ Consistent with these
40 findings, a Cochrane systematic review reported that sub-anesthetic doses of perioperative
41 ketamine were associated with decreased postoperative pain, decreased morphine
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9 consumption, and decreased nausea and vomiting.³⁸ Adverse effects were mild or absent.³⁸ An
10 updated systematic review, which included 70 small studies involving 4,701 patients, recently
11 confirmed that, in a dose-dependent manner, sub-anesthetic intraoperative ketamine was
12 consistently associated with decreased postoperative pain despite decreased opioid
13 consumption.³⁹ The more painful the surgical procedure, the greater was the analgesic benefit
14 attributable to ketamine.³⁹ In keeping with decreased opioid consumption, postoperative nausea
15 and vomiting were also less frequent in patients who received ketamine. However, patients who
16 had been randomized to ketamine reported hallucinations and nightmares more frequently.³⁹
17 While efficacy data, based on numerous small studies, strongly suggest that supplementary
18 ketamine should be used to decrease pain and opioid usage postoperatively, most practitioners
19 have not incorporated low dose ketamine into their routine practice. Preliminary data gathered
20 from 5 institutions (see below for details) involved in the PODCAST Trial suggest that, despite
21 their knowledge regarding the analgesic and opioid-sparing effects, practitioners do not
22 administer low-dose ketamine for pain because of concern for complications such as delirium.
23 Thus, effectiveness data regarding the relationship of ketamine, delirium and pain are needed.
24 Although numerous small efficacy studies have shown that ketamine decreases acute
25 postoperative pain, its role in preventing persistent postoperative pain has not been rigorously
26 explored. Many causal mechanisms that are thought to be implicated in persistent pain and a
27 single intraoperative intervention might not be sufficient to decrease its occurrence. However,
28 there have been encouraging findings about the potential of NMDA antagonists to decrease
29 postoperative persistent pain. In the ENIGMA trial, patients were randomized to receive
30 intraoperative oxygen with either nitrogen or nitrous oxide, which, like ketamine, is an NMDA
31 antagonist. The investigators found that among those patients who received nitrous oxide, there
32 was an absolute decrease in the percentage of patients who experience persistent pain
33 (baseline incidence = 15%) at 3 months postoperatively of 7% (95% CI, 1.9% to 13.9%).⁴⁰ A
34 randomized study has examined the potential beneficial effect of intraoperative ketamine on
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9 persistent postoperative pain among patients undergoing total hip replacement.⁴¹ This trial
10 found a reduction in the ketamine group from 21% to 8% (reduction = 13%; 95% C.I., 1.3% to
11 24.9%) in patients experiencing persistent pain at 6 months after their surgery.⁴¹ The PODCAST
12 study would demonstrate whether sub-anesthetic dose intraoperative ketamine is effective at
13 preventing acute postoperative pain in a real world setting. If ketamine were shown to have a
14 substantial effect in decreasing acute postoperative pain, a next step would be to investigate
15 rigorously its impact on persistent pain.
16
17
18
19
20

21 22 23 Current Utilization of Low-Dose Ketamine

24 A survey of anesthesia clinicians was conducted at five of the institutions (Washington
25 University in St. Louis, University of Michigan, University of Manitoba, Weill Medical College of
26 Cornell University, and Medical College of Wisconsin) participating in the PODCAST clinical
27 trial. In total, 270 clinicians responded to the surveys; 18% (range among institutions 12% to
28 40%) of respondents currently incorporate adjunctive sub-anesthetic ketamine into their
29 practice. Interestingly, 84% of survey respondents believe that low dose ketamine decreases
30 acute postoperative pain, 81% feel that it decreases postoperative opioid consumption, and
31 51% believe that it decreases chronic postoperative pain. However, the reason that a minority of
32 practitioners are currently administering adjunctive ketamine is probably because many remain
33 concerned about the neurological side effects of even low dose ketamine; 68% of respondents
34 expressed concern about hallucinations, 62% about delirium and 55% about nightmares.
35
36
37
38
39
40
41
42
43
44
45

46 Potential Impact of PODCAST

47
48 The PODCAST trial has a novel focus in that it is assessing the impact of an intervention (sub-
49 anesthetic- racemic ketamine administration) on both delirium and pain, two adverse and
50 potentially linked outcomes that have not previously been jointly evaluated in a single large
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9 clinical trial. Both delirium and pain are surprisingly common acute postoperative complications
10 with major negative consequences for patients.^{1,35} Currently, there are no official guidelines to
11 screen patients for delirium and only few preventive measures have been investigated, with
12 disappointing results. Since most patients with postoperative delirium have a hypoactive
13 phenotype, it is frequently missed in clinical practice. As noted previously, postoperative
14 delirium is associated with increased intensive care and hospital stay, with persistent cognitive
15 decline and with increased mortality. Thus, any intervention that could decrease the incidence of
16 postoperative delirium would probably have major positive implications for older patients
17 undergoing surgical procedures. Unlike delirium, acute postoperative pain is routinely assessed
18 and the Joint Commission has prioritized the prevention of severe postoperative pain as a
19 universal goal. Unfortunately this objective has not been met, and both severe acute pain and
20 debilitating chronic pain continue to afflict many surgical patients.^{35,36} Of note, both pain and its
21 treatment with opioid analgesics can be risk factors for delirium. Opioid analgesics are the
22 mainstay therapy for postoperative pain, but their administration is curtailed in older patients
23 particularly for safety considerations regarding respiratory depression, but also for concerns
24 about causing sedation and delirium.

25
26
27
28
29
30
31
32
33
34
35
36
37 Pragmatic trials are intended to generate evidence of effectiveness of a test, treatment,
38 procedure, or health-care service.^{42,43} At present, there is a lack of pragmatic trials for candidate
39 interventions to prevent important and common postoperative neurologic and psychiatric
40 complications including delirium and pain. Ketamine is a plausible prophylactic option for each
41 of these neurological and psychiatric complications. The American Society of Anesthesiologists
42 has published Practice Guidelines for the management of acute and chronic pain, which, based
43 on small efficacy or observational trials, include ketamine as a treatment option.^{44,45} There are
44 currently no guidelines for the prevention of postoperative delirium. Thus, a multicenter
45 pragmatic trial comparing low dose ketamine with placebo is timely. It is important to emphasize
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9 that any one of several potential results of the PODCAST trial will have important and
10 immediate positive implications for older surgical patients. First ketamine might decrease both
11 delirium and pain. This result would provide clear support for a larger comparative effectiveness
12 trial testing ketamine as a prophylactic measure for both of these outcomes. Second, ketamine
13 might decrease pain without increasing delirium. This result would provide compelling data that
14 encourage the use of ketamine to prevent pain without concern for cognitive side effects such
15 as delirium. Third, ketamine might decrease delirium and have no impact on pain. Although the
16 lack of effect on pain is unlikely, this result would also encourage further study of the use of
17 prophylactic intraoperative ketamine. However, low dose ketamine may be found to increase
18 delirium, regardless of its impact on pain. This result would suggest that the incorporation of
19 intraoperative ketamine into routine clinical practice for older surgical patients is not warranted
20 and would negate the need for a larger pragmatic trial. Furthermore, the PODCAST trial will
21 help determine ketamine dose-related effects by comparing two doses (0.5 mg/kg and 1 mg/kg)
22 to placebo. As such, all of these potential results of the PODCAST trial have the potential to
23 impact clinical practice and will be generalizable to all older surgical patients undergoing major
24 surgical procedures because of the permissive inclusion criteria and the simplicity of
25 intervention.⁴²

40 METHODS AND ANALYSIS

43 Study design

44 PODCAST is a prospective randomized controlled trial has been designed in accordance with
45 CONSORT guidelines⁴⁶ and will evaluate whether a single bolus dose of **racemic** ketamine (0.5
46 mg/kg or 1 mg/kg) following induction of anesthesia and before surgical incision decreases the
47 incidence or severity of postoperative delirium and pain in a mixed elderly (>60 years) surgical
48 patient population. Patients will undergo the standard preoperative anesthesia assessment.
49
50
51
52
53
54
55
56
57
58
59
60

Formatted: None, Space Before: 0 pt, After:
0 pt

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Follow up information will be collected from the medical chart for up to 5 years. The overall study design is outlined in Figure 1.




Figure 1: Study Enrollment

Eligibility criteria

Formatted: None, Space Before: 0 pt, After: 0 pt

1
2
3
4
5
6
7
8
9 Patients 60 years old and older, who are competent to provide informed consent and who are
10 undergoing major open cardiac surgery (e.g., coronary artery bypass graft, valve replacement)
11 or non-cardiac surgeries (e.g., thoracic surgery, major vascular surgery, intra-abdominal
12 surgery, open gynecologic surgery, open urologic surgery, major orthopedic surgery, hepato-
13 biliary surgery and major ENT surgery) receiving general anesthesia will be eligible for inclusion.
14 The exclusion criteria are based on the contraindications to ketamine from the 2005 ketamine
15 package insert. Patients with an allergy to ketamine and those in whom a significant elevation of
16 blood pressure would constitute a serious hazard (e.g., pheochromocytoma, aortic dissection)
17 will be excluded. We shall also exclude patients with drug misuse history (e.g., ketamine,
18 cocaine, heroin, amphetamine, methamphetamine, MDMA, phencyclidine, lysergic acid,
19 mescaline, psilocybin), patients taking anti-psychotic medications (e.g., chlorpromazine,
20 clozapine, olanzapine, risperidone, haloperidol, quetiapine, paliperidone, amisulpride,
21 sertindole), and patients with a weight outside the range 50 kg – 200 kg (110 lbs – 440 lbs).
22 Patients will be enrolled either during a preoperative clinic visit or in the hospital prior to surgery.
23
24
25
26
27
28
29
30
31
32
33
34

35 **Baseline Assessment**

36 At the time of enrollment, patients will undergo the same delirium and pain evaluation that will
37 be used postoperatively (see Outcomes section). Additionally patients will be screened for
38 functional dependence using the Barthel Index of Activities of Daily Living,⁴⁷ for depression
39 using the patient health questionnaire (PHQ-8),⁴⁸ and for obstructive sleep apnea using the
40 STOP-Bang criteria.⁴⁹ Patients will be asked if they have a history of delirium, and if this
41 presented after surgery. They will also be asked about any falls they have experienced in the six
42 months prior to surgery. Comorbid conditions, including the components of the Charlson
43 Comorbidity Index,⁵⁰ will be obtained by reviewing the patients' medical records. Any available
44 preoperative lab results, including electrolytes and blood counts, will also be recorded.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Interventions

As this is a pragmatic trial, apart from administration of the study drug (ketamine or normal saline), all decisions about anesthetic technique will be made by the anesthetic team assigned to each patient. The only exception is that clinicians will be instructed not to administer any ketamine other than the study drug. The intention of this trial is to interfere as little as possible with the usual process of care, which will increase the applicability of the findings.⁴³ Following induction of general anesthesia, an intravenous dose of 0.5 mg/kg **racemic** ketamine, 1 mg/kg **racemic** ketamine, or an equivalent volume of normal saline will be injected via a reliable (free flowing) central or peripheral intravenous line. Clinicians will be blinded to the treatment arm of the study. Anesthetic factors such as the use of nitrous oxide, protocols for pain prevention, use of neuraxial anesthesia, use of nerve blocks, and other practices that could potentially affect primary or secondary outcomes will be assessed in a *post hoc* manner.

Outcomes

Primary outcomes

Trained members of the research team who are blinded to the treatment arm of the study will assess patients for **delirium** (primary outcome) using the Confusion Assessment Method (CAM)⁵¹ and the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU)^{52,53} for patients who are unable to speak (e.g., have a tracheal tube or tracheostomy) on the intensive care unit. These methods (the CAM and the CAM-ICU) have been shown to be reliable and to have good agreement with the DSM-IV criteria for delirium.⁵³⁻⁵⁵ Delirium assessments will be performed when patients can be aroused sufficiently in order to be assessed for delirium (Richmond Agitation and Sedation Score > -4). The first delirium assessment will be attempted if feasible on the day of surgery in the afternoon / evening. Patients will then be assessed for delirium twice daily (from postoperative day 1 to postoperative day 3) in the morning and in the

1
2
3
4
5
6
7
8
9 afternoon / evening with at least 6 hours between assessments. Each patient will be assessed
10 for delirium up to seven times. At the Washington University site, the patients' family members
11 will perform the Family Confusion Assessment Method (FAM-CAM) separately from the
12 investigators performing their assessments.⁵⁶ Investigators and family members will be blinded
13 to each other's assessments. The FAM-CAM has demonstrated high sensitivity and specificity
14 for detection of delirium and good agreement with the CAM⁵⁶, but has not been specifically
15 evaluated in the postoperative setting. After the final delirium assessment, patients will
16 complete the Delirium and Pain Self-Assessment Questionnaire (Appendix A). Incident delirium
17 subsequent to this period is unlikely to be directly related to anesthetic or other intraoperative
18 factors.
19
20
21
22
23
24
25
26
27

28 Secondary outcomes

29
30 Study team members blinded to the treatment group of the patient will assess all secondary
31 outcomes. **Acute pain** (secondary outcome) will be assessed prior to surgery and then
32 postoperatively by using the Behavioral Pain Scale (BPS)⁵⁷ or the Behavioral Pain Scale for the
33 Non-Intubated patient (BPS-NI)⁵⁸ and the 10-cm VAS (Visual Analog Scale) (Appendix E and F)
34 at the same times as patients are assessed for delirium. The BPS-NI has been shown to be a
35 valid and reliable tool for measuring pain in a predominantly delirious patient population.⁵⁸
36 Interviewers will rate the BPS or BPS-NI prior to asking the patient to complete the VAS to
37 prevent bias in the BPS and BPS-NI assessments. Postoperative daily amount of opioids and
38 sedatives administered will be ascertained from the patient's electronic health record spanning
39 the period after surgery until the final delirium assessment is complete. After the final delirium
40 assessment, patients will complete the Delirium and Pain Self-Assessment Questionnaire
41 (Appendix A). **Postoperative nausea and vomiting** (secondary outcome) will be assessed at
42 the same time points that patients are assessed for delirium by asking patients to rate the
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Formatted: Not Highlight

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

severity of their nausea and vomiting, if present, on a three point scale (mild, moderate, severe). Patients will be questioned at each assessment about side effects, especially hallucinations and nightmares. Intensive care unit and hospital length of stay will be obtained from the patient's medical record. At some of the participating sites in the PODCAST trial, patients will receive a survey, which will be sent by mail or email one month following surgery. This survey will collect patient reported outcomes (PROs) on depressive symptoms, affect, persistent pain, functionality and quality of life. Depressive symptoms will be assessed with the eight item Patient Health Questionnaire (PHQ-8), Affect will be assessed with two 10-item mood scales that comprise the Positive and Negative Affect Schedule (PANAS) within three to six months postoperatively.⁵⁹ The same screens for depressive symptoms and affect will also be conducted in the hospital on postoperative day 3. Persistent pain will be assessed with the Brief Pain Inventory Short Form (BPI-SF). The Barthel Index will be used to report functionality and quality of life will be assessed from the Veteran's Rand-12 (VR-12) questionnaire.

Standardization of training and outcomes assessment

All study team members who perform delirium assessments will undergo a rigorous training process. For the initial training, representatives from each study site participated in a full-day training program led by Dr. Sharon Inouye, the original creator of the CAM. Those who attended this initial training will oversee the training of other team members at their sites. Trainees must demonstrate competence at both conducting CAM interviews and in scoring these interviews. For the initial part of training, trainees must conduct at least two satisfactory CAM interviews in the presence of a trained team member. These interviews will not be on patients enrolled in the PODCAST trial. To establish their ability to score CAM interviews reliably, trainees will accompany trained team members to conduct CAM interviews. A trained member of the research team will conduct each CAM interview for patients enrolled in the

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

PODCAST trial. The trainee will observe the interview, but will score the CAM independently.

The trainee must agree with the trainer on the presence or absence of all twelve cognitive features assessed by the CAM on a minimum of two delirious and two non-delirious patients.

After meeting the stipulations of training, the newly trained team member will conduct their first interview of a patient enrolled into the PODCAST trial in the presence of a previously trained team member.

Assessment of the standardization and reliability of delirium assessments

After training, all PODCAST team members administering delirium assessments will be invited to participate in a project to demonstrate the validity and reliability of the CAM in our study population. Participants will view and rate eight videos of standard interviews depicting delirious and non-delirious patients. Participants will independently score the CAM for each scenario.

Demographic information, level of education, level of clinical experience, and primary language will also be collected from all participants. Data will be de-identified. All scores and data will be submitted to the lead site, Washington University. The group's scores will then be compared to determine the reliability of delirium assessments across sites. Additionally, the group's scores will be compared to a set of "gold standard" scores for the videos (determined by Dr. Inouye's team) This comparison is intended to demonstrate validity of the CAM in our study setting.

Overall, the goal of the project is to demonstrate standardization of the delirium outcome across all study sites.

Sample size

Based on published delirium incidences in the scientific literature (Table 1), we estimate conservatively that the incidence of postoperative delirium in a mixed major surgical population

1
2
3
4
5
6
7
8
9 of older patients will be between 20% and 25%. Based on data from a sub-study of the BAG-
10 RECALL trial that we have recently completed, the incidence of delirium among patients
11 admitted to our cardiothoracic intensive care unit at Barnes-Jewish Hospital is 25% within three
12 postoperative days. Hudetz et al found that ketamine was associated with a 28% (95% CI, 8%
13 to 46%) absolute risk reduction in delirium (from a baseline incidence of 31%).²⁷ A 28%
14 reduction is likely to be an over-optimistic effect size for designing a pragmatic study; 10% is
15 more realistic as the most optimistic effect size and remains consistent with the confidence
16 interval for the effect size found by Hudetz et al.²⁷ Assuming a two-sided type I error rate of 5%,
17 a sample size of 600 will give greater than 80% power to detect a decrease in the incidence of
18 delirium from 25% to 15% with ketamine. On the other hand, we consider the minimum
19 clinically important difference (MCID) or effect size to be 2%, which corresponds to a number
20 needed to treat of 50 surgical patients to prevent one episode of delirium. The rationale for the
21 low MCID is that delirium is a serious postoperative complication that is associated with
22 increased mortality and the proposed intervention (low dose ketamine) is safe, inexpensive and
23 not likely to have adverse effects.
24
25
26
27
28
29
30
31
32
33
34

35 There are two specific issues to clarify in this study: i) the likely effect size with ketamine; and ii)
36 the optimal ketamine dose. Ketamine might increase delirium, decrease delirium or have no
37 impact on delirium. If ketamine increases delirium, it is more likely to increase delirium at a
38 higher dose (1 mg/kg). If ketamine decreases delirium, it might have a dose response effect –
39 less delirium at the higher ketamine dose (1 mg/kg). We anticipate that ketamine will decrease
40 pain in a dose dependent manner – 1mg/kg will be superior to 0.5 mg/kg. Accrual of 200
41 patients to each dose of ketamine along with a placebo arm will allow a more robust
42 assessment of the dose-response efficacy for postoperative analgesia than previous studies
43 with fewer numbers. In general, the higher ketamine dose might have more side effects. As
44 such, this trial might inform whether the higher ketamine dose can be used, in view of its
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

possibly superior analgesia, with a potential benefit in relation to delirium and without excessive side effects. The dosage determination going forward will depend on the observed incidence of delirium with each dose, analgesia efficacy with each dose, and side effect profile with each dose. The proposed design for the study is shown in Table 2.

Group	N
Placebo	200 patients
Ketamine Low Dose (0.5 mg/kg)	200 patients
Ketamine Moderate Dose (1 mg/kg)	200 patients

Table 2: Patient Allocation.

With this approach, we believe that this study will clearly inform whether it is indicated, both in terms of efficacy and in terms of feasibility, to pursue a larger study. The purpose of the larger study (PODCAST2) will be to determine definitively whether ketamine is associated with a reduction in delirium (and pain) in high-risk older surgical patients, without incurring an increase in side effects. As the main effect evaluated will be whether ketamine decreases delirium, Table 3 provides a useful guide for the potential findings of the current study with their implications.

Delirium Incidence in Placebo Groups (N=200)	Delirium Incidence in Ketamine Groups (N=400)	Effect Size (Reduction in delirium with ketamine)	95% Confidence Interval (CI) for Effect Size
25% (N=50)	25% (N=100)	0%	-7.6% to 7.1%
<i>Implication:</i> Consider Pursuing a larger study only if pain is decreased in ketamine groups, and there is no increase in side effects.			
25% (N=50)	22.5% (N=90)	2.5%	-4.5% to 10.0%
<i>Implication:</i> Although the point estimate is >2% (MCID), a 9,500 patient study would be required to			

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

clarify more precisely the effectiveness of ketamine in preventing delirium. Other outcomes in the study (e.g., pain reduction and side effects) would inform the approach.			
25% (N=50)	20% (N=80)	5%	-1.9% to 12.4%
<i>Implication:</i> Pursue larger study with approximately 2,500 patients to clarify more precisely the effect of ketamine on preventing delirium.			
25% (N=50)	17.5% (N=70)	7.5%	0.7% to 14.8%
<i>Implication:</i> Pursue larger study (approximately 1,200 patients) to clarify whether effect size >2% (MCID) and to define it more precisely.			
25%	15%	10%	3.3% to 17.1%
<i>Implication:</i> For main effect, lower bound of CI >2% (MCID). Ketamine's benefit in decreasing delirium is very likely, but a larger study (approximately 1,200 patients) would define its effect more precisely.			

Table 3: Potential Findings of PODCAST.

Recruitment

This clinical trial will be conducted at Washington University in St. Louis and other sites. Our research team has conducted large randomized, controlled trials, which enrolled (approximately) 2,000 patients over 14 months in the B-unaware trial,⁶⁰ 6,000 patients over 26 months in the BAG-RECALL trial⁵⁹ and 22,000 patients over 24 months in the Michigan Awareness Control Study.⁶¹ Based on the inclusion criteria and the number of eligible surgical patients, we estimate that one year will be sufficient for patient enrollment to the proposed trial, and a further one year for data analysis.

Allocation

Subjects will be block randomized by the hospital pharmacy departments in groups of 15 (1:1:1 ratio - 0.5 mg/kg ketamine: 1 mg/kg ketamine: placebo), stratified by site, in order to keep the randomization balanced and the groups more homogeneous. The outcome of this random

1
2
3
4
5
6
7
8
9 assignment will be concealed from the study team and all study subjects and trial staff will be
10 blinded to the randomization. Codes will be held by the hospital pharmacies and they will
11 dispense medication. Randomization codes will remain concealed until the primary analysis is
12 completed. Prepared syringes of either placebo or ketamine will be directly delivered to the
13 operating room in which surgery of the consented patient will take place as soon as the
14 research team informs the pharmacy about the patient going to the operating room for surgery.
15
16
17
18
19

20 21 22 **Data analysis and management**

23
24 Data analysis for this investigation will require comparisons of patient outcomes (e.g., delirium,
25 pain, length of stay, adverse events) in the three study groups to assess for significant
26 differences among ketamine doses (placebo, 0.5 mg/kg and 1 mg/kg). For proportions and
27 categorical outcomes, such as incident delirium, we will use the chi square test (or Fisher's
28 exact test in the case of sparse data) to compare proportions across the three groups and the
29 Cochran-Armitage test to test for dose response trends. For continuous outcomes, such as
30 visual analog pain scores and opioid consumption, we will use repeated-measures analysis of
31 variance tests to detect the main effects. The Tukey post-hoc test will also be run on all
32 significant interactions to determine differences between individual and combined groups (e.g.,
33 placebo versus combined ketamine groups; 0.5 mg/kg ketamine versus 1 mg/kg ketamine). For
34 multivariate analyses, we will apply the Cox proportional-hazards model for recurrent events to
35 investigate the effects of low doses of intraoperative ketamine on delirium by comparing its
36 occurrence and timing across the study groups. We will also model the number of postoperative
37 delirium incidents using a Poisson hurdle regression to find out the difference in the proportion
38 of patients with and without delirium, and for those who experience delirium, the difference in its
39 recurrence. Both models (Cox proportional-hazards and hurdle model) will account for
40 differences in ketamine effectiveness in cardiac versus non-cardiac surgery by including
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9 interaction terms for ketamine dose and cardiac surgery status, while adjusting for other
10 influential variables. We will also use mixed-effects regression models to assess differences
11 among the subgroups in continuous outcome variables over time (e.g., postoperative pain
12 scores and opioid consumption). These models will likewise account for interactions between
13 ketamine dose and cardiac surgery status. All statistical testing will be two sided, and p values
14 <0.05 will be regarded as significant. No interim analyses are planned. Appropriate adjustment
15 will be made for multiple analyses.
16
17
18
19

20
21 The Division of Biostatistics Informatics Core at Washington University will be used as a central
22 location for data processing and management. Washington University belongs to a consortium
23 of institutional partners that work to maintain a software toolset and workflow methodology for
24 electronic collection and management of research and clinical trial data. REDCap (Research
25 Electronic Data Capture) data collection projects rely on a thorough study-specific data
26 dictionary defined in an iterative self-documenting process by all members of the research team
27 with planning assistance from the Division of Biostatistics Informatics Core. The iterative
28 development and testing process result in a well-planned data collection strategy for individual
29 studies. REDCap servers are securely housed in an on-site limited access data center managed
30 by the Division of Biostatistics at Washington University. All web-based information transmission
31 is encrypted. The data is all stored on a private, firewall protected network. All users are given
32 individual user ids and passwords and their access is restricted on a role-specific basis.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
REDCap was developed specifically around HIPAA-Security guidelines and is implemented and
maintained according to Washington University guidelines. REDCap currently supports >500
academic/non-profit consortium partners on six continents and 38,800 research end-users.⁶²

Monitoring

1
2
3
4
5
6
7
8
9 The research team will monitor the study for adverse events. All serious adverse events will be
10 reported to the IRB according to IRB stipulations. The monitoring plan for this study is
11 appropriate for the planned pragmatic trial. As an anesthetic drug, ketamine has an excellent
12 safety profile and record. In particular, low dose ketamine (0.5 mg/kg or 1 mg/kg) administered
13 prior to surgical incision is unlikely to be associated with major adverse events, and even minor
14 side effects manifesting after induction of anesthesia and the start of surgery are
15 improbable.^{37,38,63}

16
17
18
19
20
21 The PODCAST trial will have an appropriate data and safety monitoring plan for a low risk
22 clinical trial. There will be a charter to guide the functions of the Data Safety and Monitoring
23 Board (DSMB), and the DSMB will produce reports in accordance with NIH guidelines. The
24 DSMB will provide independent oversight of the PODCAST trial and will review general conduct
25 of the trial as well as study data for participant safety.⁶⁴ The DSMB will be comprised of
26 independent, multidisciplinary experts who will make recommendations regarding the
27 continuation, modification, or termination of the trial.⁶⁵ The members will have the requisite
28 expertise to examine accumulating data, to protect the integrity of the clinical experiments to
29 which the patients have consented to participate, and to assure the regulatory bodies and the
30 public (and possibly funding agencies) that conflicts of interest do not compromise either patient
31 safety or trial integrity.⁶⁶ There will be no pre-specified interim analysis given the size of this
32 study; frequent analyses might increase the likelihood of bias.⁶⁴ There will be a provision for
33 early stoppage for safety concerns, but not for efficacy or for futility.⁶⁴ Trials that stop early for
34 benefit show implausibly large treatment effects, particularly when the number of events is
35 small.⁶⁷ Truncated trials have been associated with greater effect sizes than trials not stopped
36 early, independent of the presence of statistical stopping rules.⁶⁸

37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9 All members of the DSMB will be at the Washington University site. Local investigators at all
10 participating sites will report serious adverse events, or unanticipated problems involving risks to
11 subjects or others, to their IRB and to the PI of the study at Washington University. If such
12 problems are considered related to the trial, then they will also be reported to IRBs at other
13 participating sites and to the chairperson of the DSMB. The members of the DSMB will have no
14 direct involvement in the conduct of the PODCAST trial. Neither will they have financial,
15 proprietary or professional conflicts of interest, which may affect the impartial, independent
16 decision-making responsibilities of the DSMB.^{64,65} Letters of invitation to prospective DSMB
17 members will include the following: "Acceptance of this invitation to serve on the PODCAST
18 DSMB confirms that I do not have any financial or other interest with any of the collaborating or
19 competing pharmaceutical firms or other organizations involved in the study that constitute a
20 potential conflict of interest." All DSMB members will sign a Conflict of Interest Certification to
21 confirm no conflict exists. There will be between three and eight people on the DSMB, in order
22 to optimize performance.⁶⁹ The DSMB will be advisory rather than executive on the basis that it
23 is the PODCAST trial investigators who are ultimately responsible for the conduct of the trial.⁶⁹
24
25
26
27
28
29
30
31
32
33
34

35 The risks associated with this study are low. There is a rare risk of breach of confidentiality. In
36 contrast to other anesthetics, protective reflexes such as coughing and swallowing are
37 maintained with low dose ketamine. The 2005 package insert for ketamine reports the induction
38 dose for anesthesia as follows: The initial dose of ketamine administered intravenously may
39 range from 1 mg/kg to 4.5 mg/kg. The average amount required to produce five to ten minutes
40 of surgical anesthesia has been 2 mg/kg. The short-term side effects of ketamine at higher
41 doses (>1-2 mg/kg) than the dosages proposed for this study (0.5 mg/kg or 1 mg/kg) include
42 tachycardia, nystagmus, hypersalivation, euphoria, emergence reactions, hallucinations and
43 nightmares.⁷⁰ It is possible, but very unlikely, that low dose ketamine (0.5 mg/kg or 1 mg/kg)
44 administered just after induction of anesthesia or administration of sedative medications will
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9 cause these side effects.^{37,38,63} Emergence reactions, hallucinations and nightmares are more
10 common in younger patients receiving ketamine. In published studies on low dose ketamine
11 (0.25 to 1 mg/kg) administered during general anesthesia, side effects have generally not been
12 found.³⁷ The main side effects that might occur are nightmares and hallucinations. Other
13 neuropsychiatric side effects might occur, most likely within the first 24 hours after surgery, and
14 will be determined from patient interviews. The incidence of these side effects in this patient
15 population is currently unknown, and thus side effects will be reported separately and jointly.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Meta-analysis suggests that ketamine might be associated with an increase in neurologic and psychiatric side effects from approximately 5% to 7.5%. This study will be >80% powered to detect an increase in side effects from 5% to 12% and 20% powered to detect an increase in side effects from approximately 5% to 7.5%. As part of the informed consent process for this study, patients will be informed of the rare risks and will be asked about them after their surgery. In the unlikely event that serious side effects occur, they will be documented and will be reported to the human research protection office and to the study's DSMB. Participants will not incur any study-related expenses, nor will they be financially compensated for their participation.

Ethics and dissemination

Ethics approval and consent

The PODCAST trial has been approved by the institutional review boards of the principal investigators' home institutions (Washington University, St. Louis and University of Michigan, Ann Arbor). Institutional review board approval has also been obtained at some of the participating sites (Postgraduate Institute of Medical Education and Research, Chandigarh, India; University of Manitoba, Winnipeg, Canada; Weill Medical College, Cornell University, New York City; Medical College of Wisconsin, Milwaukee) and is ongoing at other sites. Recruitment ~~is anticipated to~~ began in February of 2014 and will continue through 2015. Potential

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

participants will be approached for enrollment by a member of the research team who will explain the purpose of the study and written informed consent will be obtained for all participants. Patients may choose not to participate in this study and there will be no penalty in terms of the care that they receive.

Confidentiality

Necessary protected health information will only be shared with members of the research team. To help protect confidentiality, research charts will be stored in a locked cabinet inside the locked research office. Electronic data and demographic information will also be kept in a password-protected electronic database stored on the departmental network drive and only accessible via password-protected departmental computers. A member of the research team will enter this information. Code numbers, rather than names, will appear on any data and documents used for evaluation or statistical analyses.

Dissemination

Dissemination plans include presentations at local, national and international scientific conferences. There are no publication restrictions and no professional writers will be involved in the generation of the manuscript.

CONCLUSIONS

In the next four decades, the US population over the age of 60 is predicted to double to more than 80 million individuals. The aging population often requires surgery, which can be frequently complicated by postoperative pain and delirium. Delirium is defined as an acute brain dysfunction that presents as fluctuating levels of inattention and disordered thinking, and has been reported to affect up to 70% of surgical patients older than 60. Likewise, severe

1
2
3
4
5
6
7
8
9 postoperative pain continues to affect a large proportion of surgical patients, especially the
10 elderly, and is another major contributor to delirium. Unfortunately, opioid medications, the
11 current standard for analgesia, can themselves lead to delirium and other adverse
12 consequences. Clinicians therefore face the paradox that both pain and the mainstay treatment
13 of pain can lead to delirium. Although causal relationships have not been established,
14 postoperative delirium is associated with increased intensive care unit and hospital stay,
15 persistent cognitive decline, and increased mortality rate. What is needed is a therapeutic
16 intervention that can both attenuate pain and decrease the occurrence of delirium. Mounting
17 evidence suggests that the intraoperative administration of low dose (i.e., sub-anesthetic)
18 ketamine, an anesthetic drug that has been in common use for 50 years, prevents delirium,
19 lessens the severity of postoperative pain, and has an opioid-sparing effect. These multiple
20 beneficial effects have been attributed to ketamine's anti-inflammatory and anti-excitotoxic
21 actions. Despite these benefits, low-dose intraoperative ketamine currently does not enjoy
22 widespread adoption, primarily because clinicians are concerned that the psychoactive
23 properties of ketamine might compromise postoperative cognition. The PODCAST randomized
24 controlled trial intends to address a gap in the field through an international, multicenter study
25 that tests the effectiveness of ketamine in reducing both delirium and pain in surgical patients
26 older than 60.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES:

1. Whitlock EL, Vannucci A, Avidan MS. Postoperative delirium. *Minerva Anestesiol* 2011;77:448-56.
2. Leslie DL, Marcantonio ER, Zhang Y, Leo-Summers L, Inouye SK. One-year health care costs associated with delirium in the elderly population. *Arch Intern Med* 2008;168:27-32.
3. Gottesman RF, Grega MA, Bailey MM, et al. Delirium after coronary artery bypass graft surgery and late mortality. *Ann Neurol* 2010;67:338-44.
4. Koster S, Hensens AG, Schuurmans MJ, van der Palen J. Consequences of Delirium After Cardiac Operations. *Ann Thorac Surg* 2011.
5. Kat MG, Vreeswijk R, de Jonghe JF, et al. Long-term cognitive outcome of delirium in elderly hip surgery patients. A prospective matched controlled study over two and a half years. *Dement Geriatr Cogn Disord* 2008;26:1-8.
6. Bickel H, Gradinger R, Kochs E, Forstl H. High risk of cognitive and functional decline after postoperative delirium. A three-year prospective study. *Dement Geriatr Cogn Disord* 2008;26:26-31.
7. Radtke FM, Franck M, Lorenz M, et al. Remifentanyl reduces the incidence of post-operative delirium. *The Journal of international medical research* 2010;38:1225-32.
8. Pandharipande P, Cotton BA, Shintani A, et al. Prevalence and risk factors for development of delirium in surgical and trauma intensive care unit patients. *The Journal of trauma* 2008;65:34-41.
9. Weed HG, Lutman CV, Young DC, Schuller DE. Preoperative identification of patients at risk for delirium after major head and neck cancer surgery. *The Laryngoscope* 1995;105:1066-8.
10. Kazmierski J, Kowman M, Banach M, et al. Incidence and predictors of delirium after cardiac surgery: Results from The IPDACS Study. *J Psychosom Res* 2010;69:179-85.
11. Rudolph JL, Inouye SK, Jones RN, et al. Delirium: an independent predictor of functional decline after cardiac surgery. *J Am Geriatr Soc* 2010;58:643-9.
12. Saczynski JS, Marcantonio ER, Quach L, et al. Cognitive trajectories after postoperative delirium. *N Engl J Med* 2012;367:30-9.
13. Marcantonio ER, Goldman L, Mangione CM, et al. A clinical prediction rule for delirium after elective noncardiac surgery. *JAMA* 1994;271:134-9.
14. Schneider F, Bohner H, Habel U, et al. Risk factors for postoperative delirium in vascular surgery. *Gen Hosp Psychiatry* 2002;24:28-34.
15. Bohner H, Hummel TC, Habel U, et al. Predicting delirium after vascular surgery: a model based on pre- and intraoperative data. *Ann Surg* 2003;238:149-56.
16. Benoit AG, Campbell BI, Tanner JR, et al. Risk factors and prevalence of perioperative cognitive dysfunction in abdominal aneurysm patients. *J Vasc Surg* 2005;42:884-90.
17. Fisher BW, Flowerdew G. A simple model for predicting postoperative delirium in older patients undergoing elective orthopedic surgery. *J Am Geriatr Soc* 1995;43:175-8.

Formatted: Space After: 8 pt, Line spacing: Multiple 1.08 li

18. Marcantonio ER, Flacker JM, Michaels M, Resnick NM. Delirium is independently associated with poor functional recovery after hip fracture. *J Am Geriatr Soc* 2000;48:618-24.
19. Lee KH, Ha YC, Lee YK, Kang H, Koo KH. Frequency, risk factors, and prognosis of prolonged delirium in elderly patients after hip fracture surgery. *Clin Orthop Relat Res* 2011;469:2612-20.
20. Inouye SK. Delirium in older persons. *N Engl J Med* 2006;354:1157-65.
21. Hudetz JA, Pagel PS. Neuroprotection by ketamine: a review of the experimental and clinical evidence. *J Cardiothorac Vasc Anesth* 2010;24:131-42.
22. Wang L, Jing W, Hang YN. Glutamate-induced c-Jun expression in neuronal PC12 cells: the effects of ketamine and propofol. *J Neurosurg Anesthesiol* 2008;20:124-30.
23. Chen X, Shu S, Bayliss DA. HCN1 channel subunits are a molecular substrate for hypnotic actions of ketamine. *J of Neurosci* 2009;29:600-9.
24. Lewis AS, Chetkovich DM. HCN channels in behavior and neurological disease: too hyper or not active enough? *Mol cell neurosci* 2011;46:357-67.
25. Cho HJ, Staikopoulos V, Furness JB, Jennings EA. Inflammation-induced increase in hyperpolarization-activated, cyclic nucleotide-gated channel protein in trigeminal ganglion neurons and the effect of buprenorphine. *Neuroscience* 2009;162:453-61.
26. Emery EC, Young GT, Berrocso EM, Chen L, McNaughton PA. HCN2 ion channels play a central role in inflammatory and neuropathic pain. *Science* 2011;333:1462-6.
27. Hudetz JA, Patterson KM, Iqbal Z, et al. Ketamine attenuates delirium after cardiac surgery with cardiopulmonary bypass. *J Cardiothorac Vasc Anesth* 2009;23:651-7.
28. Hudetz JA, Iqbal Z, Gandhi SD, et al. Ketamine attenuates post-operative cognitive dysfunction after cardiac surgery. *Acta Anaesthesiol Scand* 2009;53:864-72.
29. Bartoc C, Frumento RJ, Jalbout M, Bennett-Guerrero E, Du E, Nishanian E. A randomized, double-blind, placebo-controlled study assessing the anti-inflammatory effects of ketamine in cardiac surgical patients. *J Cardiothorac Vasc Anesth* 2006;20:217-22.
30. Fine J, Finestone SC. Sensory disturbances following ketamine anesthesia: recurrent hallucinations. *Anesth Analg* 1973;52:428-30.
31. Lilburn JK, Dundee JW, Nair SG, Fee JP, Johnston HM. Ketamine sequelae. Evaluation of the ability of various premedicants to attenuate its psychic actions. *Anaesthesia* 1978;33:307-11.
32. Phillips DM. JCAHO pain management standards are unveiled. Joint Commission on Accreditation of Healthcare Organizations. *JAMA* 2000;284:428-9.
33. Brennan F, Carr DB, Cousins M. Pain management: a fundamental human right. *Anesth Analg* 2007;105:205-21.
34. Cousins MJ, Lynch ME. The Declaration Montreal: access to pain management is a fundamental human right. *Pain* 2011;152:2673-4.


- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9 35. Dolin SJ, Cashman JN, Bland JM. Effectiveness of acute postoperative pain
- 10 management: I. Evidence from published data. *Br J Anaesth* 2002;89:409-23.
- 11 36. Macrae WA. Chronic post-surgical pain: 10 years on. *Br J Anaesth* 2008;101:77-
- 12 86.
- 13 37. Elia N, Tramer MR. Ketamine and postoperative pain--a quantitative systematic
- 14 review of randomised trials. *Pain* 2005;113:61-70.
- 15 38. Bell RF, Dahl JB, Moore RA, Kalso E. Perioperative ketamine for acute
- 16 postoperative pain. Cochrane database of systematic reviews 2006:CD004603.
- 17 39. Laskowski K, Stirling A, McKay WP, Lim HJ. A systematic review of intravenous
- 18 ketamine for postoperative analgesia. *Can J Anaesth* 2011;58:911-23.
- 19 40. Chan MT, Wan AC, Gin T, Leslie K, Myles PS. Chronic postsurgical pain after
- 20 nitrous oxide anesthesia. *Pain* 2011;152:2514-20.
- 21 41. Remerand F, Le Tendre C, Baud A, et al. The early and delayed analgesic
- 22 effects of ketamine after total hip arthroplasty: a prospective, randomized,
- 23 controlled, double-blind study. *Anesth Analg* 2009;109:1963-71.
- 24 42. Zwarenstein M, Treweek S, Gagnier JJ, et al. Improving the reporting of
- 25 pragmatic trials: an extension of the CONSORT statement. *Bmj* 2008;337:a2390.
- 26 43. Treweek S, Zwarenstein M. Making trials matter: pragmatic and explanatory trials
- 27 and the problem of applicability. *Trials* 2009;10:37.
- 28 44. Practice guidelines for acute pain management in the perioperative setting: an
- 29 updated report by the American Society of Anesthesiologists Task Force on
- 30 Acute Pain Management. *Anesthesiology* 2012;116:248-73.
- 31 45. Practice guidelines for chronic pain management: an updated report by the
- 32 American Society of Anesthesiologists Task Force on Chronic Pain Management
- 33 and the American Society of Regional Anesthesia and Pain Medicine.
- 34 *Anesthesiology* 2010;112:810-33.
- 35 46. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 Explanation and
- 36 Elaboration: Updated guidelines for reporting parallel group randomised trials. *J*
- 37 *Clin Epidemiol* 2010;63:e1-37.
- 38 47. Wade DT, Collin C. The Barthel ADL Index: a standard measure of physical
- 39 disability? *Int Disabil Stud* 1988;10:64-7.
- 40 48. Kocalevent RD, Hinz A, Brahler E. Standardization of the depression screener
- 41 patient health questionnaire (PHQ-9) in the general population. *Gen Hosp*
- 42 *Psychiatry* 2013;35:551-5.
- 43 49. Chung F, Yegneswaran B, Liao P, et al. STOP questionnaire: a tool to screen
- 44 patients for obstructive sleep apnea. *Anesthesiology* 2008;108:812-21.
- 45 50. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying
- 46 prognostic comorbidity in longitudinal studies: development and validation. *J*
- 47 *Chronic Dis* 1987;40:373-83.
- 48 51. Inouye SK, van Dyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying
- 49 confusion: the confusion assessment method. A new method for detection of
- 50 delirium. *Ann Intern Med* 1990;113:941-8.
- 51 52. Ely EW, Inouye SK, Bernard GR, et al. Delirium in mechanically ventilated
- 52 patients: validity and reliability of the confusion assessment method for the
- 53 intensive care unit (CAM-ICU). *JAMA* 2001;286:2703-10.
- 54
- 55
- 56
- 57
- 58
- 59
- 60

53. Ely EW, Margolin R, Francis J, et al. Evaluation of delirium in critically ill patients: validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). *Crit Care Med* 2001;29:1370-9.
54. Luetz A, Heymann A, Radtke FM, et al. Different assessment tools for intensive care unit delirium: which score to use? *Crit Care Med* 2010;38:409-18.
55. Plaschke K, von Haken R, Scholz M, et al. Comparison of the confusion assessment method for the intensive care unit (CAM-ICU) with the Intensive Care Delirium Screening Checklist (ICDSC) for delirium in critical care patients gives high agreement rate(s). *Intensive Care Med* 2008;34:431-6.
56. Steis MR, Evans L, Hirschman KB, et al. Screening for delirium using family caregivers: convergent validity of the Family Confusion Assessment Method and interviewer-rated Confusion Assessment Method. *J Am Geriatr Soc* 2012;60:2121-6.
57. Payen JF, Bru O, Bosson JL, et al. Assessing pain in critically ill sedated patients by using a behavioral pain scale. *Crit Care Med* 2001;29:2258-63.
58. Chanques G, Payen JF, Mercier G, et al. Assessing pain in non-intubated critically ill patients unable to self report: an adaptation of the Behavioral Pain Scale. *Intensive Care Med* 2009;35:2060-7.
59. Avidan MS, Jacobsohn E, Glick D, et al. Prevention of intraoperative awareness in a high-risk surgical population. *N Engl J Med* 2011;365:591-600.
60. Avidan MS, Zhang L, Burnside BA, et al. Anesthesia awareness and the bispectral index. *N Engl J Med* 2008;358:1097-108.
61. Mashour GA, Shanks A, Tremper KK, et al. Prevention of intraoperative awareness with explicit recall in an unselected surgical population: a randomized comparative effectiveness trial. *Anesthesiology* 2012;117:717-25.
62. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform* 2009;42:377-81.
63. Neshar N, Serovian I, Marouani N, Chazan S, Weinbroum AA. Ketamine spares morphine consumption after transthoracic lung and heart surgery without adverse hemodynamic effects. *Pharmacol Res* 2008;58:38-44.
64. Tharmanathan P, Calvert M, Hampton J, Freemantle N. The use of interim data and Data Monitoring Committee recommendations in randomized controlled trial reports: frequency, implications and potential sources of bias. *BMC Med Res Methodol* 2008;8:12.
65. Fleming TR, DeMets DL. Monitoring of clinical trials: issues and recommendations. *Control Clin Trials* 1993;14:183-97.
66. Smith MA, Ungerleider RS, Korn EL, Rubinstein L, Simon R. Role of independent data-monitoring committees in randomized clinical trials sponsored by the National Cancer Institute. *J Clin Oncol* 1997;15:2736-43.
67. Montori VM, Devereaux PJ, Adhikari NK, et al. Randomized trials stopped early for benefit: a systematic review. *JAMA* 2005;294:2203-9.
68. Bassler D, Briel M, Montori VM, et al. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. *JAMA* 2010;303:1180-7.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

69. Grant AM, Altman DG, Babiker AB, et al. Issues in data monitoring and interim analysis of trials. *Health Technol Assess* 2005;9:1-238, iii-iv.
70. Strayer RJ, Nelson LS. Adverse events associated with ketamine for procedural sedation in adults. *Am J Emerg Med* 2008;26:985-1028.

For peer review only



-AUTHORS' CONTRIBUTORSHIP

Michael Avidan and George Mashour are the primary authors of the PODCAST protocol. Their contributions include drafting and editing the protocol, conceptualizing the study design, and organizing conduct across all sites. Bradley Fritz contributed to the PODCAST trial by editing the protocol, conceptualizing study design, creating the electronic database, REDCap used for data collection, and co-authoring a manual of operations for study conduct. Hannah Maybrier contributed to PODCAST by editing the protocol, co-authoring the manual of operations, recruiting patients for enrollment, collecting data, and coordinating the study across all sites. Maxwell Muench contributed to PODCAST by co-authoring a manual of operations, recruiting patients for enrollment, and collecting data. Krisztina Escallier contributed to PODCAST by editing the protocol, conceptualizing study design, and co-authoring a manual of operations. Yulong Chen contributed to PODCAST by editing the protocol and conceptualizing study design. Arbi Ben Abdallah contributed to PODCAST by editing the protocol and conceptualizing study design, including the statistical modelling of the study. Sharon Inouye contributed to PODCAST by training investigators to perform delirium assessments and conceptualizing study design. Stephen Choi, Robert Downey, Hilary Grocott, Gyujeong Noh, Judith Hudetz, Eric Jacobsohn, Heiko Kaiser, Paul Pagel, Kane Pryor, Ryan Pong, Robert Veselis, and Virendra Kumar Arya contributed to PODCAST by editing the study protocol, conceptualizing study design, recruiting participants, and collecting data.

All authors including Avidan, Mashour, Fritz, Maybrier, Muench, Escallier, Chen, Ben Abdallah, Inouye, Veselis, Grocott, Hudetz, Pryor, Pagel, Arya, Pong, Jacobsohn, Gyujeong, Kaiser, Downey, and Choi have critically revised the PODCAST protocol and approved the final version.

All authors agree to be accountable for the accuracy and integrity of all aspects of the PODCAST trial.

ACKNOWLEDGMENTS

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

PODCAST research group: A Alexander, R Arora, J Bang, M Bottros, A Cai, BM Choi, IC Choi, ME Davis, R Downey, D Emmert, M Engoren, SD Gandhi, L Girling, N Hanson, Z Iqbal, A Jayant, E Lenze, M Maile, ~~ER Marcantonio~~, J McVagh, J Neal, S Oskar, KM Patterson, E Rogers, ~~E Schmitt~~, B Tellor, T Wildes, A Villafranca, H Yulico

FUNDING

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

COMPETING INTERESTS

None of the authors have conflicts of interest to disclose.




Figure 1: Study Enrollment
196x223mm (300 x 300 DPI)

Appendix A - Delirium and Pain Self-Assessment Questionnaire:

(Following the final delirium assessment, the following questionnaire will be given to patients):

A. Following your surgery, were there any periods that you felt you could not pay attention to people or things?

Yes

No

B. If yes, can you say when:

Today: morning

afternoon

Yesterday: morning

afternoon

Day before yesterday: morning

afternoon

C. Following your surgery, were there any period that you felt you were not thinking in a logical or organized way?

D. If yes, can you say when:

Today: morning

afternoon

Yesterday: morning

afternoon

Day before yesterday: morning

afternoon

E. Did these feelings negatively affect your experience after the surgery?

Yes

No

F. Following your surgery, were there any periods when your pain was uncontrolled?

Yes

No

1
2
3
4
5
6 G. If yes, can you say when:

7 Today: morning afternoon

8 Yesterday: morning afternoon

9 Day before yesterday: morning afternoon

10
11
12
13
14
15
16 H. Did any family members tell you that there were periods following your surgery that you felt
17 you could not pay attention to people or things?

18
19
20 Yes No

21
22
23
24
25 I. Did any of your family members tell you that there were periods following your surgery when
26 you were not thinking in a logical or organized way?

27
28 Yes No

29
30
31
32
33 J. Following your surgery, did you have bad dreams nightmares?

34
35 Yes No

36
37
38 K. If yes, can you say when:

39 Today: morning afternoon

40 Yesterday: morning afternoon

41 Day before yesterday: morning afternoon

42
43
44
45
46
47 L. Following your surgery, did you have hallucinations (you saw things or heard things or felt
48 things that were not there)?

49
50 Yes No

51
52
53
54 M. If yes, can you say when:

55 Today:

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Today:	morning	afternoon
Yesterday:	morning	afternoon
Day before yesterday:	morning	afternoon

For peer review only



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	_____1_____
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	_____1_____
	2b	All items from the World Health Organization Trial Registration Data Set	_____4_____
Protocol version	3	Date and version identifier	_____1_____
Funding	4	Sources and types of financial, material, and other support	_____4_____
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	_____1_____
	5b	Name and contact information for the trial sponsor	_____1-3_____
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	_____n/a_____
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	_____7_____

1				
2				
3	Introduction			
4				
5	Background and	6a	Description of research question and justification for undertaking the trial, including summary of relevant	_____14_____
6	rationale		studies (published and unpublished) examining benefits and harms for each intervention	
7				
8		6b	Explanation for choice of comparators	_____21_____
9				
10	Objectives	7	Specific objectives or hypotheses	_____19_____
11				
12	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group),	
13			allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	_____21_____
14				
15				
16	Methods: Participants, interventions, and outcomes			
17				
18	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will	_____30, 5_____
19			be collected. Reference to where list of study sites can be obtained	
20				
21	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and	_____23_____
22			individuals who will perform the interventions (eg, surgeons, psychotherapists)	
23				
24	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be	_____24_____
25			administered	
26				
27		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose	_____33_____
28			change in response to harms, participant request, or improving/worsening disease)	
29				
30		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence	_____n/a_____
31			(eg, drug tablet return, laboratory tests)	
32				
33		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	_____24_____
34				
35	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood	_____24-26_____
36			pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg,	
37			median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen	
38			efficacy and harm outcomes is strongly recommended	
39				
40				
41	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for	_____22_____
42			participants. A schematic diagram is highly recommended (see Figure)	
43				
44				
45				
46				
47				
48				
49				

1				
2				
3	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	_____28_____
4				
5				
6	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	_____30_____
7				

8 **Methods: Assignment of interventions (for controlled trials)**

9 Allocation:

10				
11				
12	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	_____31_____
13				
14				
15				
16				
17				
18	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	_____31_____
19				
20				
21				
22	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	_____31_____
23				
24				
25	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	_____24-25_____
26				
27				
28		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	_____31_____
29				
30				
31				

32 **Methods: Data collection, management, and analysis**

33				
34	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	_____24-26_____
35				
36				
37				
38				
39		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	_____n/a_____
40				
41				
42				
43				
44				
45				

1				
2				
3	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	_____ 32 _____
4				
5				
6				
7	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	_____ 31 _____
8				
9				
10		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	_____ 32 _____
11				
12		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	_____ n/a _____
13				
14				
15				
16	Methods: Monitoring			
17				
18	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	_____ 34 _____
19				
20				
21				
22				
23		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	_____ 33 _____
24				
25				
26	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	_____ 33 _____
27				
28				
29	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	_____ 34 _____
30				
31				
32				
33	Ethics and dissemination			
34				
35	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	_____ 35 _____
36				
37				
38	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	_____ n/a _____
39				
40				
41				
42				
43				
44				
45				
46				
47				
48				
49				

1				
2				
3	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	_____36_____
4				
5				
6		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	_____n/a_____
7				
8				
9	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	_____36_____
10				
11				
12	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	_____43_____
13				
14				
15	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	_____32_____
16				
17				
18	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	_____35_____
19				
20				
21	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	_____36_____
22				
23				
24				
25				
26		31b	Authorship eligibility guidelines and any intended use of professional writers	_____36_____
27				
28		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	_____36_____
29				
30	Appendices			
31				
32	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	_____separate file_____
33				
34				
35	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	_____n/a_____
36				
37				

38 *It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items.
 39 Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons
 40 "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.
 41